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General introduction
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GENERAL INTRODUCTION
The folded surface of the human brain, the brain cortex, has intrigued scientists for cen-
turies. It was recently discovered that the mathematical formula predicting the degree of 
folding of a paper ball can also be applied to predicting the degree of folding of the brain 
cortex, and that its pattern depends on the cortical thickness and total surface area.1
As this thesis will show, finding an explanation for abnormal development of the cortex 
has been less straightforward, although our knowledge regarding its mechanisms is 
rapidly expanding.
The human brain is roughly built up of two main structures, the cortex which is the 
outer layer (the grey matter) and the inner white matter. The cortex contains the 
cell bodies of the neurons, and the white matter contains the axons connecting 
neurons from the same or from different brain regions to each other. All congenital 
abnormalities related to the development of the brain cortex are collectively called 
malformations of cortical development (MCD). The majority of MCD are either forms 
of microcephaly, megalencephaly, lissencephaly, heterotopia or polymicrogyria.2 This 
thesis focuses on heterotopia and microcephaly. Before describing the details of these 
malformations, I will briefly summarize the normal development of the brain cortex.
DEVELOPMENT OF THE BRAIN CORTEX
The adult male brain contains around 86 billion neurons and 85 billion non-neuronal 
cells. 3 It is thought that the majority of these neurons are already present in the 
newborn brain.
Early development
After formation of the neural tube around the fourth week, the cranial region develops 
into three, and later five structures: the rhombencephalon, from which the myelen-
cephalon and metencephalon are formed, the mesencephalon, and the prosencepha-
lon, which later forms the diencephalon and telencephalon (cerebrum). The ventricles 
are formed from the hollow cavity of the neural tube.
Intriguingly, neurons are born within deep brain structures and then migrate outwards 
to form the cortex. Therefore, the formation of the cortex can roughly be divided into 
three main stages; neurogenesis, neuronal migration and cortical organization.
Neurogenesis
Neurogenesis starts from the pool of neuroepithelial cells (NECs) lining the surface of 
the ventricles (Fig. 1). During cell cycle, the nucleus moves from the basal side during 
S phase towards the apical (ventricular) side during M phase and then back to the 
basal side. This is a critical process and disturbance will lead to cell cycle exit and /or 
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apoptosis and thus to depletion of the progenitor pool. The NECs give rise to apical 
radial glial cells (RGCs). Both NECs and RGCs are polarized and connected through 
adherens junctions. The RGCs undergo both symmetric and asymmetric cell divisions, 
in turn expanding the cell pool by giving rise to RGCs, neurons (direct neurogenesis), 
and intermediary progenitor cells (IPCs), which in turn will also give rise to neurons 
(indirect neurogenesis).4
Neuronal migration – radial
Newborn neurons migrate toward the cortical plate on the outer surface to eventually 
form a six-layered folded cortex (Fig. 1). The RGCs form long processes extending 
MZ
CP
IZ
SVZ
VZ
radial
migra�on
neo
cor
tex
 tangen�al 
 migra�on
Lateral
ventricle
Neuronal
progenitor
Postmito�c 
neuron
Figure 1. Schematic representation of the developing mammalian brain. 
(A) Coronal section of one half of the mammalian developing forebrain. There are two main migratory 
streams of post-mitotic neurons: the radial migration of excitatory cortical pyramidal neurons from the 
ventricular zone (VZ) to the cortical plate (CP) (black arrow) and the tangential migration of inhibitory 
GABAergic interneurons from lateral- and medial- ganglionic eminences (LGE/MGE) into the neocortex 
(blue arrow). (B) The developing cerebral cortex in mammals is multi-layered with different neuronal cell 
populations. Near the lateral ventricle surface, neural progenitors (NPs) reside in the ventricular zone (VZ). 
This progenitor zone is extended to subventricular and intermediate zones (SVZ and IZ, respectively). 
Newly born neurons from the division of NPs undergo extensive radial neuronal migration to enter the 
cortical plate (CP). The marginal zone (MZ) is the most superficial layer (66). [reused with permission from 
John Wiley and Sons]
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through the cortical plate and connecting to the pial lamina, hereby forming a scaffold 
for the migration of newborn neurons to the cortical plate. These neurons migrate 
radially along the RGC extensions and are also guided by extracellular cues. The 
migrating neuron first extends its leading process, and then the centrosome moves 
into the leading process followed by the nucleus. The cytoskeleton (actin filaments and 
microtubules) and its associated proteins are crucial components of these processes.4 
Neurons that migrated radially to the cortex will become glutamatergic excitatory 
pyramidal neurons.
Neuronal migration - tangential
In contrast to the pyramidal neurons, the inhibitory GABAergic interneurons migrate 
tangentially and originate in the ganglionic eminences (Fig. 1). The ganglionic 
eminences (GE) form transiently during brain development and provide a source of 
neurons destined for the cortex and for the basal ganglia. The GE disappear around 
one year of age.5 The caudal GE is the major source of cortical interneurons, but the 
medial and lateral GE also contribute.6 The GABAergic neurons travel tangentially from 
the GEs through the subventricular zone or through the marginal zone, and, in contrast 
to the glutamatergic neurons, without a radial glia scaffold.6 As a consequence, 
interneurons seem to end up randomly dispersed throughout the mammalian cortex.7,8
Cortical organization
The normal human cortex is built up of six distinct cellular layers. Its size is unique to 
humans and other primates, and this is achieved by expansion of neuronal progenitors 
and folding (gyrification) of the cortical plate. When the neurons have reached their 
final destination in the cortex, their axons and dendrites mature, they commence 
synaptogenesis and assemble into microcircuits.9
Malformations of cortical development
Malformations of cortical development (MCD) comprise a large and heterogeneous 
group of malformations resulting from defects in the process of cortical formation, 
from ventricular and subventricular zone neurogenesis to neuronal migration to 
post-migrational development.2 This term is preferred to “cortical malformations” to 
include gray matter heterotopia which are located beneath the cortex but also result 
from defective corticogenesis.
Prevalence and impact
The prevalence of MCD in the general population is unknown. In the 2012 MCD 
classification 2, 200 MCD subtypes are recognized, each subtype being very rare. Taken 
together, however, they form a substantial burden on health care and society, account-
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ing for 3% of intellectual disability, 25% of pediatric partial seizures, 5-15% of adult 
epilepsy, and 20-40% of therapy-resistant epilepsy. 10-14
Symptoms can present at all ages; from pregnancy into late adulthood.15-17 In the 
majority of individuals, the brain abnormalities are discovered on brain imaging 
(MRI= magnetic resonance imaging) during childhood, initiated by the presence of 
developmental delay and/or seizures. As for the majority of patients, only symptomatic 
therapy and no curative therapy is available, MCD have a lifelong impact on the health 
and wellbeing of the affected patients and their families.
Classification
Classically, MCD are grouped into the presumed stage of defective development;
I) proliferation or apoptosis disorders (primary microcephaly, megalencephaly),
II) migration disorders (heterotopia, lissencephaly, cobblestone malformation),
III) organization disorders (polymicrogyria, schizencephaly, focal cortical dysplasia, 
postmigrational microcephaly).2
It was anticipated that mutations in genes unique to each disorder and developmental 
stage would be identified. Data from imaging and genetic studies and subsequent 
functional and animal studies have greatly advanced our understanding of MCD 
pathophysiology. It has however also led to the recognition that the current classifica-
tion is not comprehensive, as malformations from more than one group can occur 
in a single patient. The discovery of mutations in for example WDR62 and TUBA1A 
has further strengthened the concept that mutations in a single gene can lead to 
multiple malformations originating in different stages of brain development.18-20 
The range of malformations associated with WDR62 mutations is broad and includes 
primary microcephaly, lissencephaly, and polymicrogyria. 19,21 WDR62 localizes to the 
centrosome and to the nucleus and in mouse embryonic brain it is expressed in both 
the ventricular zone and the cortical plate.22,23 It has been proposed that the WDR62-
related malformations result from the combined effects on nucleokinesis, centrosome 
assembly and movement in both progenitors and differentiating post-mitotic neurons, 
leading to a diminished progenitor pool, altered migration and disturbed cortical 
organization.4,22 Ultimately, a new classification based on integrated clinical, imaging, 
genetic and biological pathway data will be established.16
Imaging
MCD were first described by neuropathologists. In the early seventies, respectively 
early eighties, the compute tomography (CT) scans and magnetic resonance imaging 
(MRI) scans became clinically available. It has taken several more years however 
before these were implemented into routine clinical practice. The use of CT scans for 
diagnosing patients with severe MCD during their lifetime emerged in the eighties.24 
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MRI, a powerful tool for recognizing MCD allowing a more detailed description of 
morphology and localization than CT, emerged in clinical practice only from the late 
eighties.25 During the nineties, more and more MCD subtypes were described and in 
1996, the first MCD classification was published.26 Comparing the first classification 
(1996) with the most recent (2012) emphasizes the explosively increased recognition of 
these disorders over less than two decades:
Group I: in 1996 16, in 2012 65 subtypes;
Group II: in 1996 40, in 2012 65 subtypes;
Group III: in 1996 8, in 2012 70 subtypes. 2,26
This growing complexity is due in part to increased use of high resolution brain 
imaging, and in part to the discovery of dozens of genes involved in MCD, much more 
than was first anticipated.
When diagnosing MCD on brain imaging, it is extremely important to systematically 
review all brain structures in order 1) to make accurate prognostic predictions 2), 
to not overlook subtle abnormalities and 3) to enable a precise diagnosis. In MCD, 
extra-cortical abnormalities can be a clue to the underlying diagnosis, for example 
basal ganglia abnormalities in the tubulinopathies.18 A useful approach would be 
to systematically review at least these structures in the following sequence: date of 
review, age of MRI, head contour/skull; extra-axial spaces, cerebral hemispheres, gyral 
pattern, hippocampus, basal ganglia and thalami, white matter, lateral ventricles, third 
ventricle, corpus callosum, brain stem, cerebellum and cerebellar vermis, posterior 
fossa (adapted from W.B. Dobyns, personal communication).
The majority of individuals described in this thesis have heterotopia and/or micro-
cephaly, and in the next section, these disorders are described in more detail.
HETEROTOPIA
Neuronal heterotopia are macroscopic clusters of misplaced neurons, most often 
situated along the ventricular walls or within the subcortical white matter. The cortex 
itself can be normal or abnormal. Naming in literature has been inconsistent and has 
included grey matter heterotopia, subependymal heterotopia, white matter heteroto-
pias, and neuronal heterotopia. According to the Barkovich classification the following 
terms are to be used for the different subtypes: subcortical band heterotopia, periven-
tricular nodular heterotopia, periventricular linear heterotopia, columnar heterotopia 
and large subcortical heterotopia.2 When situated above the cortex (e.g. overmigration 
of neurons) they form a distinct entity named leptomeningeal glioneuronal heteroto-
pia. The different subtypes can be distinguished on MRI (Fig. 2). Both periventricular 
nodular heterotopia and subcortical heterotopia are the subject of this thesis.
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Periventricular nodular heterotopia
Although its true prevalence is unknown, in multiple cohort studies periventricular 
nodular heterotopia (PNH) were one of the most frequently occurring MCD.27-29 Patients 
most commonly present with seizures, which will develop in 80-90% of individuals.16 
However the severity and the age of presentation depends largely on the underlying 
etiology and associated malformations, rendering it very important to establish a 
specific and whenever possible, an etiological diagnosis.
Imaging
PNH are clusters (nodules) of mislocalized neurons and glial cells along the walls of 
the lateral ventricles.30 They are recognized on brain imaging as an irregular or bumpy 
surface lining of the ventricular walls. The nodules display the same signal intensity 
as the cortex, and are more easily recognized in the mature (myelinated) brain. Their 
localization can be anywhere along the ventricular wall, bilateral or unilateral, continu-
ous or scattered. The differential diagnosis includes subcortical heterotopia, white 
matter abnormalities, and tubers associated with tuberous sclerosis complex, although 
these can be very well differentiated by careful MRI review. Single or scattered PNH 
are sometimes overlooked, especially on low-resolution imaging and/or in young 
children in whom myelination is still ongoing. PNH can be an isolated finding on brain 
imaging, or occur in combination with a wide range of other brain malformations. 
X-linked PNH caused by FLNA mutations is commonly associated with posterior fossa 
abnormalities, mainly mega cisterna magna.31 Patients with ARFGEF2- associated PNH 
have microcephaly and hyperintensities of the basal ganglia on T2-weighted and FLAIR 
images (Fig. 2).32,33 In a large retrospective study of 200 patients with PNH, additional 
MCD were found in 33%, subcortical heterotopia, polymicrogyria, and microcephaly 
being most common.8 Polymicrogyria is commonly observed in combination with PNH, 
with polymicrogyria most commonly found in the perisylvian areas or more posterior 
in the occipital-parietal-temporal cortex.5,34 The latter pattern has been associated 
with the 6q terminal deletion syndrome 35 and was found in a female with large 
chromosome Xq21 deletion (G.M.S. Mancini, personal communication). We and others 
have observed PNH in patients with neural tube defects.36 Sometimes a thin curvilinear 
gray-matter band can be seen within the white matter.37
Etiology
The number of genes associated with PNH is still small, but several chromosomal 
imbalances and monogenetic syndromes have been reported to include PNH as a 
main or minor feature (Table 1). The Baraitser-Winter Neurogenetics database [v.1.0.32 
London Medical Databases] lists 39 syndromes with PNH. Non-genetic causes are not 
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very well studied. There has been one report on the association with prenatal alcohol 
exposure.38
The most studied form is that of X-linked dominant periventricular heterotopia caused 
by mutations in the FLNA gene. In around half of bilateral PNH cases FLNA mutations 
can be identified, and this number rises to 83-100% in familial cases.39,40 Females can 
be asymptomatic or present with mildly disturbed cognitive functioning, seizures, 
connective tissue abnormalities, lung disease, and cardiovascular malformations.41-43 
Mutations in males usually result in embryonic lethality, however the few surviving 
A B C D
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Figure 2. Magnetic resonance imaging of heterotopia patients. 
(A) scattered PNH, bilateral perisylvian polymicrogyria and enlarged lateral ventricles. (B) PNH in patient 
with Smith-Magenis syndrome caused by a 17p11.2 deletion. (C) extensive bilateral PNH in a female 
patient with a FLNA mutation. (D) mega cisterna magna in the same FLNA patient. (E-H) patient with bial-
lelic ARFGEF2 mutations showing bilateral PNH (E) extending to the occipital horns (F) and hyperintensity 
of the putamen on FLAIR imaging. (H) she had dystonic posturing and excessive drooling. (I) subcortical 
band heterotopia in male patient with a mosaic DCX mutation. (J) extensive bilateral curvilinear subcorti-
cal heterotopia. (K) curvilinear subcortical heterotopia limited to the frontal lobes. (L) same patient as in 
(K) showing partial agenesis of the corpus callosum.
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males present with a plethora of congenital abnormalities affecting the CNS, cardio-
vascular, pulmonary, gastro-intestinal, and genito-urinary systems.40,44 The intra- and 
interfamilial variability is great, and outcome largely depends on the associated 
abnormalities.
A clinically distinct disorder is caused by autosomal recessive mutations in ARFGEF2.32 
Since its discovery in 2004 only 6 families, with 13 affected patients, have been 
described.32,33,45-47 Patients suffer from severe neurological disease with seizures, spastic 
quadriplegia, profound ID, progressive microcephaly, and movement disorder. Recently 
obstructive cardiomyopathy has been recognized as an additional feature.46,47 MRI 
shows progressive generalized cerebral atrophy, bilateral PNH, which can be continu-
ous or scattered, abnormal intensity of the putamen, hippocampal atrophy, thin corpus 
callosum, and relatively preserved brainstem and cerebellum.32,33,45-47
Several studies have reported deletions of chromosome band 6q27 in patients with 
variable combinations of the following structural brain malformations: PNH predomi-
nantly situated in the temporal horns, polymicrogyria, agenesis or hypoplasia of the 
corpus callosum, colpocephaly, under-rotated hypoplastic hippocampi, and cerebellar 
hypoplasia.35,48,49 In a patient who had PNH, developmental delay, and seizures a 
heterozygous missense mutation in the ERMARD gene (located on 6q27, previously 
named C6orf70) was identified.35 Additional studies are warranted to clarify the role of 
ERMARD mutations in PNH.
Subcortical band heterotopia
Subcortical band heterotopia (SBH) is considered the mild end of the lissencephaly 
spectrum. In contrast to lissencephaly, where the cortex is thickened and has dimin-
ished number of gyri (agyria or pachygyria), in SBH the cortex is normally organized 
into six layers, although the sulci can be shallow.16 A normal white matter layer is 
present right beneath the cortex, followed by a layer of varying depth consisting of 
misplaced neurons. On brain MRI, this appears as a smooth band of similar signal 
intensity to the cortex.16 Patients can have seizures and mild to moderate intellectual 
disability, or be entirely asymptomatic.50
SBH is caused by mutations in genes also causing lissencephaly, most commonly DCX 
(Table 2), but the migration defect is less severe due to X-linked dominant inheritance 
(DCX mutations causing lissencephaly in males and SBH in females), milder (missense) 
mutations (LIS1), or mosaicism (LIS1, DCX).51,52 Together DCX and LIS1 constitute about 
80% of mutations causing SBH.50
Other subcortical heterotopia
All other heterotopia located between the cortex and lateral ventricles have collec-
tively been referred to as subcortical heterotopia. The few available reports of subcorti-
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cal heterotopia show remarkable heterogeneity in location, size and pattern.15,53-56 
Its cause is largely unknown, but for a few, mostly rare, subtypes a possibly or likely 
genetic etiology has been implied (Table 3). Exogenic causes have also been suggested 
due to the occurrence of subcortical heterotopia in patients with a prenatal history of 
twinning, near miscarriage or trauma.54,57
Rare other heterotopia
Other types of heterotopia exist, but reports are rare. Bilateral undulating ribbon-like 
heterotopia have been reported in two adults with epilepsy and normal intelligence, 
but was also observed in a girl with severe developmental delay, seizures, and cata-
racts.39,58 Van Maldergem syndrome is a disorder characterized by intellectual disability, 
craniofacial, auditory, renal, skeletal and limb malformations.59 Affected individuals 
variably have periventricular heterotopia ranging from nodular to confluent “laminar” 
heterotopia, and occasionally extending into the white matter. 59,60
MICROCEPHALY
Microcephaly is defined by a head circumference equal to or less than 2 – 3 standard 
deviations below the mean for age.61 Post-migrational microcephaly is characterized 
by a severe postnatal slowing in brain growth.2 When present at birth is it referred 
to as congenital microcephaly. Congenital microcephaly is due to either reduced 
proliferation or accelerated apoptosis.2 Primary microcephaly is traditionally defined as 
a congenital microcephaly, <-3SD at birth, with a non-progressive mental retardation 
and, apart from a simplified gyral pattern, with normal brain architecture.62
Imaging
Brain imaging is not obligatory, but should be carefully considered in any child with 
microcephaly, especially when neurological deficits or seizures are present. In children 
with severe microcephaly (<-3 SD), imaging abnormalities are found in 80%.63 This 
is in contrast to children with milder microcephaly (between -2 and -3 SD) in whom 
abnormalities are found in 40%.63 Most frequently MCD or abnormalities of the corpus 
callosum are identified. Congenital microcephaly is often associated with a simplified 
gyral pattern, resulting in fewer gyri and sulci, especially of the frontal lobes. Although 
usually considered a separate entity in combination with microcephaly, it has become 
evident that this is the direct result of the diminished brain volume, and therefore not a 
separate malformation.1,64
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Etiology
Dozens of genes have already been associated with microcephaly, and the majority en-
code proteins involved in the cell cycle and DNA repair mechanisms. 61 This is especially 
true for the genes associated with primary microcephaly, of which already 16 have 
been identified (OMIM MCPH1-16). It is thought that mutations in these genes lead to 
cell cycle arrest or cell death and ultimately a diminished neuroprogenitor pool. Genes 
associated with micrcocephaly in combination with MCD are listed in Table 4. Many 
syndromes and chromosomal aberrations also have microcephaly as a key feature, as 
well as prenatal teratogen exposures. This heterogeneity complicates the diagnostic 
trajectory of the microcephaly patient, and any additional features which might point 
to the diagnosis should be actively sought for. A practical for the diagnostic approach 
was proposed by Woods and Parker.65
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BACKGROUND OF THE THESIS
In the Erasmus MC-Sophia, multidisciplinary expertise on MCD has been built by dedi-
cated professionals from the departments of Clinical Genetics, Radiology and Pediatric 
Neurology starting in the late nineties. This has resulted in the joint neurogenetics 
clinic, now embedded within the “ national expertise center for central nervous system 
malformations”(registered by the Dept. of Health in 2015); and a laboratory offering 
state-of-the-art molecular diagnostics, first targeted Sanger sequencing, FISH or MLPA 
of individual genes, and currently SNP arrays, a next-generation sequencing panel with 
103 genes and whole-exome sequencing.
The main purpose of this study was to enhance our knowledge on MCD and to dis-
seminate our findings to the clinical and the scientific community. Therefore we aimed 
to improve the existing classification, to identify genetic causes of MCD and to describe 
in great detail imaging manifestations and associated symptoms and malformations. In 
particular I have focused on two common types of MCD: heterotopia, one of the poorly 
explained types of MCD, and microcephaly, which is etiological very heterogeneous 
and is frequently associated with structural MCD.
SCOPE OF THE THESIS
In Chapter 1, a general introduction to the presentation and etiology of MCD is given.
In the Erasmus MC-Sophia we identified several patients with rare, unpublished forms 
of subcortical heterotopia. For the research described in Chapter 2, I visited the Center 
for Integrative Brain Research, Seattle Children’s / University of Washington (U.S.A.) to 
search the world’s largest database of MCD patients (>7,500) collected by professor 
W. B. Dobyns, for additional patients. This, in combination with searches of three 
other large databases of MCD patients collected by professor A.J. Barkovich, professor 
R. Guerrini, and dr. G.M.S. Mancini, has resulted in a classification for subcortical 
malformations, with data of >100 patients (Chapter 2.1). In the next chapter, patients 
from the Seattle database of dr. D. Doherty are described who presented with a distinct 
cerebellar dysplasia. We identified mutations in multiple tubulin genes and named the 
mild cortical abnormalities associated with tubulinopathies dysgyria (Chapter 2.2).
In Chapter 3, Expanding phenotypes, we diagnosed MCD in patients with known 
syndromes and/or gene mutations: PNH in KBG syndrome (Chapter 3.1); microcephaly, 
PNH and cortical dysplasia associated with chromosome 21q22 deletions (Chapter 
3.2); polymicrogyria and PNH in a boy with an ARX mutation (Chapter 3.3); multi-
organ involvement and PNH in a FLNA pedigree with three affected males (Chapter 
3.4); and progressive neurodegeneration with microcephaly and ataxia associated with 
PNKP mutations (Chapters 3.5 and 3.6).
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In Chapter 4, New gene and mechanism, we describe the discovery of a novel gene for 
profound intellectual disability, microcephaly and PNH, INTS8 (Chapter 4.1).
Finally, in Chapter 5, our findings and future studies are discussed.
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Defining imaging characteristics

Chapter 2.1
Subcortical heterotopia: clinical and 
imaging findings of 107 patients and a 
new classification
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ABSTRACT
Subcortical heterotopia (SUBH) represent a rare and heterogeneous brain malforma-
tion classified as a malformation of cortical development. From four large databases, 
we collected imaging and clinical data of 107 patients with subcortical heterotopia. 
This extensive survey led to the first comprehensive classification of these distinctive 
malformations. Curvilinear SUBH formed the largest group (n=66), followed by deeply 
infolded SUBH (n=19). We also describe several rare forms including solid SUBH in the 
peritrigonal optic pathway (n=5), brain-in-brain malformation (N=5), and ribbon-like 
SUBH (n=2). The large majority (84%) was scanned during childhood, and more than 
half (59%) before age 4 years. Although most patients had early developmental delay, 
learning difficulties, intellectual disability and/or spasticity, 19% had normal motor and 
cognitive development. Epilepsy occurred in 69%, the age of the onset ranging from 
the newborn period up to 25 years of age. For the majority, the etiology is unknown 
but its sporadic occurrence and often asymmetric appearance of the curvilinear SUBH 
suggests de novo germline or somatic mutations, or a prenatal disruptive event. Indeed 
several patients had a history of twinning. Several of the rare, bilateral forms are associ-
ated with mutations in microtubule- and centrosome-associated genes (EML1, TUBB, 
KATNB1, CENPJ, GPSM2), revealing a possible overlapping pathomechanism to primary 
microcephaly and other MCD. In conclusion, this study provides novel insights into the 
broad clinical and imaging spectrum of this malformation.
Subcortical heterotopia 39
Ch
ap
te
r 2
.1
INTRODUCTION
Malformations of cortical development (MCD) comprise a large and heterogeneous 
group of brain malformations that result from defects in the formation of the human 
cortex. This process includes neurogenesis, neuronal migration, and post-migrational 
development.1 While their prevalence is unknown, they account for 3% of intellectual 
disability, 25% of pediatric focal epilepsy, 5-15% of adult epilepsy, 20-40% of therapy-
resistant epilepsy, and 42% of children undergoing epilepsy surgery.2-6 Therefore, MCD 
collectively place a substantial burden on health care and society.
The increasing availability and resolution of magnetic resonance imaging (MRI) 
technology over the past 30 years has led to an immense change in our appreciation of 
MCD from fewer than 10 to currently more than 200 different types.1,7-9 Several of these 
are classified as gray matter heterotopia, which represent clusters of neurons derived 
from neurogenesis in the ventricular or subventricular zone that failed to locate to 
their normal position in the cortex. The most commonly encountered heterotopia 
are those found as nodules along the walls of the lateral ventricles (periventricular 
nodular heterotopia). In contrast, the more rarely identified subcortical heterotopia 
(SUBH) are located between the cortex and lateral ventricles. Although, according 
to previous reports, SUBH are heterogeneous regarding nomenclature and imaging 
patterns, they frequently show extensive and asymmetric involvement of the cerebral 
hemispheres.10-19 A distinct group is formed by the subcortical band heterotopia, which 
are classified within the lissencephaly spectrum.1
While analyzing brains scans from individuals with MCD, we recognized several novel 
SUBH with predominant subcortical localization, suggesting far more diversity of SUBH 
than had been previously recognized. This led us to systematically search our four large 
MCD databases containing records on more than 10,000 subjects (based in Chicago/
Seattle, Rotterdam, Florence, and San Francisco) for subjects with SUBH. We selected 
107 subjects with MCD and a prominent subcortical component, grouped them based 
on shared imaging characteristics, and analyzed the neuroimaging and clinical features 
for each subtype.
From this extensive survey, we reconceive subcortical heterotopia as a diverse class of 
MCD, and present the first comprehensive classification of these distinctive malforma-
tions. We hypothesize that SUBH result not only from defects in neuronal migration as 
previously proposed 1, but also from defects arising in the outer subventricular zone of 
the developing brain, the site of origin of a majority of neurons in the human brain.20,21
40 Chapter 2.1
METHODS
Subjects
We identified subjects with SUBH by first searching our large Chicago/Seattle database 
of patients with developmental brain disorders (Lisdb, N>8000 subjects) using search 
terms for known SUBH as well as for potentially overlapping malformations including 
cortical dysplasia not otherwise specified, cortical infolding, schizencephaly especially 
rare familial forms, and transmantle malformations. After defining many different 
patterns of SUBH, we searched the other three MCD databases (Rotterdam, Florence, 
San Francisco) for patients with similar malformations. All patients were examined 
by, or referred for MRI review to one of the senior authors. Institutional review boards 
(IRBs) of Seattle Children’s Hospital, The University of Chicago, University of Minnesota, 
Erasmus University Medical Center, University of Florence, and University of Califor-
nia – San Francisco approved our inclusion of these patients in research studies.
We selected for review all subjects with any SUBH, defined as grey matter visible in 
at least one region at a level where only white matter would normally be expected, 
for whom sufficient imaging was available to perform a detailed review (e.g. subjects 
were excluded when only a few images or only computed tomography scans were 
available). We excluded subjects who had PNH with no subcortical component or only 
a few small immediately adjacent subcortical heterotopia, and those with subcortical 
band heterotopia.
Clinical data
We searched available clinical notes and referral information and, whenever pos-
sible, re-contacted their referring physicians and parents or guardians. We sought a 
minimum data set comprising age at first MRI (as a surrogate for age at presentation); 
neurological outcome especially development and cognitive functioning; behavioral 
abnormalities such as autism; presence and age of onset of seizures; and head circum-
ference (OFC). Data regarding pregnancy, other congenital anomalies, developmental 
milestones, type of seizures, relevant family history, and genetic testing were noted 
when available in our records.
Definitions
We use the terms subcortical malformation or subcortical heterotopia to include any 
MCD in which the most prominent and usually largest component is grey matter 
between the cortex and the lateral ventricles. In this context, this implies clusters of 
neurons located in an abnormal position within the subcortical white matter. Many 
SUBH contain cerebrospinal fluid (CSF) within a sulcus or cleft that clearly communi-
cates with extra-axial CSF. Others contain short, discontinuous and often curvilinear 
spaces with the same signal intensity as CSF. When the connection to extra-axial or 
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intraventricular CSF is absent or not easily identified, we will describe these as “CSF-
like” spaces. Several other descriptive terms are defined in Box 1.
Brain imaging
All patients selected for review underwent at least one T1-weighted or volumetric 
sequence and one T2-weighted sequence, and all underwent imaging in at least two 
planes. All available images were reviewed using a standardized approach by WBD and 
RO, with representative examples reviewed by all authors. We systematically assessed 
the location (bilateral symmetric or asymmetric, unilateral right or left; anterior-, 
central- or posterior-predominant, or diffuse; lobes affected), size including presence 
of mass effect on surrounding structures, morphology and general orientation (see 
Box 1), connection to the cortex and ventricular wall, and relationship to CSF spaces. 
Next, the imaging was scored for the presence and distribution of cortical malforma-
tions per se, PNH (only scored if clearly separated from SUBH), and any non-cortical 
brain malformations especially complete (ACC) and partial (pACC) agenesis of the 
corpus callosum; diffuse (CBLH) or vermis-predominant (CBVH) cerebellar hypoplasia, 
and Dandy Walker malformation (DWM).
Approach to classification
Our prior review of SUBH separated them into nodular (solid masses without CSF-like 
signal found in deep white matter), curvilinear (convoluted masses often containing 
CSF-like spaces and blood vessels within the central or peripheral white matter), and 
mixed heterotopia.16 We have now added many additional patterns of subcortical-
Box 1. Definitions of descriptive terms used for brain imaging
Columnar Vertical, narrow and generally cylindrical heterotopia that are usually transmantle
Curvilinear Thick convoluted and generally longitudinal heterotopia with CSF-like spaces and blood 
vessels coursing within the gray matter mass
Fan-like Generally radial heterotopia that appear narrow at or near the ventricular surface then fan 
out to become much wider at or near the cortex
Infolded Inward folding of an area of cerebral cortex containing gyri and sulci thereby forming a 
longitudinal space connected to the extra-axial space and situated within the solid cerebral 
tissue
Laminar Thin horizontal heterotopia, most of which are found in the deep white matter
Lobular Continuous masses of gray matter with small round projections on the periphery of the 
main tissue mass
Longitudinal Oriented from anterior to posterior, parallel to ventricular wall and cortex; also horizontal
Nodular Solid and often round masses of gray matter without adjacent CSF-like spaces; may be 
single or multiple and if multiple, separate or contiguous
Radial Oriented from ventricular wall outward to cortex, perpendicular to both; also vertical
Ribbon-like Thin longitudinal heterotopia that undulate in and out along their course
Transmantle Any subcortical malformation that extends from the ventricular wall to the cortex
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predominant MCD, including several types with areas of infolded cortex that include 
linear sulci with direct and obvious communication with the extra-axial space. We 
therefore chose to continue using the pattern of CSF-containing spaces as our first 
criterion for separating SUBH into those with (1) abnormally deep infolded sulci 
enclosing linear CSF-containing spaces that have direct and obvious communication 
with the extra-axial space, (2) short often curvilinear areas with CSF-like signal and little 
or less obvious communication with the extra-axial space, and (3) no CSF signal at all 
(solid SUBH). We also considered using location, orientation (longitudinal or radial) and 
shape (Box 1), contiguity with the cortex, and associated CNS malformations, but these 
proved to be highly variable and indeterminate in many subjects. We used a combina-
tion of these features as secondary criteria.
In order to establish a comprehensive classification, we searched for publications of 
SUBH subtypes in PubMed. We limited our search to the English language literature, 
with publication dates between January 1985 and December 2015, and used key 
words including “subcortical heterotopia”, “heterotopia AND brain”, “brain-in-brain”, and 
“aventriculy”. We also searched our own libraries and references of relevant publica-
tions for additional papers.
Statistical analysis
Analysis was performed using IBM SPSS Statistics software v21. Frequencies and 
percentages were calculated to compare groups. To test for Normal distribution, 
the Shapiro-Wilk test was used. To compare characteristics between groups, the Chi 
square test and Fisher’s exact test were used. The Kruskal–Wallis rank-sum was used to 
compare the age at presentation and age at seizure onset among groups. The non-
parametric Mann-Whitney U test was used to compare seizure onset with the bilateral 
presence of the SUBH. When information on a given feature was not available, the 
patient was excluded for analysis of that feature.
RESULTS
From 188 patients identified by database searches, we identified 107 individuals 
with subcortical malformations and sufficient imaging available for classification, 
including 65 from Chicago/Seattle, 18 from Florence, 10 from Rotterdam, and 14 from 
San Francisco. Among 95 individuals with sex recorded (54 males, 41 females), a mild 
skewing of the sex ratio was observed: 57% to 43% (Table 1).
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Clinical features
Clinical records were available for most subjects. The data are summarized in Table 1, 
with complete data listed in Supplementary Table 1. Selected individual clinical sum-
maries from each group are included in the Supplementary Clinical Reports section.
For 83 individuals, age at first MRI was recorded and ranged from 2 days to 32 years. 
Unsurprisingly, age was significantly skewed towards infancy and early childhood 
(mean 6.4 years, median 2.0 years, p= 1.5x10-10). A large majority of subjects were 
scanned during childhood (70/83, 84%), and more than half before age 4 years (49/83, 
59%). Data regarding development were available for 68 individuals and almost 
one-fifth (13/68, 19%) had normal development. The remainder had developmental 
and neurologic dysfunction consisting of early developmental delay, intellectual 
disability, learning difficulties, and spasticity. The severity varied from isolated motor or 
language delay to profound global intellectual disability with no major developmental 
milestones reached. Behavioral abnormalities were noted for 17 of 44 (39%) subjects 
with data available. Most patients had epilepsy (50/72; 69%) with the age of first 
seizure ranging from the neonatal period to 25 years but significantly skewed towards 
towards infancy and early childhood (mean 7.3 years, median 4.5 years, p<0.001). We 
were able to document epilepsy surgery in only one patient. Almost half (32/69; 48%) 
had a major extra-CNS malformation. The range of malformations was wide, and the 
eyes, limbs and genitourinary system were most commonly affected.
Imaging patterns
Brain imaging studies on all 107 patients were reviewed and classified based first on 
the presence and type of CSF spaces, and secondarily on other features, including 
morphology, location and the presence of other brain malformations. We defined four 
major groups of heterotopia and 14 subgroups (Table 2), which are further described 
below. The most common pattern by far was curvilinear SUBH (66/107; 62%).
For only a few patients, we did not have sufficient imaging to assess all brain structures 
(Supplementary Table 1). We found that in addition to SUBH, most patients had 
non-cortical brain malformations that included abnormalities of the corpus callosum 
(65/102, 64%), basal ganglia, thalami or both (44/104, 40%), and cerebellum, posterior 
fossa or both (47/106, 44%). The prevalence of basal ganglia/thalami abnormalities, 
cerebellar/posterior fossa abnormalities, and PNH differed significantly among groups 
(p= 2.591x10-7; p= 0.004; p=0.004, respectively). The group of all subjects with bilateral 
SUBH was significantly enriched for the presence of extra-CNS malformations (p=0.01), 
and also enriched, although non-significantly, for abnormal development (p= 0.09). 
Whether the SUBH were unilateral or bilateral did not influence the presence or age of 
onset of seizures.
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Groups
We observed no significant differences between groups regarding age at first MRI, 
age of seizure onset, development, behavioral abnormalities, presence of seizures, 
microcephaly or macrocephaly. Remarkably, all but one individual with normal 
development (13/14) had curvilinear SUBH (group 2a). Also, all subjects in group 4 
with bilateral complex SUBH had developmental delay and ID and this group had the 
highest percentage of extra-CNS malformations (72%).
1. Deeply infolded subcortical heterotopia with longitudinal CSF spaces
This group is characterized by (1) extension of two opposing cortices separated by 
CSF into the deep white matter well beyond the usual cortical-white matter boundary 
but in clear continuity with the overlying cortex, (2) mild thickening (5-10 mm) and 
irregularity of all or most of the infolded cortex consistent with polymicrogyria, (3) and 
clear connection of CSF spaces with overlying sulci and extra-axial space. While the CSF 
spaces lined by dysplastic cortex resemble the clefts observed in schizencephaly 22, 
they have a branching pattern typical of sulci and do not communicate with the lateral 
ventricles. When the deeply infolded SUBH extend all the way down to the ependymal 
surface, the SUBH can be seen bulging into the ventricle, as opposed to closed-lip 
schizencephaly – where a dimple is seen at the ventricular surface.23
We observed deeply infolded SUBH – parieto-occipital subtype in 10 individuals 
with infolding patterns of similar morphology and variable, posterior predominant, 
Table 2. Proposed classification of subcortical heterotopia
1. Deeply infolded subcortical heterotopia with longitudinal CSF spaces
a. Deeply infolded SUBH – parieto-occipital subtype 
b. Deeply infolded SUBH – parasagittal subtype 
c. Deeply infolded SUBH – other subtypes 
2. Curvilinear SUBH with CSF-like spaces
a. Curvilinear SUBH 
b. Diffuse curvilinear SUBH with interhemispheric cysts and agenesis of the corpus callosum 
3. Solid subcortical heterotopia  -  no CSF-like signal
a. Transmantle columnar SUBH 
b. Nodular SUBH in region of peritrigonal optic pathway 
c. Multinodular small SUBH, often anterior of frontal horns 
4. Subcortical heterotopia with bilateral complex patterns
a. Aventriculy with SUBH 
b. Brain-in-brain malformation 
c. Transmantle columnar and fan-like SUBH with clefts 
d. Ribbon-like SUBH (EML1) 
e. Mesial parasagittal SUBH (Chudley-McCullough syndrome) 
f. Complex chaotic SUBH 
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localization. The parietal and/or occipital regions were predominately affected, but the 
frontal and temporal lobe were sometimes involved as well (Fig. 1 LP97-007, LR12-324). 
1b LR08-049
1a LP97-007
1a LR12-324
1b LR12-429
Figure 1. Representative MRI images from individuals from group 1; deeply infolded SUBH. 
Each row depicts images from the same patient. First column: midline sagittal, second column: axial at 
the level of the basal ganglia (except LP97-007; axial), third column: axial, fourth column: coronal images 
(except LP97-007; axial). Deeply infolded SUBH was identified in LP97-007 and LR12-324 (parieto-occipital 
subtype), originating posteriorly in the perisylvian areas with an oblique orientation relative to the sagittal 
plane. Images from LR08-049 and LR12-429 (parasagittal subtype) show a highly similar pattern of bilat-
eral parasagittal deep infolded SUBH touching the ependyma. Both individuals are microcephalic (OFC -3 
SD and -5 SD, respectively). Other brain structures are relatively preserved.
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The infolding always involves the mesial parietal and occipital cortex, and in several 
subjects a strictly mesial connection was observed. In its most complete form, the 
SUBH extends from the mesial parietal and occipital region behind the splenium of the 
corpus callosum, around the occipital horn and trigone of the lateral ventricles, and to 
the posterior perisylvian region. Other brain structures were preserved or only mildly 
affected in most patients. Thinning or partial agenesis of the corpus callosum occurred, 
but none had complete agenesis; all had normal deep grey nuclei except one patient 
with globular-shaped thalami; and five had mild cerebellar abnormalities. This was 
previously classified as unilateral or bilateral parasagittal parieto-occipital PMG 24, and 
was identified in 11/328 individuals with polymicrogyria.25
In the parasagittal subtype, a continuous band of deeply infolded SUBH that 
resembles polymicrogyric cortex is seen. It is located parallel to the mid-sagittal plane, 
extending from anterior-lateral to posterior medial and deeply into the white matter 
touching the ventricular walls (Fig. 1 LR08-049, LR12-429). The SUBH is bilateral and 
highly symmetric in appearance and is best recognized in axial and coronal planes. 
Although abnormalities of the corpus callosum were observed, none of the six patients 
had complete agenesis of the corpus callosum. Of note, all patients had normal deep 
grey nuclei and a normal cerebellum. We were able to identify only one previous 
mention of this subtype: a single image from one of our patients (LR01-283) was 
presented as bilateral superior parasaggittal PMG, and defined as unilateral or bilateral 
‘bands’ of polymicrogyria lining abnormal lateral parasagittal sulci.25 We collected 
clinical data on all six patients with this subtype. They all presented with early motor 
delay; four developed spasticity, and one had a normal neurological exam at 10 years. 
Three had intellectual disability, and two were cognitively normal. Seizures that began 
during puberty were seen in three patients. The other three, without seizures, had 
not yet reached puberty. For three individuals, OFC data were available and all had 
microcephaly ranging from -3 SD to -5 SD. Interestingly, four out of six had a feature 
(twinning or jejunal atresia) which has been previously associated with schizencephaly, 
suggesting the possibility of a similar pathogenesis.26
In the remaining three patients with deep infolding (deeply infolded SUBH – other 
subtypes), SUBH occurred in a different location, but all involved the frontal lobes.
2. Curvilinear SUBH were present in 61 patients, forming the largest group in our 
cohort. These malformations are usually large, occupying one or more lobes, and the 
CSF-like spaces may be prominent or subtle (Fig. 2). The overlying cortex is abnormally 
thin with shallow sulci and the SUBH always connects to the overlying cortex in at least 
one, but usually in multiple, locations. Sulci extending abnormally deep into the white 
matter are sometimes seen, although extensive cortical malformations are uncommon. 
They may resemble some deeply infolded SUBH, but curvilinear SUBH have a more 
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complex morphology making it difficult to define continuity of the CSF-like spaces 
with extra-axial spaces. The name curvilinear subcortical heterotopia was previously 
proposed by one of the authors 16 and we consider this the best descriptive term 
to describe this group. The morphology is variable – often even within the same 
individual – and besides the curvilinear spaces can contain areas with nodular, laminar 
and/or lobular appearance. Any lobe can be affected either unilaterally or bilaterally. 
We found an equal distribution of unilateral and bilateral examples (31 vs. 30), but even 
with bilateral curvilinear SUBH the brain appears asymmetrically affected. Evidence of 
pressure on surrounding structures is often apparent (e.g. compression of the adjacent 
lateral ventricle or contralateral hemisphere). The affected hemisphere is usually 
smaller than the unaffected one. Also, either or both hemispheres may cross the 
midline. Ipsilateral and/or contralateral PNH are seen in more than two-thirds (70%) of 
patients. Abnormal configuration or even partial obliteration of the ipsilateral ventricle 
and basal ganglia and abnormalities of the corpus callosum were also frequently 
observed (40% and 62%). We identified abnormalities of the cerebellum and/or 
posterior fossa in 36% of patients.
We identified five patients with a distinct subtype of diffuse curvilinear SUBH 
combined with multiple interhemispheric cysts and agenesis of the corpus 
callosum (Fig. 2, LR03-395). This pattern was reported in three individuals from a 
series of patients with callosal agenesis, and was designated as “callosal agenesis with 
cyst type 2c”.27 Another patient was reported to have mismatch-repair deficiency due 
to a biallelic MLH1 mutation.28 This suggests that this subtype represents a specific, 
recurrent pattern.
3. Solid subcortical heterotopia
Solid SUBH contain no CSF-like spaces. We reserve the term transmantle columnar 
SUBH for a small distinct band or wedge of gray matter perpendicular to the cortex 
that extends from the ependyma to the cortex (Fig. 3 LR08-415). These may be difficult 
to distinguish from closed lip schizencephaly, the primary distinction being the 
absence of a pia-ependymal cleft and dimple at the ventricular wall.23 Also, transmantle 
columnar SUBH should not be confused with transmantle dysplasia (bottom-of-the-
sulcus dysplasia) or sign associated with focal cortical dysplasia (FCD type IIb), which is 
a streak of abnormal signal intensity within the white matter.23
In five patients including two sisters, we encountered solid nodular SUBH situated 
in the region of the peritrigonal optic pathway posterior to the deep grey nuclei 
(bilateral in 4 of the 5) (Fig. 3 LR07-197, GM-R06). All had borderline to profound (-11 
SD) microcephaly. We found previous mention of three microcephalic patients with 
similar SUBH, two of whom were sibling.29,30
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2a LR05-282
2a LR01-079
2a LR13-408
2b LR03-395
Figure 2. Representative MRI images from group 2; curvilinear SUBH. 
Each row depicts images from the same patient. First column: midline sagittal, second column: axial at 
the level of the basal ganglia, third column: axial, fourth column: upper three coronal, lower two axial. 
Images from individual LR05-282 show extensive giant SUBH with curvilinear CSF-like spaces in the right 
hemisphere. The SUBH touches both the overlying cortex and the ependymal in several occasions. The 
left hemisphere crosses the midline. The right frontal horn and right caudate nucleus cannot be identified, 
instead a large heterotopic mass is seen. LR01-079: Curvilenar with subtle CSF-like spaces in the right 
hemisphere. The affected hemisphere is notably smaller, although there is a local mass effect, also the 
lateral ventricle and basal ganglia are not identified. Note ACC, brainstem hypoplasia and severe CBLH. 
LR13-408: extensive involvement of both hemispheres with both curvilinear SUBH connecting to the 
cortex and multiple nodular SUBH. LR03-395: bilateral asymmetric SUBH with IHEM. Note also ACC and 
hypoplastic pons and cerebellar vermis. CSF-like spaces are clearly identifiable in the third column.
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3b LR07-197
TUBB
3b GM-R06
CENPJ
3a LR08-415
Figure 3. Representative MRI images from individuals from group 3; Solid SUBH. 
Each row depicts images from the same patient. First column: midline sagittal, second column: axial at 
the level of the basal ganglia, third column: axial and coronal (GM-R06), fourth row: axial (LR08-415) and 
coronal images. LR08-415: Transmantle columnar SUBH in the left frontal lobe. The overlying cortex is 
dysplastic, the lateral ventricles are mildly enlarged. LR07-197 has bilateral, left larger than right, peritri-
gonal optic pathway SUBH (2nd and 4th column). The genu of the corpus callosum and brainstem are 
hypoplastic (1st column), the cerebellum is dysplastic (3rd column). This individual was found to have a 
de novo TUBB mutation c.860C>G (p.Pro287Arg). GM-R06 has bilateral peritrigonal optic pathway SUBH 
(2nd-4th column). She also has profound microcephaly (-11 SD). She is compound heterozygous for CENPJ 
mutations c.1805_1808del (p.Glu602fs) and c.289dupA (p.Thr97fs).
Figure 4 (opposite page). Representative MRI images from individuals from group 4; microventriculy 
with SUBH and brain-in-brain malformation. 
Each row depicts images from the same patient. First column: midline sagittal, second column: axial at 
the level of the basal ganglia, third column: axial and coronal, fourth column: axial images of cerebellum 
(except LR00-237: coronal). All had absent or barely identifiable lateral ventricles (LV). The SUBH resemble 
disorganized sulci deeply infiltrating the white matter. LR00-237, LR05-320, and LR13-329 have high oc-
cipital encephalocele, LR05-320 and LR13-202 have turricephaly with high parietal interhemispheric cyst 
(1st column). Non-separated thalami are suspected in all and in addition, alobar holoprosencephaly in 
LR00-237 and middle interhemispheric fusion in LR99-240 (3rd column). The cerebellum is hypoplastic in 
all, and severe dysplastic in all but LR13-329 (4th column for all, except LR00-237, 2nd column).
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4b LR13-202
1a LP98-117
1a LR13-2604b LP99-240
4b LR00-237
4a LR05-320
4a LR13-329
Figure 4. Representative MRI images from individuals from group 4; microventriculy with SUBH and 
brain-in-brain malformation. 
52 Chapter 2.1
Multinodular small SUBH anterior to the frontal horns can sometimes be identified 
in young babies, from birth until 2 months postnatally. These may represent residual 
neurons from the germinal zones, and are most likely a normal variant.
4. Subcortical heterotopia with bilateral complex patterns
The group microventriculy with SUBH is based on two patients with a distinctive 
complex brain malformation consisting of SUBH, absent or very small lateral ventricles, 
unseparated thalami, and encephalocele (Fig. 4 LR05-320, LR13-329). The SUBH 
consists of seemingly disorganized deeply infolded fissures lined with dysplastic 
cortex, combined with vessels, white matter, and CSF. Both patients also had cerebellar 
dysplasia. Absence of the ventricles (aventriculy) in combination with absent separa-
tion of midline structures was first described by Garfinkle in 1996.31 Since then, only 
four additional patients have been reported.32-35 SUBH were present in at least three of 
these patients.
The above group shows considerable overlap with the brain-in-brain malformation, 
originally defined as a midline mass of dysplastic cortex with holoprosencephalic 
features.36 We classified four patients with a midline mass of grey and white matter 
signal intensity as brain-in-brain malformation. Two of these patients also had 
microventriculy and three had continuity of cerebral structures across the midline (the 
middle interhemispheric fusion subtype of holoprosencephaly, unseparated thalami 
and/or mesencephalosynapsis) (Fig. 4 LR00-237, LP99-240, LR13-202, LR15-229). 
Another key feature was an encephalocele or turricephaly with high parietal interhemi-
spheric cysts. Also, CSF-like spaces and blood vessels may be present. We identified 
one patient who had SUBH and a midline mass with signal intensities suggesting a 
Figure 5 (opposite page). Representative MRI images from individuals from group 4; Transmantle 
columnar and fan-like SUBH with clefts, ribbon-like SUBH, Chudley-McCullough syndrome and com-
plex chaotic SUBH.
Each row depicts images from the same patient. First column: midline sagittal, second column: axial, third 
column: axial (except LR01-016a2, coronal), fourth column: axial images of cerebellum (LR03-112 and 
LR03-246), axial image T1-weighted (vs. T2-weighted in 3rd column, LP98-117), coronal images (LR01-
016a2, LR13-260, LR11-273, LR11-450). LR01-016a2 has transmantle columnar and fan-like SUBH (right 
hemisphere) and bilateral clefts. LP98-117 and LR13-260 both show a bilateral single undulating ribbon-
like SUBH throughout the white matter. The cortex is polymicrogyria-like. Both individuals are megalen-
cephalic. The lateral ventricles are enlarged in LP98-117, LR13-260 received a VP-drain shortly after birth 
for treatment of hydrocephalus. A homozygous EML1 mutation was identified in LR13-260. LR03-112 and 
LR03-246 have longitudinal SUBH in the parasagittal plane, on more upwards cuts the SUBH connects 
to the highly dysplastic mesial cortex (not shown). The cerebellum is dysplastic (4th column). Note also 
enlarged lateral ventricles and midline cyst in LR03-246 (2nd column). This pattern is associated with 
Chudley-McCullough syndrome. LR11-273 and LR11-450 show complex chaotic SUBH. Both show a mixed 
morphology of longitudinal undulating SUBH (especially in LR11-273) and smaller, more nodular shaped 
SUBH. Multiple CSF-like spaces can be identified. In LR11-450, lower cuts showed absence of SUBH (shown 
in 2nd column). The cortex is highly dysplastic in LR11-450, but relatively preserved in LR11-450.
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4e LR03-112
4e LR03-246
4d LP98-117
4d LR13-260
4f LR11-450
4f LR11-273
4c LR01-016a2
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mix of grey and white matter, but with normal midline structures. This patient may 
possibly reflect the milder end of the spectrum. In hindsight, the patient described by 
Garfinkle also shows a midline mass and could possibly be classified as brain-in-brain 
malformation.31 Shaw & Alvord published pathology studies of three patients with 
“global cerebral dysplasia” which in hindsight could also be classified as brain-in-brain 
malformations.35 These patients had a large central mass without distinguishable deep 
grey nuclei. The ventricular system of a fetal case was filled with disorganized germinal 
cells that the authors presumed to be dislocated from the subependymal matrix.35 The 
cause of these rare and complex malformations remains to be determined.
We observed two patients with solid transmantle columnar and fan-like SUBH in 
addition to clefts typical of schizencephaly (Fig. 5 LR01-016a2) In both, two or more 
distinct transmantle SUBH or clefts were seen in each hemisphere. One child had a 
sibling with bilateral severe open-lip schizencephaly and was previously published 
as a rare form of familial schizencephaly.37 Ribbon-like SUBH (EML1). Two patients 
had recognizable SUBH with a ribbon-like appearance that consists of a bilateral and 
symmetric single continuous, undulating ribbon-like layer of gray matter located in 
the frontal, parietal and occipital lobes (Fig. 5 LP98-117, LR13-260). High-resolution 
imaging revealed a continuous thick undulating layer of gray matter with no or little 
connection to the overlying cortex. The absence of veins or CSF-like spaces distinguish-
es these malformations from those in Groups 1 and 2. The cortex appears diffusely thin 
and dysplastic with shallow sulci. Other features include prenatal-onset ventriculo-
megaly or hydrocephalus, megalencephaly, and agenesis of the corpus callosum. This 
is a rare malformation and only two families have been previously published, including 
a patient from this study, LR13-260.38 In both families EML1 mutations following an 
autosomal recessive inheritance pattern were identified. 38
Mesial parasagittal SUBH (Chudley-McCullough). Two patients were found to have a 
distinct pattern of SUBH extending along the mesial side of the lateral ventricles, with 
direct connection to mesial PMG-like cortex at the anterior and posterior limits of the 
heterotopia (Fig. 5 LR03-112, LR03-246). A separate SUBH of similar morphology was 
present in the temporal lobes. Both also had dysmorphic cerebellar folia and arachnoid 
cysts. This same pattern has been reported in multiple patients with Chudley-
McCullough syndrome associated with mutations of the GPSM2 gene.39,40
Complex chaotic SUBH. This group includes two patients with a complex subcortical 
malformation with diffuse and bilateral involvement. The key features consist of both 
gyriform and nodular SUBH along with areas of CSF “inclusions” lined by grey matter 
(Fig. 5 LR11-273, LR11-450). Multiple SUBH connect to the cortex. These two patients 
may either represent distinct entities, or represent more extensive forms of the 
curvilinear SUBH.
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Etiology
According to the available medical records, the etiology was unknown in the 
majority of patients. No pathogenic chromosomal aberrations were noted, although 
it is unknown in how many patients karyotyping or chromosome microarray was 
performed. In a few patients, single gene mutations were reported. In one patient 
with nodular SUBH in the region of the peritrigonal optic pathway (3b) a de novo TUBB 
mutation was identified, and in another patient compound heterozygous mutations 
in CENPJ. One patient with ribbon-like SUBH (4c) had a homozygous EML1 mutation.38 
No DNA was available to test the second patient in this subgroup. An OFD1 mutation 
was found in a patient with diffuse SUBH with interhemispheric cysts and agenesis of 
the corpus callosum (2b).41 A summary of genes associated with SUBH in this and in 
previous studies is shown in Table 3.
DISCUSSION
We have described the imaging patterns and, when available, the associated clinical 
features of 107 patients with SUBH. We classified these patients into 14 distinct MCD 
Table 3. Genes associated with subcortical heterotopia
Gene
Protein function
Inheritance SUBH subtype, other imaging features Reference
TUBB
microtubule component
de novo 
dominant
In optic radiation tract, primary microcephaly Breuss et al. 2012, 
this study
CENPJ
regulation of microtubule 
assembly and nucleation
autosomal 
recessive
In optic radiation tract, primary microcephaly This study
KATNB1
microtubule disassembly 
at centrosomes
autosomal 
recessive
In optic radiation tract, primary microcephaly Mishra-Gorur et 
al. 2014
GPSM2
 activation of G proteins, 
spindle pole orientation
autosomal 
recessive
mesial longitudinal in Chudley-McCullough 
syndrome, fronto-mesial PMG, partial ACC, 
ventriculomegaly, cerebellar dysplasia, 
arachnoid cysts
Doherty et al. 
2012
EML1
microtubule-binding 
protein
autosomal 
recessive
ribbon-like with HYD, MEG, and ACC Kielar et al. 2014, 
this study
BRCA1
DNA damage response, 
centrosome/ mitotic 
function
?type 2 
mosaicism
Giant SUBH Eccles et al. 2003 
& 2005
MLH1
DNA mismatch repair
?autosomal 
recessive
Giant SUBH, ACC, and interhemispheric cysts Baas et al. 2013
OFD1
regulation of centriole 
length, ciliogenesis
X-linked 
dominant
Giant SUBH, PMG, ACC, intracerebral cysts, 
cerebellar and brainstem abnormalities, 
porencephaly
Bisschoff et al. 
2013; Del Giudice 
et al. 2014
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groups that predominately involve the subcortical regions, among which we define 
several new and rarely described subtypes. From prior experience, we had expected 
to find mostly localized focal-segmental SUBH, but also found numerous bilateral and 
diffuse forms.
As few pathological descriptions have appeared and for only few subtypes the underly-
ing causes have been identified, this classification system is necessarily imaging-based. 
In our prior comprehensive MCD classification, MCD were classified in a framework 
of three main groups of malformations, namely those due (I) to abnormal neuronal 
proliferation, (II) to abnormal neuronal migration, or (III) to abnormal postmigrational 
development.1 SUBH were classified in group II. It is arguable that other mechanisms 
play a role in its etiology, e.g. proliferation in abnormal locations, which has been 
suggested as a cause of the ribbon-like SUBH 38, or abnormal organization of the 
cortex, as several SUBH resemble abnormally deep infolded cortex. Therefore, for the 
SUBH, we chose not to use this framework but instead defined the group of SUBH by 
its anatomical location only. We have included genetic data when available, but so far 
this applies only to a few very rare subtypes of SUBH.
Previous studies focused mainly on neurological symptoms associated with the SUBH. 
As expected, abnormal cognitive and/or motor development and epilepsy were 
present in the majority of patients. We also observed a high frequency of extra-CNS 
malformations (46%), with eyes, limbs and genitourinary tract being most frequently 
affected. We therefore recommend, in addition to a careful neurological exam, a full 
physical examination focusing on congenital anomalies, an ophthalmological exam 
and renal ultrasound in all patients with SUBH.
Curvilinear SUBH
By far the largest group in our cohort consisted of curvilinear SUBH with CSF-like 
spaces (62%). In previous reports, several different terms have been used for this group 
including giant subcortical nodular heterotopia 10, focal subcortical heterotopia 23,42, 
massive heterotopia 11, subcortical nodular heterotopia 43, and curvilinear transmantle 
heterotopia 1. We discourage the use of any secondary descriptive terms for the group 
as a whole - such as giant, large, focal, etc. – as the size and location vary considerably 
among patients with otherwise similar morphology. When assessed on a single plane, 
curvilinear heterotopia may have a multinodular appearance. However, high-resolution 
images in multiple planes show the curvilinear morphology. A few additional nodules 
may be seen surrounding the main body of the curvilinear SUBH, but these should be 
distinguished from the isolated solid nodules placed in group 3.
The clinical spectrum regarding development was very broad. Thirteen individuals 
within this group had normal cognitive and motor development, which seems 
remarkable judging from the size and extent of the malformation. Reports on this 
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malformation mostly involved single patient reports or small series.10,12,13,15,17,43 The 
largest reported series described imaging and clinical features of 24 patients; all had 
seizures and almost all had pyramidal signs, mostly contralateral to the brain lesion.16 
No correlation between clinical outcome and radiological features was found in this 
published study. Another report compared nine patients with PNH only to nine other 
patients with both PNH and unilateral SUBH.43 The latter group had lower average IQ 
scores and higher incidence of developmental delay and neurological signs compared 
to the PNH only group. In contrast to previous reports, we did not find an excess of 
subjects with unilateral curvilinear SUBH.16,17,43 We cannot explain this difference, other 
than that the curvilinear SUBH usually affects the brain asymmetrically and subtle 
involvement of the contralateral hemisphere could be overlooked.
Etiology
It is striking that no syndrome or etiological diagnosis was noted for any patient with 
curvilinear SUBH, and we did not encounter any sibling recurrences. Based on incom-
plete data, two mechanisms have limited support. The first is a genetic etiology, most 
likely a postzygotic or mosaic mutation. The asymmetric and unilateral forms meet 
criteria for mosaicism 44, a mechanism already demonstrated for several other cortical 
malformations.45-47 Two unrelated patients have been reported with germline BRCA1 
mutations and SUBH, leading the authors to propose a postzygotic, somatic mutation 
on the second allele as a cause for the brain malformation.42,48 An exogenic cause, 
e.g. vascular disruptive or infectious, remains another possibility. In our cohort, one 
individual had an absent right internal carotid artery. In addition, 2 of 61 patients had 
a history of twinning, and another had absence of an arm. A vascular disruptive cause 
has also been suggested in other reports based on prenatal history of twinning, near 
miscarriage or trauma in patients with curvilinear SUBH. Further, both of the BRCA1 
patients with SUBH were one of twins.11,12,14,42,48 However, from these small numbers of 
patients, no definitive conclusions may be drawn regarding a vascular disruptive cause.
We identified a subgroup of curvilinear SUBH with interhemispheric cysts and corpus 
callosum agenesis. One patient in this subgroup was diagnosed with oro-facial-digital 
syndrome type 1 (OFD1, OMIM #311300). In OFD1 patients, brain malformations 
are frequent, including complex MCD with striking infolding, SUBH and PNH and 
abnormalities of the corpus callosum, interhemispheric cysts, ventriculomegaly, and 
cerebellar vermis abnormalities.41,49 OFD1 can be diagnosed on the basis of recogniz-
able clinical features, especially oral findings (bifid tongue, tongue hamartomas, teeth 
abnormalities, oral frenulae, (pseudo)cleft of the upper lip) and is caused by mutations 
in the X-linked OFD1 gene. A syndrome to consider in females with SUBH and infantile 
spasms is Aicardi syndrome. In addition, patients have chorioretinal lacunae and 
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complex brain malformations with deficiency of the falx cerebri, subependymal 
heterotopia and polymicrogyria.27,50 The etiology of Aicardi syndrome is unknown.
We found strong evidence for a disruptive pathogenesis in the group of deeply 
infolded SUBH. Four of six patients from the parasagittal subtype had a feature 
(twinning or jejunal atresia) which has been previously associated with schizencephaly, 
suggesting a similar pathogenesis.26 We had less prenatal data on the larger parieto-
occipital subgroup, but the records of one patient noted a fetus papyraceus and in 
another heavy maternal vaginal bleeding either just before or early in the pregnancy.
Microtubule defects in rare bilateral forms
Several genes have been associated with rare forms of bilateral SUBH (table 3). Due to 
the high recurrence risk in autosomal recessive disorders, recognizing these groups is 
of high importance. All of these SUBH are bilateral and solid, and either microcephaly 
or megalencephaly are frequently observed in these patients. Interestingly, several 
of these genes can be associated to the mitotic spindle and microtubules. This is not 
surprising because both primary microcephalies as well as multiple MCD with complex 
brain malformations have been linked to similar mechanisms.51,52 The CENPJ gene 
encodes a centrosomal protein with tubulin-dimer binding activity.53 KATNB1 forms 
with KATNA1 the microtubule-severing protein katanin which localizes to the centro-
somes.30 TUBB encodes a beta-tubulin, and beta-tubulins together with alpha-tubulins 
form the core of the microtubules.29 These findings suggest that defects in microtubule 
formation underlie solid SUBH in the peritrigonal optic pathway. Mutations in another 
microtubule-associated gene, EML1, cause an extensive ribbon-like SUBH, combined 
with agenesis of the corpus callosum, dysplastic cortex (PMG-like), hydrocephalus and 
megalencephaly.38 The Eml1-deficient mouse (HeCo mouse) develops similar brain 
abnormalities and at the microscopic level shows ectopic neuronal progenitors and 
oblique mitotic spindle orientation.38 Patients with Chudley-McCollough syndrome 
have a distinct bilateral form of SUBH. This syndrome is caused by mutations in GPSM2, 
a gene which is associated with cell polarity and mitotic spindle orientation. 39,54
CONCLUSIONS
This study represents an attempt to increase awareness of the frequency and complex-
ity of the heterogeneous group of malformations known as subcortical heterotopia 
(SUBH). Increased awareness of the imaging patterns of SUBH and its subtypes will 
lead to better recognition of the patients and stimulate scientific research regarding 
the causes, manifestations, and eventually therapies for this complex malformation. 
Although this study has contributed substantial knowledge to the field, it is striking 
that the causative mechanism is unknown for the great majority of the patients. 
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We have shown that the etiology is heterogeneous with both genetic and possibly 
prenatal disruptive factors.
Elucidating the pathomechanisms underlying SUBH should be the next crucial step 
in the understanding of these disorders and will enable the development of targeted 
therapies. As this classification is based on imaging appearance, it will probably need 
revision as underlying genes and pathways are discovered. However, this classification 
will not just be useful to the clinician, but also to the genetic researcher, as correct 
phenotyping is crucial when interpreting genetic variants.
Supplementary Table 1 is available online at http://cluster15.erasmusmc.nl/oegema. 
Username oegema, password renske.
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SUPPLEMENTARY CLINICAL REPORTS
Deeply infolded SUBH
LP97-007 presented with developmental delay and right hemiparesis around 6 months 
of age. She was born after an uncomplicated pregnancy at 42 GW. Birth weight was 
3485 grams, Apgar scores were unremarkable and OFC “normal”. She spoke her first 
words at 9 months. She was able to crawl at 13 months and stand alone at 18 months. 
She has adequate social skills and speech development and has not had seizures up to 
22 months. Height and weight are normal. She had mild to moderate spasticity of the 
right limbs. Family history was negative for brain malformations and brain MRI in the 
mother was normal.
LR01-283a1 & a2. These identical twin girls were born prematurely (35-36 GW) after an 
uneventful pregnancy. For LR01-283a2 neonatal asphyxia was reported in her medical 
records, without further detail. Motor milestones were delayed, she walked unassisted 
at age three and had mild mental delay. She spoke first words at age 3. On examination 
she had mild spastic paraparesis (more severe on the left), motor clumsiness in fine 
motor skills, and a bilateral deficit of stereognosis. Wechsler intelligene scale (age 33) 
showed IQ of 68. At age 11 years, she had a first seizure, focal somatosensitive involv-
ing the left hand. Since the age of 17 she suffers from two types of seizures 1) impaired 
awareness with forced grasping of objects, and 2) hypertonic extension of the left leg 
causing falling to the ground. The seizures occur in clusters, usually during menstrua-
tions, and are drug-resistant. EEG showed bilateral discharges.
Her sister, LR01-283a1, also showed early developmental delay. She walked indepen-
dently at 4 years of age and spoke her first word at 3. She has short stature, scoliosis, 
lumbar hyperlordosis, an asymmetric spastic paraparesis (more severe on the right 
side), and bilateral deficit of stereognosis. Wechsler intelligence scale (33 years) showed 
IQ of 59 (VIQ 58 and PIQ 67). Her first seizure occurred at age 17 years. The seizures 
are manifested with a feeling of unfamiliarity, loss of contact, eye and head rotation 
towards the right, oral and hand automatisms. Occasionally a seizure is followed by 
slow falling to the ground. She has many seizures per day, intercalated with seizure-
free intervals of a few days. EEG showed bilateral temporal foci. Lumbar spine X-ray 
showed the presence of 4 lumbar vertebral bodies, and schisis of the posterior laminae 
of S1.
LR09-150 was born at 40 GW, birth weight 3827 grams, length 53.3 inch. She experi-
enced complex partial seizures at 2 months, rapidly evolving to infantile spasms. At 19 
months she continues to have spasms and tonic seizures every couple of days despite 
AED. She has developmental delay, starting rolling at 16 months, and is not sitting 
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or standing at 19 months. At 6 months, her height is at p25, and weight >p95. On 
examination she has mild hypotonia, plagiocephaly, and mild facial dysmorphism with 
synophrys, short palpebral fissures, hypertelorism and poorly formed philtrum. She has 
a right optic nerve coloboma.
Curvilinear SUBH
LR02-038. She has bilateral iris coloboma, right chorioretinal coloboma, mild dys-
morphic features (small chin, upturned nose with hypoplastic alae nasi, asymmetric 
narrow palpebral fissures, prominent ears), and right-sided subtle thumb hypoplasia. 
Echocardiogram at 2 months showed partial anomalous pulmonary venous return 
and patent foramen ovale. Torticollis at 4 months prompted MRI studies. She showed a 
mild motor delay (rolling at 6 moths, sitting supported at 7 months) but there were no 
cognitive concerns at 13 months. At 6.5 years, she is in general good health, has fluent 
speech, and uses miralax for constipation. She has not had seizures, she has occupa-
tional, speech and physical therapy. On neurological examination she had symmetric 
tendon reflexes with Babinski sign on the left, some difficulty with toe walking and 
intact coordination. Height, weight and FC fall within normal limits. No hearing loss, 
normal skeletal survey and abdominal ultrasound. She has normal female karyotype 
and normal FISH 22q11 results.
LR01-079. An intracranial cyst was noted on prenatal ultrasounds and confirmed after 
birth. 2 VP-drains were placed, one in posterior fossa cyst and one in a 3rd ventricle cyst. 
He had transient hypothyroidism. He has developmental delay, and at 2 years, he can 
arm craw but not sit up. He speaks several words and some two-word sentences. His 
failure to thrive with both weight and height <p3, improved on a high-caloric diet. He 
started walking with support at 3 years (at 4 years still using a walker) and speaks short 
sentences at this age. Facial features include a frontal upsweep, prominent forehead, 
hypertelorism, low nasal bridge, mild epicanthal folds, downturned corners of the 
mouth. He is normocephalic (p50). He has strabismus and myopia. He underwent 
surgery for hip dislocation at 3.5 years. His seizures started before 2 years and are well 
controlled with lamictal. Karyotyping and FISH 17p studies showed normal results.
LR11-239 was born to a healthy, 21-year old woman at 36 GW after a spontaneous, 
uncomplicated delivery. A 19 GW ultrasound was normal. The mother was diagnosed 
with hypertension at 31 GW. His BW was 7 pounds, 1 ounce. He received 3 days of 
phototherapy due to neonatal jaundice. He was admitted for GI reflux and hyperten-
sion at 5 weeks, and bilateral kidney cysts were noted on ultrasound. At age 2, he has 
global developmental delay, slight hypotonia and non-dysmorphic facies. He walked 
independently at 2.5 years. At 3 years, he is a clumsy walker, has no pencil grip, wears 
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insoles for his inward posture of the feet and has a significant language delay. He had 
brisk reflexes and mild hypotonia. Karyotype, microarray and extensive metabolic 
investigations were normal.
LR06-375. Prenatal ultrasound at 32 GW showed ventriculomegaly, subsequent MRI 
showed ACC, decreased WM and an arachnoid cyst. After birth, brain imaging showed 
several midline cysts and at surgery for fenestration at least five major and several 
smaller cysts were identified. Due to growth of several cysts at 5 months he underwent 
again craniotomy and fenestration. At 13 months he is crawling, pulling himself up, 
take assisted steps, has pincer grasp, can drink from a straw and is babbling and saying 
mama. He has had a single episode of stiffening and unresponsiveness. He showed left 
hand preference but used both hands. His weight was at p50-p75, height p10-p25 and 
OFC p25. Neurological exam was grossly normal.
LR04-376. Prenatal ultrasound at 25 GW showed enlarged ventricles and an irregular 
fetal heart rate. He was delivered at 41 GW by cesarean section due to large head 
size. BW was 4876 grams, length 56 cm. An occipital encephalocele was noted, two 
VP-shunts were placed after birth one in the posterior fossa cyst and in the enlarged 
ventricles. He was intubated neonatally due to recurrent apnea with oxygen need. 
Feeding difficulties necessitated tube feeding. Seizures started in the first days of life 
and were difficult to control. At age 3 years he experienced multiple seizure types. 
He had severe developmental delay with no major milestones reached at 3.5 years 
and showed limited interaction with the environment. Physical examination showed 
a microcephalic boy with brachyplagiocephaly. He has clouded cornea due to an 
inability to close his eyes early in life. His facial profile is flat, with arched eyebrows, 
narrow palpebral fissures, a small mouth, peg shaped teeth, transverse palmar creases. 
He has radio-ulnar synostosis, cutaneous syndactyly of the 4th and 5th finger, a broad, 
possibly duplicated hallux on the left and sandal gap on the right. He has truncal 
hypotonia with spastic tetraplegia. He passed away at age 7 years.
Solid SUBH in peritrigonal optic pathway
LR07-197 is the first child of healthy, non-consanguineous parents of Turkish descent. 
On prenatal ultrasound oligohydramnios, and IUGR with small head size were noted. 
She was born at 39 weeks by uncomplicated vaginal delivery. Birth weight was 2930 
grams and OFC 31.3 cm. Postnatally, edema of the hands, feet and eyelids were noted. 
Turner syndrome was excluded by chromosome studies. Increased muscle tone and 
feeding difficulties occurred in infancy. Around 9 months she was diagnosed with 
global developmental delay and spastic quadriparesis. She presented with recur-
rent apnoeic episodes at age 3 years, and EEG showed left occipital epileptiforme 
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discharges. Seizures responded well to AED. She has mild dysmorphic features with 
asymmetry of the face and strabismus. Lymphedema of both legs and the right arm 
persisted causing recurrent skin infections (erysipelas). At age 13 she was diagnosed 
with scoliosis. Her height and OFC are at -3 SD.
Complex bilateral SUBH
Ribbon-like subcortical heterotopia
LR13-260 was born at 33 3/7 GW by caesarean section performed because of progres-
sive hydrocephalus on ultrasound examinations. A VP-drain was placed after birth. At 
age 6 years he has profound ID and is wheelchair bound. He has a responsive smile 
and can roll over. He frequently aspirates on liquids and is unable to eat solid foods. 
He has short stature (-4 SD) and is macrocephalic (+3.3 SD). He has severe cerebral 
visual impairment with absence of visual tracking. EEG age 7, when taking keppra and 
valproic acid, showed severe epileptic encephalopathy and continuous multifocal 
epileptic discharges and frequent electrodecremental events with accompanied by 
tonic seizures.
Brain-in-brain
LP99-240 was born at 35 weeks by cesarean section. A VP shunt was placed after birth. 
Seizures started after birth. An encephalocele was repaired and VP-shunt placed at 5 
months. He was diagnosed with craniofacial disproportion and underwent cranial vault 
expansion and cranioplasty at 11 months. At 4 years he has “focal events” of horizontal 
eye nystagmus and unresponsiveness lasting ten to fifteen seconds, up to 100 a day. 
These events were not associated with abnormal EEG activity. He is on phenobarbital, 
Carbatrol, and Topamax. He is learning sign language and able to sign 4 words. He has 
spastic quadriparesis and is wheelchair bound. He is fed by a G-tube. He wears a back 
brace for scoliosis. He is extremely hypotonic and needs necks support, he is able to lift 
his arms and legs. He is smiling, alert and attentive. He has bilateral esotropia and slow 
pupil reactions. He is allergic to latex and multiple fruits.
LR00-237: Within a few weeks after birth, seizures started (rhythmic eye twitching, 
arching of head and back, jerking of arms, lasting 45sec to 3 min) over 30 a day. 
Examination at 4 weeks showed a microcephalic infant (weight 2.73 kg, OFC 28 cm, ICD 
2.0 cm, OCD 5 cm) with a low sloping forehead, high nasal bridge, upslanted palpebral 
fissures and 4x4x3.5 cm cephalocele at the posterior midline. No other facial anomalies 
(pictures in db). She had no interaction with the environment and moderate hypotonia. 
At 4 years she takes lamictal, keppra. She has mild scoliosis. She his hypotonic and has 
pseudobulbar palsy. Telomere FISH normal. At age 5, seizures frequency had increased 
to dozens a day, especially at night (under lamictal and keppra). She is allergic to 
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phenobarbital and penicillin. Weight 20.9 kg, height 96.5 cm, OFC 40.5 cm. She has 
clonus throughout and fisted hands.
LR13-202: A prenatal ultrasound showed enlarged ventricles and he was diagnosed 
with hydrocephalus after birth and VP-shunt was placed. He started having seizures in 
the first weeks, tonic with bending of the arms and drawing the hands in front of the 
chest, lasting 1-2 minutes. These seizures stopped at 8 months. Around 3 years, shortly 
after a shunt revision, he started having partial seizures, mostly involving the left arm, 
but sometimes spreading to a generalized seizures, and also had absence seizures. 
At age 11, he still has these and they have been difficult to control. He is hypotonic 
with spastic quadriplegia, has difficulty keeping his head up and is mostly wheelchair 
bound, although he can stand and take several steps with support. He is a generally 
happy boy who vocalizes and interacts with his environment. He hears well. His eye 
movements are limited in both vertical and horizontal gaze, and he has decreased 
peripheral vision. He has no abnormalities of the retina or optic nerve (according to 
parents). He has a turricephalic head shape with a soft mass on the top of his skull, 
covered by an epidermal nevus and a dark lock of hair. He had left-sided temporal 
alopecia, unclear whether this was congenital or have an extrinsic cause (e.g. caused by 
a skin infection and/or rubbing of the head). He has small hands, brachydactyly of the 
toes with a cutaneous 2-3 syndactyly.
Complex chaotic SUBH
LR11-273: Pregnancy history was significant for herpes simplex and valacyclovir 
exposure. He was born at 39 GW, Apgar scores 8/9, BW 3035 grams (p40-p50). He 
was referred for multiple congenital anomalies and respiratory distress after birth, 
including a left pelvic kidney and bilateral hand anomalies consisting on the left of 
a hypoplastic thumb and 2nd and 5th finger, and on the right an absent thumb, and 
radioulnar synostosis with short radius. He had a stridor due to laryngomalacia. He was 
later noted to have a single central incisor, and submucosal cleft palate. At 8 months he 
has a mild global developmental delay, mild limb hypertonia and is able to sit without 
support and roll over. His weight is p30, height p20 and OFC 43.5 cm (-1 SD). At 14 
months he was babbling and able to say mama.
no increased chromosomal breaks after mitomycin C or DEB treatment in blood cells. 
Sequencing and MLPA of SHH, SIX3, TGIF, and ZIC2 normal. SNP array showed 420kb 
deletion of 16q23.1 (bp75,823,175-76,243,191 HGB 36, containing the ADAMST18 
gene). Parental studies were pending.
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ABSTRACT
Mutations in alpha- and beta-tubulins are increasingly recognised as a major cause 
of malformations of cortical development (MCD), typically lissencephaly, pachygyria 
and polymicrogyria; however, sequencing tubulin genes in large cohorts of MCD 
patients has detected tubulin mutations in only 1-13%. We identified patients with a 
highly-characteristic cerebellar dysplasia but without the lissencephaly, pachygyria 
and polymicrogyria typically associated with tubulin mutations. Remarkably, in 7 of 
9 patients (78%), targeted sequencing revealed mutations in three different tubulin 
genes (TUBA1A, TUBB2B, TUBB3), occurring de novo or inherited from a mosaic 
parent. Careful re-review of the cortical phenotype on brain imaging revealed only 
an irregular pattern of gyri and sulci, for which we propose the term tubulinopathy-
related dysgyria. Basal ganglia (100%) and brainstem dysplasia (80%) were common 
features. Based on in silico structural predictions, the mutations affect amino acids 
in diverse regions of the alpha/beta-tubulin heterodimer, including the nucleotide 
binding pocket. Cell-based assays of tubulin dynamics reveal various effects of the 
mutations on incorporation into microtubules: TUBB3 p.Glu288Lys and p.Pro357Leu 
do not incorporate into microtubules at all, while TUBB2B p.Gly13Ala shows reduced 
incorporation, and TUBA1A p.Arg214His incorporates fully, but at a slower rate than 
wild-type. The broad range of effects on microtubule incorporation is at odds with 
the highly stereotypical clinical phenotype, supporting differential roles for the three 
tubulin genes involved. Identifying this highly characteristic phenotype is important 
due to the low recurrence risk compared to the other (recessive) cerebellar dysplasias 
and the apparent lack of non-neurological medical issues.
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INTRODUCTION
Since the first discovery in 2007 of TUBA1A (OMIM *602529) as a novel gene for 
lissencephaly, genes encoding alpha- and beta-tubulins, the main components of 
microtubule polymers, are now being recognised for their major involvement in 
malformations of cortical development (MCD) 1,2 and these disorders are now col-
lectively termed tubulinopathies. Mutations in TUBA1A are predominantly associated 
with a variable spectrum of lissencephaly, pachygyria, and polymicrogyria-like cortical 
malformations, with or without microcephaly and abnormalities of other brain struc-
tures (in particular the basal ganglia and corpus callosum).1,3-11 TUBB2B (OMIM *612850) 
mutations frequently cause polymicrogyria-like abnormalities, as well as lissencephaly, 
cortical dysplasia, schizencephaly, and microcephaly to a lesser extent.12-17 Two major 
subgroups of TUBB3 (OMIM *602661) mutations have been previously described: 
those associated with mildly abnormal gyral pattern (microgyria, gyral disorganiza-
tion), and those with congenital fibrosis of the extraocular muscles type 3 (CFEOM3) 
with neurological symptoms.2,18,19 Mutations in TUBB (OMIM *191130, previously 
referred to as TUBB5) have been associated with microcephaly with structural brain 
abnormalities, TUBB4A (OMIM *602662) variants with hypomyelination 20,21 and, most 
recently, mutations in TUBB2A (OMIM *615101) have been identified in individuals with 
simplified gyral patterning or unaffected cerebral cortex but with infantile seizures.22 
In addition to alpha- and beta-tubulins, mutations in a gamma-tubulin gene, TUBG1 
(OMIM *191135), have also been associated with pachygyria 10, further highlighting the 
importance of tubulin and microtubule function during brain development.
Clinically, individuals with tubulin mutations display a range of outcomes, from severe 
intellectual disability and intractable seizures to learning difficulties and absence of 
epilepsy. 12,16,18 Screening tubulin genes in large cohorts of MCD patients has yielded a 
mutation detection rate of only 1-13.3%.6,8,9,12,13 Selection of MCD patients for sequenc-
ing of these genes is difficult because of the variable clinical and imaging features.
It is clear, however, that overall brain development is affected in these patients and, 
besides predominant cortical malformations, the basal ganglia, corpus callosum, brain 
stem, and cerebellum are frequently affected. The cerebellum and vermis are often 
described as hypoplastic or dysplastic, without further specification of the abnormality. 
6,19 The range of overlapping phenotypes stemming from tubulin gene variation has 
been examined extensively; however, all studies published to date have ascertained 
patients based exclusively on the presence of MCD.
In this study, we present ten patients ascertained due to their characteristic cerebellar 
dysplasia combined with basal ganglia dysplasia and frequently brainstem asymmetry. 
Although lissencephaly, pachygyria and polymicrogyria-like malformations were 
absent, this combination of imaging features prompted us to sequence tubulin genes. 
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Strikingly, this yielded a high mutation detection rate; as seven out of nine patients 
carry tubulin mutations (78%, six of eight families).
MATERIALS AND METHODS
Patient selection
From the large cohort of patients with hindbrain imaging abnormalities referred to the 
University of Washington Hindbrain Research Program, we identified patients with a 
distinct combination of brainstem asymmetry, superior cerebellar dysplasia and basal 
ganglia dysplasia and without a diagnosis of MCD (e.g. pachygyria, polymicrogyria). 
Clinical information was collected through chart review and structured interviews with 
the parents. All MRIs were systematically reviewed for abnormalities of the cortex, basal 
ganglia, white matter, ventricles, corpus callosum, hippocampus, brainstem, cerebel-
lum, cerebellar vermis, and cranial nerves (by RO, GI, DD). When possible, DNA was 
collected from blood and/or saliva. Patients were enrolled through a human subjects 
research protocol approved at the University of Washington. Informed consent was 
provided by the patients, their parents or their legal guardians.
Genetic studies
TUBA1A (RefSeq Accession: NC_000012.12), TUBB3 (NC_000016.10), TUBB2B 
(NC_000006.12), and TUBA8 (NC_000022.11) were sequenced using molecular 
inversion probe (MIP) capture and sequencing on a MiSeq as previously described 
23. The MIPs targeted all coding exons and 10bp of exon-flanking intronic sequence. 
In patients without mutations, we performed Sanger sequencing of TUBB2A 
(NC_000006.12) and TUBB4A (NC_000019.10). All variants were confirmed by Sanger 
sequencing (primer sequences available on request) and checked against four online 
polymorphism databases: 1,000 genomes (www.1000genomes.org), the Exome Variant 
Server (http://evs.gs.washington.edu/EVS/), dbSNP (http://www.ncbi.nlm.nih.gov/snp) 
and ExAC (http://exac.broadinstitute.org).
Bioinformatics Analysis of Tubulin Gene Variants
Combined Annotation–Dependent Depletion 1.0 (CADD; http://cadd.gs.washington.
edu) bioinformatics software was used to analyse predicted deleterious effects of iden-
tified mutations on protein function. 24 In addition, well-phenotyped TUBA1A, TUBB2B 
and TUBB3 variants included in a study by Bahi-Buisson et al. were also analysed to 
enable comparison between mutations associated with unaffected/simplified gyration 
and with other, more severe, cortical abnormalities: microlissencephaly, lissencephaly, 
central pachygyria, central and general polymicrogyria-like cortical malformations.12
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Homology Modelling
In silico structural predictions of wild-type and variant TUBA1A, TUBB2B and TUBB3 
proteins were generated via a previously described homology modelling pipeline. 25 
The best homologies for these models were based on 99%, 100% and 94% identities of 
alpha- and beta-tubulin templates (PDB: 4I4T).26 Microtubule lattice architecture was 
based on a previously published template (PDB: 2XRP).27
Cell Culture
Human Embryonic Kidney (HEK293) cell culturing, seeding and transfection were 
performed as previously described.22
Expression Construct Generation
In vitro functional analysis of TUBA1A and TUBB2B variants was performed using 
expression constructs derived from a C-terminally FLAG-tagged TUBA1A (pRK5TUBA1A-
CFLAG) clone as previously published. 6 pRK5TUBA1A-FLAG was subsequently modified 
to reflect wild-type TUBB2B (pRK5TUBB2B-CFLAG) by directional cloning. Tubulin gene 
variants were introduced into wild-type TUBA1A and TUBB2B, as well as a C-terminally 
DDK-tagged human TUBB3 expression construct (OriGene Technologies; pCMV6 entry), 
using QuickChange site-directed mutagenesis (Stratagene, UK). Entire wild-type and 
variant transgene coding regions were sequence validated following maxiprep yields 
(QIAgen). The TUBA1A p.Ile219Val variant was only identified in the final stages of this 
study and in vitro analysis was therefore not available. We included this patient due to 
the position of the affected amino acid, its de novo inheritance, and the similarity of the 
resulting phenotype with that of others in the cohort.
Immunocytochemistry
HEK293 cells were fixed in -20oC methanol for three minutes and cell membranes sub-
sequently permeablised with Phosphate-Buffered Saline (PBS; Sigma) plus 0.5% Triton 
X-100 (Sigma) to facilitate immunocytochemical staining of intracellular epitopes. Cells 
expressing TUBA1A and TUBB2B constructs were stained using primary antibodies 
specific to FLAG (Sigma, Cat. F1804; 1:500 dilution), alpha-tubulin (Sigma Cat. T6199; 
1:500 dilution) and fluorescently-conjugated secondary antibodies raised against 
rabbit and mouse (Life Technologies, Cat. A-11011 & A-11001). TUBB3-expressing cells 
were sequentially stained for transgenic and endogenous tubulin protein as previously 
outlined.22 Immunostained cells were mounted onto glass slides using ProLong Gold 
Antifade Reagent (Life Technologies) and images acquired using confocal microscopy 
(Zeiss LSM 710 & Zen Software).
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Microtubule Polymerisation Assay
HEK293 cells expressing wild-type and variant tubulin gene constructs were incubated at 
4oC to induce depolymerisation of the microtubule polymer network. After 30 minutes, 
HEK293s were returned to 37oC. At specified times following their return to optimal 
temperature, cells were removed, methanol fixed and immunostained to observe the 
rate of microtubule re-polymerisation in the presence of each tubulin construct.
RESULTS
From the large cohort of patients with hindbrain imaging abnormalities referred to 
the University of Washington Hindbrain Research Program, we identified ten patients, 
including two siblings, with a distinct combination of brainstem asymmetry, superior 
cerebellar dysplasia and basal ganglia dysplasia and without a diagnosis of MCD (e.g. 
pachygyria, polymicrogyria).
Clinical features
All individuals displayed delayed psychomotor development, with a broad range of 
severity (Table 1). Motor development was usually more affected than speech. Four 
patients had documented seizures. Four were reported to have significant behavioural 
problems, ADHD and aggression being most common. OFC was available for nine 
individuals, five of whom had microcephaly (>2 standard deviations below the mean) 
and two of whom had macrocephaly (>2 standard deviations above the mean). Of 
note, abnormal eye movements were recorded in seven individuals, including oculo-
motor apraxia (OMA) in four. Strabismus was present in five. Polyneuropathy and/or 
congenital fibrosis of the extraocular muscles (CFEOM) were not reported in any of the 
patients. No patients had dysmorphic features, non-central nervous system malforma-
tions or hearing loss.
Brain imaging
Brain MRI studies were performed between eight months and eight years of age for all 
ten individuals (Table 2).
Cerebellum and cerebellar vermis
All patients have a distinct dysplasia of the superior cerebellum, especially the vermis 
(with “diagonal” folia; folia crossing the midline at an oblique angle), best visible at the 
midline on axial and coronal views (explained in Supplementary Fig.1, see also Fig. 1 & 
Supplementary Fig.2, 2nd column). The vermis is hypoplastic in all but three individuals 
(7/10), with the anterior vermis more severely affected. The cerebellar hemispheres are 
either normal size or mildly hypoplastic with mild asymmetry.
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Brainstem
In eight of 10 individuals, the pons is asymmetrically hypoplastic with a midline ventral 
indentation and asymmetrical inferior and middle cerebellar peduncles. Additional 
diffusion tension imaging (DTI) studies of individual UW165-3 showed asymmetry of 
the corticospinal tracts at the level of the pons (Supplementary Fig. 3). In five of ten, 
the medulla has a globular contour, with indistinct demarcation between the pyramids 
and the olivary nuclei.
Basal ganglia, thalami, and corpus callosum
The basal ganglia are asymmetrically dysplastic with bulbous appearance in all indi-
viduals, with diffuse, branched, or absent anterior limb of the internal capsule (Fig. 1 
& Supplementary Fig. 2, 3rd column). The lateral ventricles have an irregular contour 
and abnormal rounding of the frontal horns (10/10), likely related to the basal ganglia 
dysplasia. The thalami are globular-shaped in all. The corpus callosum is variably 
affected, ranging from almost complete agenesis to normal (Fig. 1 & Supplementary 
Fig. 2, 4th column).
Cortex
As cortical malformations are considered a key feature in the tubulinopathies, but not 
reported in our cohort, we carefully re-reviewed the cortex in all individuals. Lis-
sencephaly, pachygyria, and polymicrogyria were not observed; however, patchy and 
asymmetric abnormalities in gyral size and orientation, and varying sulcal depth are 
present in all individuals (for example see Supplementary Fig. 1). A pattern involving 
a cluster of multiple shallow sulci was frequently observed, especially in the frontal 
lobes. This pattern differs from polymicrogyria (normal cortical thickness, no microgyri, 
no blurring of the grey-white matter boundaries) and from simplified gyral pattern, 
where the gyri are too few in number (Barkovich and Raybaud, 2011).
Variants in TUBA1A, TUBB2B, and TUBB3
DNA was available for nine of ten patients, and we identified mutations in seven (78%). 
In six individuals these were novel, unreported variants: TUBB2B c.38G>C (p.Gly13Ala) 
in two siblings; TUBB3 c.1070C>T (p.Pro357Leu) in two unrelated patients; TUBB3 
c.862G>A (p.Glu288Lys) and TUBA1A c.655A>G (p.Ile219Val) in sporadic patients. 
In addition, we identified in one patient the previously published missense change 
TUBA1A c.641G>A (p.Arg214His).12 All variants are de novo, except TUBB2B p.Gly13Ala, 
which was inherited by two affected sisters from their mosaic, apparently asymp-
tomatic father (Supplementary Fig. 4). Variants were determined to be absent from 
1,000 genomes, the Exome Variant Server, dbSNP142 and ExAC databases. We did not 
identify mutations in TUBA8, TUBB2A or TUBB4A.
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Figure 1. Brain imaging of mutation-positive patients. 
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CADD scores were generated for each mutation and previously published disease-
associated tubulin gene variants (Supplementary Table 1).12 The TUBA1A mutations 
associated with the mild phenotype (p.Arg214His, p.Ile219Val and p.Val353Ile), have 
a lower average CADD score than the TUBA1A mutations associated with microlis-
sencephaly, consistent with the difference in severity of the phenotypes (Student’s 
T-test, p=0.04). In contrast, CADD scores for TUBB2B and TUBB3 variants did not differ 
significantly across phenotypic groups, although the sample sizes are small.
Homology Modelling
Altered amino acids are located in a variety of positions throughout the alpha/beta-
tubulin heterodimer (Fig. 2A & Fig. 2B; Table 3), with each substitution affecting highly 
conserved residues (Supplementary Fig. 5). None of the substitutions are predicted to 
affect interactions with microtubule-associated proteins (MAPs) that predominantly 
associate with the external face of microtubule polymers.
TUBA1A: p.Arg214His affects an arginine that is conserved in most human alpha-
tubulin isoforms. Positioned on alpha-helix 6 of the alpha-tubulin subunit, Arg214 
is on the surface of the protein, within the inter-protofilament interface between an 
adjacent alpha-tubulin subunit when incorporated within a microtubule polymer. 
It is also in relative proximity to (but not predicted to associate with) helix 10 of the 
beta-tubulin within the same heterodimer. p.Ile219Val affects an isoleucine conserved 
throughout alpha-tubulins. Five amino acids from Arg214, this residue is located within 
a short loop between two alpha-helices at the interface with an adjacent alpha-subunit 
of a neighbouring microtubule protofilament. The branched isoleucine side chain 
does not extend into this interface, but is instead orientated towards the centre of 
the protein. Ile219 is predicted to form a hydrogen bond with Cys213, however this is 
preserved when substituted with a valine.
TUBB2B: p.Gly13Ala affects a glycine located on the first alpha-helix, within the core 
of the beta-tubulin subunit. Hyper conserved through alpha- and beta-tubulins, this 
residue is positioned within a tight groove between the alpha-helix and the preceding 
Figure 1 (opposite page). Brain imaging of mutation-positive patients. 
Representative images from brain MRI, each row represents one patient. First – third column axial T2 
images, fourth column sagittal midline T1 images. First column, level of the cerebellum and brainstem; 
brainstem asymmetry (except UW169-3, UW169-4) and enlarged 4th ventricle (black asterisks), normal 
sized cerebellum (except UW167-3). Second column, level of superior cerebellum showing distinct “diago-
nal” dysplasia of the foliar pattern. Third column, level of basal ganglia; dysplastic and amorphous basal 
ganglia in all, also note the irregularities in sulcal depth (dysgyria); representative examples in UW168-3 
of shallow sulci (marked by white asterisks) and deep sulci (#). Fourth column; thinning of brainstem in all, 
hypoplastic vermis (except UW169-3, UW169-4, and UW164-3), abnormal corpus callosum (CC) in three 
(partial agenesis in UW168-3 and UW167-3, thin CC in UW170-3). See Table 2 for details of imaging by 
individual.
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Figure 2. Tubulin variants affect amino acids located in varying regions of the heterodimer. 
Affected TUBA1A residues (Arg214 & Ile219) are highlighted on an alpha-tubulin protein subunit (green) 
and TUBB2B Gly13 and TUBB3 Glu288 & Pro357 on a beta-tubulin subunit (blue) as part of a heterodimer 
incorporated into a microtubule polymer lattice depicted from (A) within the microtubule polymer and 
(B) from above. TUBA1A Arg214 & Ile219 and TUBB3 Glu288 & Pro357 residues are located at the surface 
of the heterodimer, whilst TUBB2B Gly13 is buried within the beta-tubulin subunit. αArg214 is positioned 
towards, but not predicted to directly interact with, both the longitudinal intradimer (between residues 
of the same heterodimer) and lateral inter-protofilament (adjacent subunits) interfaces. βGlu288 is also 
positioned at an interface between an adjacent protofilament subunit but with no direct interaction 
predicted. When incorporated into a polymer, the βPro357 residue faces into the microtubule lumen. It is 
not predicted to have lateral or longitudinal contact with neighbouring subunits. Due to their location, 
none of the affected residues are predicted to affect interaction with microtubule-associated proteins that 
predominantly associate with the exterior surface of the polymer lattice, as demonstrated by DCX in the 
model (grey).
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beta-strand, facilitated by glycine’s lack of side chain (Supplementary Fig. 6). As a result 
of the substitution, the side chain of the resulting alanine is predicted to protrude into 
the groove. The surrounding residues at the end of the first beta-strand and beginning 
of the helix are involved in direct interaction with a guanosine nucleotide (GTP/
GDP) bound at the Exchangeable (E)-site of the beta-tubulin 28. Consequently, further 
subtle changes are predicted in the orientation of additional side chains involved with 
nucleotide binding, especially Gln11 & Cys12.
TUBB3: p.Glu288Lys is located within the 9th alpha-helix of the beta-tubulin subunit. 
When incorporated within a microtubule polymer, the acidic glutamate side chain 
is orientated laterally towards a beta-tubulin subunit of an adjacent protofilament. 
This residue is conserved through both alpha- and beta-tubulins, and substitution 
with a basic lysine residue is predicted to disrupt two putative hydrogen bonds 
between Glu288 and Thr285 within the same subunit (Supplementary Fig. 7). TUBB3, 
p.Pro357Leu affects one of two neighbouring prolines in a loop between beta-strands 
9 and 10 of the beta-tubulin subunit. When incorporated within polymer lattice, Pro357 
faces into the microtubule lumen (Fig. 2B). This residue is not predicted to interact with 
longitudinal or laterally adjacent tubulin subunits.
Table 3. Summary of homology modelling and functional analysis
Gene Variant In silico Conservation In vitro consequences
TUBA1A p.Arg214His
(c.641G>A)
Alpha-helix 6.
Within intradimer and 
interprotofilament 
interfaces
αArg214 conserved 
in most alpha-tubulin 
isoforms
Incorporates into 
microtubules but 
at a reduced rate 
following cold-induced 
depolymerisation
p.Ile219Val
(c.655A>G)
Loop between alpha-
helices 6 & 7.
αIle219 conserved 
throughout alpha-tubulin 
isoforms
Not determined
TUBB2B p.Gly13Ala
(c.38G>C)
Alpha-helix 1.
Within beta-tubulin core.
3 predicted H-bonds 
between β-subunit and 
GDP disrupted.
βGly13 hyper conserved 
in both beta- and alpha-
tubulin isoforms
Reduced Incorporation 
into microtubules
TUBB3 p.Glu288Lys
(c.862G>A)
Alpha-helix 9. Within 
interprotofilament 
interface.
Loss of 2 H-bonds with 
Thr285 (intrasubunit) 
predicted.
βGlu288 conserved in 
beta- and most alpha-
tubulin isoforms
Does not incorporate 
into microtubules
p.Pro357Leu
(c.1070C>T)
Loop between beta-
strands 9 & 10.
Facing microtubule lumen.
βPro357 hyper conserved 
in both beta- and alpha-
tubulin isoforms
Does not incorporate 
into microtubules
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Effect of tubulin gene variants on microtubule incorporation and 
polymerisation in vitro
To investigate the in vitro functional consequences of tubulin gene variants identified, 
wild-type and variant TUBA1A, TUBB2B and TUBB3 constructs were transiently-
expressed in HEK293 cells and immunocytochemically stained with antibodies specific 
to endogenous and transgenic tubulin. Mutations had variable effects on co-assembly 
with endogenous alpha- or beta-tubulin subunits and incorporation into microtubule 
polymers (Fig. 3 & Table 3).
Figure 3. Tubulin gene variants demonstrate varying levels of microtubule incorporation in vitro.
Wild-type and variant FLAG-tagged TUBA1A (A-F), TUBB2B (G-L) and DDK-tagged TUBB3 (M-U) expres-
sion constructs were transfected into HEK293 cells to observe incorporation into microtubule polymers 
during interphase. Cells were fixed for immunocytochemical examination 24h post-transfection, and 
stained using anti-FLAG (A, D, G, J) or anti-DDK (M, D, G) antibodies to detect the transgenic tubulin, and 
anti-α-tubulin (B, E, H, K, N, Q, T) to detect the endogenous microtubule network. TUBA1A p.Arg214His 
successfully incorporates into microtubule polymers, as evident by the presence of fibre-like arrangement 
in the anti-FLAG channel (D). In comparison to wild-type TUBB2B, p.Gly13Ala also demonstrates integra-
tion into microtubules but at a reduced level (J-L); polymer fibres are notably less well-defined in the 
anti-FLAG channel in comparison to endogenous alpha-tubulin and an increased proportion of the visible 
p.Gly13Ala beta-tubulin remains unpolymerised in the cell cytoplasm. This is supported by predominantly 
green polymers observed in the merged cell image (L). Neither TUBB3 p.Glu288Lys nor p.Pro357Leu 
demonstrate any evidence of microtubule incorporation in vitro as indicated by diffuse cytoplasmic stain-
ing instead of defined microtubules (M-U). Whereas wild-type TUBB3 can be seen to co-assemble with 
endogenous alpha-tubulin into microtubule polymers, both variants remain unpolymerised throughout 
the cell cytoplasm. Images were acquired blind to construct type and are representative of >95% of cells 
observed. Bar=10μm.
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TUBA1A p.Arg214His demonstrates a diminished rate of microtubule reintegration 
following cold-induced depolymerisation in comparison to wild-type protein (Fig. 4). 
Despite its ability to polymerise, this suggests that the arginine to histidine substitu-
tion subtly perturbs the rate that affected heterodimers integrate into growing 
microtubules. TUBB2B p.Gly13Ala demonstrates a notable reduction in microtubule 
incorporation in vitro, with very faint polymers visible and the majority of variant beta-
tubulin remaining unpolymerised throughout the cell cytoplasm. Neither of the TUBB3 
variants demonstrate any signs of microtubule incorporation, as transgenic protein 
remains diffuse throughout the cell with no polymer arrangement observed.
Figure 4. TUBA1A p.Arg214His demonstrates slowed microtubule reincorporation following cold-
induced depolymerisation. 
To examine the effect of the p.Arg214His amino acid substitution on microtubule dynamics in vitro, 
HEK293 cells expressing wild-type and variant TUBA1A were incubated at 4oC to induce microtubule 
polymer depolymerisation. After 30 minutes, coverslips were returned to 37oC to promote microtubule 
re-polymerisation. To observe the rate of microtubule growth in the presence of each construct, cells were 
removed after 0 (A-C, M-O), 15 (D-F, P-R), 30 (G-I, S-U) and 45 (J-L) minutes of polymer rescue and metha-
nol fixed prior to immunocytochemical staining. Wild-type TUBA1A (M-U) demonstrates reincorporation 
at a similar rate to endogenous tubulin. After 15 and 30 minutes at 37oC (D-I), microtubule repolymerisa-
tion in TUBA1A p.Arg214His-expressing cells can be observed in the endogenous alpha-tubulin channel 
(E, H), whilst transgenic protein remains unpolymerised with no visible microtubules (D, G). TUBA1A 
p.Arg214His incorporation is evident after 45 minutes at 37oC (J), however the proportion of variant 
tubulin appears to be at a markedly lower level than that of endogenous alpha-tubulin (L). Images were 
acquired blind to construct type and are representative of >95% of cells observed. Bar=10μm.
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DISCUSSION
This study describes a highly recognisable pattern of cerebellar dysplasia, brainstem 
asymmetry and basal ganglia dysplasia without major cortical malformation in 10 
patients with developmental delays and eye movement abnormalities. In the majority 
of tested patients (78%) we identified mutations in TUBA1A, TUBB2B or TUBB3 that were 
either de novo or inherited from a mosaic parent. Four out of five mutations identified 
are novel. Our data add a distinct and recognizable phenotype to the tubulinopathy 
spectrum, with relatively mild cortical involvement.12 Although the cohort presented 
is small, the mutation detection rate suggests that the described pattern of brain 
abnormalities is highly predictive for tubulin mutations. This detection rate is much 
higher than any previously published in patients with cortical malformations, ranging 
from 1-13.3%. 6,8,9,12,13 We expect this number to be higher in selected cohorts of 
patients with cortical malformations combined with other abnormalities, (e.g. of basal 
ganglia, corpus callosum) and indeed a detection rate of 30% has been found for the 
combination of lissencephaly with cerebellar hypoplasia.6
Clinical implications
The Baraitser-Winter Neurogenetics Database (www.lmdatabases.com, v 1.0.32) 
includes 336 conditions encompassing cerebellar vermis hypoplasia or aplasia, 
making it challenging to identify specific genetic causes in patients with cerebellar 
malformations. A more detailed understanding of the imaging abnormalities associ-
ated with each genetic condition is essential for accurately diagnosing these patients. 
For example, identifying the characteristic cerebellar dysplasia of the tubulinopathies 
distinguishes them from other disorders with cerebellar dysplasia that are often 
autosomal recessive and associated with other medical issues such as hearing loss 
(Chudley-McCullough syndrome), retinal dystrophy (Poretti-Boltshauser syndrome), 
muscular dystrophy (dystroglycanopathies), as well as progressive retinal, kidney and 
liver disease (Joubert syndrome).
While previous studies have not focused on cerebellar abnormalities in tubulinopa-
thies, cerebellar dysplasia has been mentioned in multiple patients (all with cortical 
malformations), confirming its association with tubulin gene mutations.11,12,15,16,19 In 
another study, up to 30% of patients with lissencephaly with cerebellar hypoplasia had 
mutations in TUBA1A, as opposed to only 1% in the classic lissencephaly cohort.6 It 
would be interesting to investigate whether cerebellar dysplasia (without hypoplasia) 
is also a useful diagnostic marker for tubulin mutations in patients with lissencephaly.
While OMA is commonly present in patients with cerebellar abnormalities, OMA has 
rarely been associated with tubulinopathies, so it is surprising that the majority of our 
patients presented with gross motor delays and OMA or other impairments of eye 
movement. In contrast, OMA has only been described in two patients with the distinct 
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tubulinopathy H-ABC (hypomyelination with atrophy of the basal ganglia and cerebel-
lum) due to TUBB4A mutations, and never in patients with TUBA1A, TUBB2B or TUBB3 
mutations.21 This may be due to under ascertainment of eye movement abnormalities 
in patients with severe disability.
Subtle cortical dysgenesis: dysgyria
No findings of lissencephaly, pachygyria, cobblestone cortex, or polymicrogyria 
(abnormal cortical thickness, irregular cortical surface and grey-white boundary and/
or microgyri) were present in the individuals recruited for this study.29 However we 
observed abnormal sulci, the majority being shallow, with less frequent areas of sulci 
extending too deeply into the white matter, the latter predominantly in the perisylvian 
areas. We therefore consider the terms simplified gyral pattern, polymicrogyria, and 
polymicrogyria-like cortical dysplasia to be potentially confusing. This is also sup-
ported by foetal pathology studies showing atypical features in polymicrogyria-like 
cortical dysplasia, suggesting a different pathophysiological mechanism from classic 
polymicrogyria.11,13 We propose using the term tubulinopathy-associated dysgyria for 
the subtle abnormalities of gyral shape without imaging evidence of lissencephaly, 
pachygyria, cobblestone cortex, polymicrogyria, or other cortical abnormalities.
Recurrence risk
We identified two affected siblings with a TUBB2B mutation, inherited from an asymp-
tomatic father who was found to be mosaic for this mutation. Familial recurrence has 
previously been described in two sisters with polymicrogyria and a TUBA1A mutation 
with mosaicism in the maternal line.5 These findings emphasise the importance of care-
ful analysis of the parental sequencing results for evidence of mosaicism and adequate 
counselling about possible recurrence, as germline mosaicism in a parent can never be 
fully excluded.
Genotype-phenotype correlations
The same tubulin mutations are frequently observed in unrelated individuals sharing 
similar brain malformations, e.g. TUBA1A p.Arg264Cys in individuals with characteristic 
central pachygyria. 3,9,12 Substitutions affecting identical residues but resulting in 
different amino acids have also produced comparable phenotypes (e.g. TUBA1A 
p.Arg402Cys and p.Arg402His.6,12 Consistent with this, in our cohort of patients with 
strikingly similar MRI findings, we identified one (TUBB3 p.Pro357Leu) mutation in 
two unrelated patients and a second mutation (TUBB2B p.Gly13Ala) in two siblings. 
Contrary to this trend, the TUBA1A p.Arg214His variant found in UW168-3 was 
previously identified in a foetus with a more severe phenotype. 11,12 Other phenotypic 
dissimilarities have also been described, e.g. TUBA1A p.Arg390Cys associated with 
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both tubulinopathy-associated dysgyria 6 and asymmetrical perisylvian polymicrogyria 
10. While these instances are relatively uncommon, they limit the utility of genotype-
phenotype correlations in clinical practice.
The large number of TUBA1A mutations that have been identified to date (49 at 
present), the majority of which are associated with severe brain malformations, makes 
it possible to evaluate whether in silico predictions such as CADD scores correlate with 
severity of the brain malformation. In fact, the TUBA1A variants associated with subtle 
cortical abnormalities have lower CADD scores than those associated with microlis-
sencephaly, so it may someday be possible to use in silico predictions to improve 
prognostic information for patients and families.
Functional effects of mutations
Our data indicate that mutations in three different tubulin genes lead to a very 
consistent clinical phenotype, implicating a shared biological mechanism. Surprisingly, 
the mutations also affect diverse regions of the alpha/beta-tubulin heterodimer, result-
ing in potential effects on microtubule dynamics, polymer incorporation or guanine 
nucleotide binding. TUBA1A p.Arg214His was associated with the mildest functional 
deficit in our in vitro pipeline, incorporating into microtubule polymers at comparable 
levels to wild-type but at a reduced rate. This mild deficit is consistent with the pre-
dicted subtle structural effects of TUBA1A p.Arg214His on the alpha-tubulin subunit. 
Despite residing at the inter-protofilament interface, closer in silico inspection suggests 
neither TUBA1A p.Arg214His nor p.Ile219Val directly affects protein-protein interac-
tions. Interestingly, both variants are in close proximity to a p.Asp218Tyr substitution, 
previously identified in an individual with lissencephaly.6 This demonstrates how 
little one can predict of the resulting phenotype based purely on the affected region 
of tubulin proteins, as substitutions affecting adjacent residues can result in notably 
different brain abnormalities.
Structural predictions indicate that TUBB2B p.Gly13Ala affects conserved residues that 
are part of the nucleotide binding site. GTP hydrolysis at the beta-tubulin subunit is 
responsible for both polymer incorporation and dynamics.30 This is consistent with 
the reduced microtubule incorporation observed in vitro and relatively high CADD 
score, but would be the first association of a mutation potentially affecting guanine 
nucleotide binding with a mild cerebrocortical phenotype.12
As with the TUBA1A variants, TUBB3 p.Glu288Lys and p.Pro357Leu substitutions are not 
predicted to affect specific intra- or intersubunit interactions; however, this observation 
may be irrelevant, since neither mutant protein incorporates into microtubules in vitro. 
We therefore hypothesise that the p.Glu288Lys and p.Pro357Leu substitutions prevent 
correct protein processing through one of several possible mechanisms including 
protein folding, alpha/beta-tubulin heterodimerisation, or subsequent integration into 
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growing microtubule polymers. This may additionally support the observation by Bahi-
Buisson et al. that impaired tubulin folding is generally associated with milder cortical 
phenotypes 12, whilst also emphasising the necessity to support in silico predictive 
modelling with in vitro cellular analysis.
Based on our in vitro assays, TUBA1A p.Arg214His has the least effect on tubulin 
polymerization, while TUBB2B p.Gly13Ala has an intermediate effect, and the TUBB3 
variants abolish polymerization entirely. The fact that all these mutations lead to the 
same brain phenotype could be due to a number of different factors, including: 1) a dif-
ferential requirement for the tubulin proteins during brain development, with TUBA1A 
being more critical than the beta-tubulins. This may be due to functional redundancy 
between the different beta-tubulins which are expressed in overlapping patterns dur-
ing brain development 31; 2) similar functional effects for all of the mutations. Complete 
lack of mutant TUBB3 polymerization might result in a similar functional consequence 
as reduced polymerization of mutant TUBA1A, possibly due to negative effects of 
mutant TUBA1A incorporated into microtubules; 3) genetic or environmental modifiers 
contributing to tubulin function and the resulting brain phenotype.
CONCLUSION
In summary, we have identified a highly characteristic combination of cerebellar, 
brainstem, basal ganglia abnormalities with subtle cortical involvement associated 
with mutations in three different tubulin genes TUBA1A, TUBB2B or TUBB3. Although 
tubulin mutations have been commonly associated with severe cortical malformations, 
this work emphasizes that the cortical involvement can be subtle in patients with more 
obvious brainstem and basal ganglia involvement. We confirm that a pipeline of in 
silico and in vitro work is necessary to add contextual evidence in tubulinopathies and 
future work will focus on the biochemical and cellular mechanisms by which tubulin 
mutations disrupt the development of the cortex, basal ganglia, cerebellum and 
brainstem.
Supplementary Material is available at Human Molecular Genetics online.
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INTRODUCTION
KBG syndrome, also known as dento-maxillo-facial syndrome (OMIM 148050), is a rare 
but well described syndrome of unknown etiology.
Its main features consist of developmental delay, facial dysmorphism, large upper 
central incisors (macrodontia) and skeletal anomalies. Seizures can also occur. Domi-
nant inheritance with variable expression has been described (Brancati et al, 2006).1
Periventricular nodular heterotopia (PNH) is a malformation of cortical development 
characterized by clusters of neurons situated around the cerebral ventricles due to 
failure of migration to the cortex during development. The causes are heterogeneous 
including chromosomal, monogenic and exogenous (Andrade, 2009).2 PNH is associ-
ated with epilepsy and developmental delay, but may also remain asymptomatic.
We report on a patient with KGB syndrome and PNH, this combination is to our 
knowledge not previously reported.
CLINICAL SUMMARY
The propositus, a girl, was born at term after a pregnancy complicated by pre-eclamp-
sia. An emergency caesarian section was performed because of fetal distress. Birth 
weight was 1895 grams (<p3). She acquired independent walking at age 18 months 
and spoke her first words at age 12 months. From the age of 3 years, developmental 
delay was noted by her parents. At the age of 10 years, her TIQ was 69. Her height 
curve since 12 months of age follows -2 SD, the weight curve between -1 and 0 SD, and 
head circumference between -2 and -2.5 SD.
On examination at age 10 years she showed brachycephaly, an oval shaped face, a high 
forehead, lateral sparsity of the eyebrows, a broad nasal tip with hypoplastic flaring 
nares and a long columnella, macrodontia of the upper central incisors (Fig.1A), a 
normal palate, and retrognathia. No anomalies of the extremities were noted. Neuro-
logical exam revealed no abnormalities besides mild developmental delay.
She is the only child of non-consanguineous Dutch parents. Anamnestically, they have 
had several miscarriages. The patient’s mother has large upper central incisors. She is 
healthy besides hypertension and has a normal intelligence.
IMAGING
Skeletal maturation was one year delayed on hand X-ray made at age of 10 years. 
Spinal X-ray revealed failed closure of the arch of the fifth lumbar vertebra and a 
decreased lumbar lordosis. Skeletal X-rays of the skull, pelvic bones, and chest showed 
no abnormalities. Macrodontia of central upper incisors is obvious on panoramic 
radiograph (Fig. 1B).
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On brain MRI performed at age of 11 years periventricular nodular heterotopia at the 
left lateral ventricle was found. Cortical gyration, central and peripheral CSF spaces 
were normal (Fig. 2).
INVESTIGATIONS
Audiogram and tympanometry had normal results. A standard EEG showed a normal 
background pattern and no epileptic discharges. Cytogenetic analysis in lymphocytes 
revealed a normal female karyotype (46, XX). Copy number change analysis with 
Affymetrix Nsp1 250K SNP array did not reveal any submicroscopic chromosomal 
abnormalities. Metabolic screen in plasma and urine and Filamin A sequence analysis 
were normal.
Figure. 1. Note macrodontia of upper incisors; (A) the propositus at age 10 years. Also note broad nasal tip 
and hypoplastic nares; (B) panoramic radiograph at age 10 years.
Figure 2. Brain MRI showing unilateral periventricular nodular heterotopia (arrows); (A) coronal FLAIR im-
age and (B) transversal T2-weighted image.
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DISCUSSION
In the propositus, cognitive impairment, dental anomalies, short stature, and skeletal 
findings suggested the diagnosis of KGB syndrome. We did not detect submicroscopic 
chromosomal abnormalities as a cause of KBG. In previously published reports, brain 
anomalies in KBG syndrome were sporadically reported and included hypoplastic 
cerebellar vermis, enlarged cisterna magna, Chiari malformation type I, meningomy-
elocele, white matter abnormalities, and microcephaly (Brancati et al, 2006, Skjei et 
al, 2007, Kumar et al, 2009).1,3,4 No defect of cortical development has previously been 
reported in KBG syndrome. PNH may remain asymptomatic but forms a risk factor for 
epilepsy. The finding of PNH in our propositus indicates that seizures in patients with 
KBG syndrome may be caused by anomalies of neuronal migration. We suggest that 
the risk of seizures should be mentioned to families, and that brain MRI should be 
included in the work-up of KBG patients if there are any abnormal neurological signs or 
symptoms.
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ABSTRACT
Partial monosomy 21 has been reported, but the phenotypes described are variable 
with location and size of the deletion. We present two patients with a partially overlap-
ping microdeletion of 21q22 and a striking phenotypic resemblance.
They both presented with severe psychomotor delay, behavioral problems, no speech, 
microcephaly, feeding problems with frequent regurgitation, idiopathic thrombocyto-
penia, obesity, deep set eyes, down turned corners of the mouth, dysplastic ears, and 
small chin. Brain MRI showed cerebral atrophy mostly evident in frontal and temporal 
lobes, widened ventricles and thin corpus callosum in both cases, and in one patient 
evidence of a migration disorder. The first patient also presented with epilepsy and a 
VSD. The second patient had a unilateral Peters anomaly. Microarray analysis showed 
a partially overlapping microdeletion spanning about 2.5 Mb in the 21q22.1-q22.2 
region including the DYRK1A gene and excluding RUNX1. These patients present with 
a recognizable phenotype specific for this 21q22.1-q22.2 locus. We searched literature 
for patients with overlapping deletions including the DYRK1A gene, in order to define 
other genes responsible for this presentation.
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INTRODUCTION
Chromosome 21 has been the subject of extensive studies. Trisomy 21 causing Down 
syndrome [DS, OMIM #190685] is one of the few trisomy syndromes compatible with 
life and is common with an incidence of about 1 in 800 live births. However, (partial) 
monosomy 21 is much rarer and few patients have been reported in literature.1-22 The 
region of the monosomy and the phenotype of reported cases are variable. The 21q22 
region seems associated with the most severe phenotype exhibiting mental retarda-
tion and microcephaly.23 Disruption of DYRK1A (Drosophila “minibrain” homologue 
gene, OMIM *600855) in this region has been associated with microcephaly, mental 
retardation and dysmorphisms in two patients 24. Studying similar patients potentially 
reveals valuable information regarding the function of the chromosome 21 genes.
We present two unrelated individuals with a partial monosomy 21 with strikingly 
similar facial features giving them a ‘moody’ appearance, similar brain imaging and a 
partially overlapping 21q22 microdeletion. This overlapping 2.5 Mb region contains 
amongst others the DYRK1A gene and covers the DS critical region [OMIM #190685]. 
Combining our data with previously published reports by others, we delineate a 
recognizable phenotype of chromosome 21q22.1-q22.2 microdeletions including the 
DYRK1A gene.
CLINICAL REPORTS
Patient 1 was referred to our department at 18 months of age. Clinical data are sum-
marized in Table 1. He was born after an uneventful pregnancy at 38 weeks of gesta-
tion as the 10th child to non-consanguineous healthy Dutch parents. His birth weight 
was 2140 grams (-2 SD) and head circumference 31 cm (-2.8 SD). The neonatal period 
was complicated by cardiac decompensation due to a persistent ductus arteriosus and 
a perimembranous ventricular septum defect (VSD). The duct closed spontaneously at 
cardiologic follow-up, the VSD was managed conservatively.
Clinical genetic examination at age 18 months showed micro- and brachycephaly, 
square forehead, deep-set eyes with long eyelashes, small nose, large pupils, thin lips 
with down-turned corners of the mouth, micrognathia, large, low-set ears, and weight 
and head circumference at -4 SD (Fig. 1).
His developmental milestones were delayed. Severe feeding problems and gastro-
esophageal reflux necessitated gastric tube feeding and Nissen fundoplication. He 
suffered from recurrent upper respiratory tract infections and had severe constipation. 
He developed epilepsy with tonic-clonic seizures requiring antiepileptic drug (AED) 
therapy.
At follow-up at age 7 years he was severely mentally retarded and exhibited no speech. 
He had a flat forehead, broad eyebrows extending onto the eyelids, deep-set eyes with 
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long eyelashes, large pupils, wide nasal ridge, large, low-set ears, full cheeks, dental 
caries, micrognathia, small hands and feet, a sandal gap between 1st and 2nd toes, joint 
hyperlaxity, pectus excavatum, truncal obesity, and cryptorchism (Fig. 1). His height 
was 110 cm (-3 SD), weight 20 kg (+1 SD), and head circumference 45.5 cm (-4 SD).
Abdominal ultrasound and skeletal X-rays revealed no abnormalities. A post-operative 
(tonsillectomy) hemorrhage prompted studies of bleeding diathesis, this revealed low 
platelet counts ranging from 82 – 149 x 109 /L (normal range: 199- 369 x109/L).
Brain MRI performed at 1 year of age (Fig. 3A, B) showed small frontal lobes, enlarged 
lateral and third ventricles with high signal of periventricular white matter on T2 
weighted images, a thin corpus callosum and brain stem, and delayed myelination. 
At two years of age, brain MRI showed similar features, although myelination had 
progressed.
He died at age 11 of a bronchopneumonia complicated by pulmonary hemorrhage.
Patient 2 was referred to our department of Clinical Genetics at the age of 8 months 
because of progressive microcephaly and dysmorphic features. She was born after an 
uneventful pregnancy at 42 weeks of gestation as the first child of non-consanguine-
ous healthy Chinese parents. Her birth weight was 2765 grams (-2 SD), length 46 cm 
(-3 SD) and head circumference 31 cm (-3.5 SD). She had a systolic murmur due to a 
persistent ductus arteriosus. It has closed spontaneously on follow-up. In infancy she 
suffered from episodic attacks of blue discoloration of the extremities. She has had two 
seizures suspect of epilepsy and one EEG showed dubious epileptic activity, requiring 
AED therapy.
On clinical examination dysmorphic features included square forehead with nevus 
flammeus, low-set and thick eyebrows, long eyelashes, peri-orbital fullness with deep 
set eyes, wide nasal ridge, anteverted nares, down-turned corners of the mouth, small 
Figure 1. Facial features of patient 1. 
(A) Age unknown. Note the full upper eyelids and cheeks, anteverted nares, down-turned corners of the 
mouth and large ears. (B and C) Age 7 years. Note thick eyebrows, full upper eye lids and cheeks, slightly 
anteverted nares, down-turned corners of the mouth, dental decay and large, low-set ears.
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chin, round ears with broad helices and a left-sided ear pit, inverted nipples, a closed 
sacral dimple, a congenital nevus on the back, a single palmar crease on the left hand, 
a contracture of the left thumb, deep set nails of the toes, and bilateral short proximally 
implanted first toes (Fig. 2)
Her developmental milestones were delayed. She started walking independently at 
age 2. She suffered from feeding problems which required gastric tube feeding in 
infancy. During follow-up up to 7 years of age she exhibited severe mental retardation 
with absent speech, no eye contact, hyperactive behavior and poor interaction with 
people. Teeth grinding was noted and diffuse dental decay was striking. At that age, 
her height was 110 cm (-3 SD), weight 25 kg (2.5 SD), and head circumference 48 cm (-2 
SD). She has severe constipation.
Ophthalmic examination revealed bilateral hypermetropia, amblyopia of the right eye, 
and a unilateral corneal opacity area consistent with a Peters anomaly. Her platelet 
counts were below normal range on two separate occasions, 104 and 137x 109/L 
(normal range: 199- 369 x109/L). Craniosynostosis was excluded with a skull X-ray. 
Congenital CMV-infection was excluded by PCR of neonatal screening blood spot. No 
skeletal abnormalities were detected.
Brain MRI performed at age 5 months and repeated MRI at age 15 months (Fig. 3C,D) 
showed cerebral atrophy with deep sulci, mostly evident in frontal and temporal lobes, 
underdeveloped frontal gyri, a thin corpus callosum with loss of periventricular white 
matter and widened lateral and third ventricles both at frontal and occipito-temporal 
areas, a thin brain stem, and no evidence for active demyelination.
Recent brain MRI at age 8 years showed evidence for a periventricular nodular hetero-
topia located in the frontal horn of the right lateral ventricle. The inferior part of the 
right frontal cortex is abnormal and suspect for polymicrogryia (Fig. 3E,F).
Figure 2. Facial features of patient 2. 
(A) Age 8 months. Note the full upper eye lids and 
cheeks, anteverted nares and down-turned corners 
of the mouth. (B and C) Age 7 years. Note thick 
eyebrows, Peters anomaly of the right eye, full 
upper eye lids and cheeks, anteverted nares and 
down-turned corners of the mouth, malformed 
ears and moody expression. (D) Severe dental 
decay and malshaped teeth.
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CYTOGENETIC AND MICROARRAY RESULTS
Routine cytogenetic analysis of patients 1 and 2 revealed a normal karyotype. DNA of 
the patients was hybridized to Affymetrix 250K SNP arrays according to the Affymetrix 
standard protocol for the GeneChip Mapping 250K NspI arrays. Copy number analysis 
using the Copy Number Analyzer for GeneChip (CNAG) v3.0 25 indicated in patient 1 a 
4.1 Mb deletion (arr 21q22.13q22.2(37053718-41102161 [hg18]x1, see Fig. 4). In patient 
2, a 4.2 Mb deletion (arr 21q22.12q22.2(35337577-39585051 [hg18])x1) was observed, 
(Fig. 4). In both cases parental DNA analysis by quantitative PCR showed a de novo 
origin of the deletion. The deletions were confirmed by fluorescent in situ hybridization 
(FISH) with chromosome 21 BAC clones (RP11-166F15 absent, RP1-63H24 present). 
Analysis of the B allele ratio of the Affymetrix array in Nexus Copy Number software 
(Biodiscovery) revealed the possibility that in patient 1 the deletion was present in 
mosaic form in leukocyte DNA. Additional FISH analysis confirmed the mosaic in 
cultured lymphocytes where 50% of the nuclei showed the presence of two normal 
copies of chromosome 21. In order to define the deletion breakpoint in patient 2 
more precisely, qPCR experiments were performed on patient DNA (primer sequences 
Figure 3. Brain T1 weighted MRI images. 
(A,B,C, and D) Note cerebral atrophy/un-
derdevelopment of frontal and temporal 
lobes, widened ventricles including the 
third ventricle, thin corpus callosum and 
brain stem. (A) Patient 1, mid sagittal 
section (B) Patient 1, transversal section 
(C) Patient 2, midsagittal section (D) 
Patient 2, transversal section. E,F patient 
2, note periventricular nodular heteroto-
pia and area suspect of polymicrogyria 
in left frontal lobe (E) Coronal section (F) 
Magnification of E, upper arrow points to 
heterotopia, lower arrow points to area 
suspect of polymicrogyria.
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available on request). This resulted in refinement of the borders, defining the deletion 
from basepair 35346296 to 39576472 (NCBI built 36.3), and, using extra- and intragenic 
probes RUNX1 was excluded from the proximal end of the deletion.
The deletion areas of the two patients partially overlap from base pair 37053718 to 
39585051 spanning 2.5 Mb on chromosome 21q22.13q22.2 , encompassing 27 genes 
(15 protein coding genes, 3 non-protein coding gene, 4 pseudogenes and 5 hypo-
thetical genes) according to the NCBI and Ensembl database annotations build 36.3 
(Table 2). The DYRK1A gene, previously associated with neurodevelopmental anomalies 
and microcephaly 24, is included in the shared deletion area.
Figure 4. Array results. 
Under the schematic representation of chromosome 21 the actual results in the 21q22.11-q22.3 region of 
the two 250K SNP arrays are shown. In the bottom panel the overlapping segments and several genes in 
the area are depicted.
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REVIEW OF 21q22 DELETIONS INCLUDING DYRK1A
Several features have been repeatedly described in partial monosomy 21 including 
intrauterine and postnatal growth retardation, down-slanting palpebral fissures, 
low-set ears, arthrogryposis-like signs, hypertonia, heart defect, and mental retardation 
19. In order to delineate a more specific phenotype relating to 21q22 deletions we 
searched Pubmed, Decipher and Ensembl databases for patients with these deletions. 
Most of the patients reported in literature have microscopic deletions with poorly 
defined breakpoints. We review only those where we can deduce overlap with the 
21q22.13q22.2 critical region of our patients and where the phenotypic description 
is sufficient for comparison. These are summarized in Table 1. The findings are fairly 
consistent regarding intra-uterine growth retardation (IUGR), microcephaly, mental 
retardation, seizures, corpus callosum abnormalities and facial features (deep-set eyes, 
micrognathia, and dysplastic ears).
Of note, also one patient described by Shinawi et al. 26 and one by Yao et al. 20 show the 
deletion in mosaic form.
DISCUSSION
The two patients presented in this paper show a distinctive phenotype that to our 
knowledge has not previously been recognized in patients with 21q22 deletions. They 
Table 2. Known genes in overlapping deletion area
Gene symbol Name OMIM
HLCS Holocarboxylase synthethase 609018
DSCR6 Down syndrome critical region gene 6 609892
PIGP Phosphatidylinositol glycan anchor biosynthesis, class P 605938
TTC3 Tetratricopeptide repeat domain 3 602259
DSCR9 Down syndrome critical region gene 9 -
DSCR3 Down syndrome critical region gene 3 605298
DYRK1A Dual-specificity tyrosine- (Y)- phosphorylation regulated kinase 1A 600855
KCNJ6 Potassium channel, inwardly rectifying, subfamily J, member 6 600877
DSCR4 Down syndrome critical region gene 4 604829
DSCR8 Down syndrome critical region gene 8 -
DSCR10 Down syndrome critical region gene 10 -
KCNJ15 Potassium channel, inwardly rectifying, subfamily J, member 15 602106
ERG V-ets erythroblastosis virus E26 onco gene homolog 165080
C21orf24 Chromosome 21 open reading frame 24 611723
ETS2 V-ets erythroblastosis virus E26 onco gene homolog 2 164740
AP001042.1 FLJ45139 protein -
PSMG1 Proteasome assembly chaperone 1 (DSCR2) 605296
BRWD1 Bromodomain and WD repeat domain 1 -
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exhibit severe mental retardation with absence of speech, microcephaly, short stature, 
and distinct cerebral abnormalities. Their facial features with square forehead, full 
eyebrows and eyelids, deep-set eyes, broad nasal ridge, and down-turned corners of 
the mouth are strikingly alike and give them a “moody” appearance. Brain MRI findings 
are quite similar in the patients, showing underdevelopment of frontal lobes with 
evidence of a migration disorder in patient 2, deep frontotemporal sulci, large lateral 
and third ventricles, loss of periventricular white matter, callosal dysgenesis and thin 
brain stem. The low resolution MRI of patient 1 did not allow recognition of minor 
cortical malformations.
Because of their resembling features, it is likely that genes in their common deleted 
area are causative of their phenotype. DYRK1A [OMIM 600855] maps to chromosome 
21q22.13 and is included in the deleted area of both patients. With its location within 
the Down syndrome critical region, DYRK1A has been suggested to play a crucial role in 
brain alterations both in trisomy and monosomy 21 patients.27 Møller et al 24 reported 
two patients with a translocation truncating the DYRK1A gene. Both patients exhibited 
prenatal onset microcephaly, intrauterine growth retardation, feeding problems, 
developmental delay and seizures. In the first patient retardation was mild, and he had 
large, low-set ears, long philtrum, and micrognathia. On brain MRI hypogenesis of the 
corpus callosum was described without other abnormalities. The second patient had 
severe mental retardation, absent speech, large ears, flat philtrum and a ventricular 
septum defect. Brain MRI showed enlarged ventricles. The DYRK1A gene is the human 
homolog of the Drosophila minibrain gene.28 It is highly conserved in mammals. In 
mice, Dyrk1a haploinsuffiency leads to a reduced body size with a disproportionate 
brain reduction, and developmental delay.29 In particular, underdevelopment of the 
ventral mid- and hindbrain structures was present in Dyrk1A+/- mice. The MRI findings 
of our patients with large third ventricle, thin corpus callosum and brain stem might 
relate to the DYRK1A haploinsufficiency.
Besides DYRK1A, there are 14 protein coding and 3 non-protein coding genes annotated 
in the common deleted area, each of which might contribute to the phenotype. Six of 
these are Down-syndrome critical region (DSCR) genes of unknown function. Among the 
genes with known function, TTC3, KCNJ6 and BRDW1 are also interesting candidates.
The TTC3 (tetratricopeptide repeat domain 3) gene is involved in neuronal cell differen-
tiation and particularly in regulation of neurite extension 30, suggesting that absence 
of TTC3 could be related to in cognitive problems and brain underdevelopment. The 
tetratricopeptide domain is also present in kinesins responsible for organization of 
axonal microtubules and cytoskeleton dynamics and in KIAA1279, the gene mutated in 
Goldberg-Sphrintzen syndrome.31
KCNJ6 [OMIM 600877], also known as GIRK2, is expressed in the brain and the 
pancreatic β-cell. Homozygous GIRK2 missense mutation in weaver mice causes severe 
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cerebellar ataxia and altered behavioral pattern.32,33 Heterozygous weaver mice have a 
decreased number of surviving granule cells and suffer sporadically from tonic-clonic 
seizures.32 Also, homozygous weaver mice have decreased levels of circulating IGF-I and 
responded to GH-treatment.34 The postnatal growth retardation in our patients might 
be partially explained by a deficient GH/IGF-I axis, as seen in mutant weaver mice.
Mutations in the RUNX1 gene [OMIM 151385] cause familial platelet disorder with pro-
pensity to acute myeloid leukemia [FPD/AML; OMIM 601399]. Shinawi et al 26 reviewed 
platelet pool storage disease caused by RUNX1 haploinsufficiency and described 
multiple problems of microdeletions at 21q22 ascribed to RUNX1 and DYRK1A. Surpris-
ingly, both our patients were diagnosed with low platelet counts, although RUNX1 is 
not deleted. Possibly, regulatory elements of RUNX1 are affected by the deletion or 
other genes in the critical area are involved in platelet disorders. In mice, regulatory 
elements have been identified distant (300 kb) from Runx1.35
Periventricular nodular heterotopia (PNH) are a new finding in 21q22 deletion. PNH is 
considered a malformation of cortical development. Of note, other cortical malforma-
tions, that is polymicrogyria 20,21 and lissencephaly 22, have been associated with 21q 
deletions. Yao et al 20 propose that an 8.4 Mb region on 21q22.11-q22.3 is associated 
with cortical dysplasia. However, the large size of this area and lack of break point 
details make comparison of these patients with ours incomplete.
Our findings suggest that a minimum 2.5 Mb microdeletion at chromosome 
21q22.13q22.2 including DYRK1A and excluding RUNX1 is responsible for a character-
istic syndrome with recognizable facial features, severe developmental delay, brain 
abnormalities, IUGR, and eye and platelet abnormalities. Our observation reduces the 
chromosomal area to which these abnormalities have been previously ascribed, and 
should encourage high resolution array analysis in patients with a similar phenotype. 
It could be worthwhile searching for mutations in DYRK1A in patients with a similar 
phenotype in whom microdeletions have been excluded.
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ABSTRACT
Mutations in the ARX gene, at Xp22.3, cause a broad spectrum of disorders, including 
infantile spasms, X-linked lissencephaly with abnormal genitalia (XLAG), callosal 
agenesis and isolated intellectual disability. Genotype/phenotype studies suggested 
that polyalanine tracts expansion is associated with non-malformative phenotypes, 
while missense and nonsense mutations cause cerebral malformations, however, 
patients with structural normal brain and missense mutations have been reported. We 
report on a male patient born with cleft lip and palate who presented with infantile 
spasms and hemiplegia. MRI showed agenesis of corpus callosum (ACC), an interhemi-
spheric cyst, periventricular nodular heterotopia (PVNH), and extensive left frontal 
polymicrogyria (PMG). Sequencing of the ARX gene in the patient identified a six 
basepair insertion (c.335ins6, exon 2). The insertion leads to a two-residue expansion of 
the first polyalanine tract and was described previously in a family with non-syndromic 
X-linked mental retardation. To our knowledge, ARX mutation causing PMG and PVNH 
is unique, but the spasms and ACC are common in ARX mutations. Clinicians should be 
aware of the broad clinical range of ARX mutations, and further studies are necessary 
to investigate the association with PMG and PVNH and to identify possible modifying 
factors.
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INTRODUCTION
The ARX gene (Aristaless-related homeobox, X-linked, OMIM *300382) encodes a 
homeodomain transcription factor. These factors play crucial roles in cerebral develop-
ment and patterning.1 The broad range of disorders associated with mutations in the 
ARX gene, at Xp22.3, includes X-linked infantile spasms, X-linked lissencephaly with 
abnormal genitalia (XLAG), agenesis of corpus callosum with abnormal genitalia, and 
isolated X-linked non-syndromic intellectual disability (NSID).2 The most severe forms 
are hydranencephalic patients 3, but little is known of the mechanisms leading to the 
different presentations.
Genotype/phenotype studies suggest that polyalanine tract expansions cause non-
malformative phenotypes, while loss-of-function mutations and missense mutations 
located in the homeodomain and near the aristaless domain cause brain malforma-
tions.2,3 However, intra- and interfamilial and genetic heterogeneity is observed 2,4 and 
several missense mutations have been shown to cause a seizure phenotype without 
gross structural brain malformations.5-7
We report a boy with infantile spasms, polymicrogyria (PMG) and periventricular 
nodular heterotopia (PVNH), further expanding the spectrum of the ARX-related 
disorders and emphasizing the phenotypic variability of these mutations.
CLINICAL REPORT
The parents of our patient are healthy, non-consanguineous and of Dutch descent. 
The mother had a spontaneous abortion prior to this pregnancy. Prenatal ultrasound 
during this pregnancy showed a cleft lip, otherwise the pregnancy was uneventful. 
The patient was born after 41 weeks and 5 days of gestation, his birth weight was 
3190 g (25th percentile), and length 51 cm (25th percentile), OFC at birth was not noted. 
Delivery was uncomplicated and Apgar scores were 9 and 10, after 1 and 5 minutes, 
respectively. Right cleft lip and palate were confirmed. Cardiac findings were normal. 
At age 2 months he developed infantile spasms with the EEG showing unilateral left 
hypsarrhythmia. He had a severe developmental delay, axial hypotonia, right spastic 
hemiplegia, and he was unable to sit or stand independently at age 18 months. No 
dystonic movements were noted at this age.
At age 3.5 months he was a boy with an OFC of 39.5 cm (-1.5 SD), brachycephaly, large 
anterior fontanel, hypertelorism, unilateral cleft lip and palate extending into the right 
nostril, “square-shaped” ears, loose nuchal skin, inverted nipples, normal male genitalia, 
and slight cutis marmorata. He had bilateral ptosis and upgaze paresis (Fig. 1). 
Ophthalmological examination showed a pigmented ring around the optic nerve, the 
significance of which is unclear. Brain MRI performed at age 3 months showed several 
abnormalities: agenesis of corpus callosum, interhemispheric cyst, dilatation of the 
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anterior left ventricle with periventricular nodular heterotopia (PVNH), and extensive 
left frontal polymicrogyria (PMG). MRI at age 2 years showed similar abnormalities 
(Fig. 2) and additionally demonstrated PMG in the right frontal lobe, although less 
extensive than the left.
His seizures responded inadequately to anti-epileptic therapy (including vigabatrin, 
ACTH, valproate, levetiracetam, clobazam, and a ketogenic diet). He experienced 
continued tonic spasms, up to 8 times per day. At age 26 months a functional hemi-
spherectomy was performed, resulting in a dramatic decrease of seizure frequency 
and improvement of alertness and psychomotor development. No tissue was taken for 
pathology studies.
Metabolic analysis (plasma amino acids, cholesterol synthesis, acylcarnitine pattern 
and sialotransferrines; urine amino- and organic acids, sialic acid, imidazoles, guanidi-
noacetic acid, creatine, and sulfite) gave normal results.
Figure 1. Frontal view of the patient showing lat-
eral downslant of eyebrows, bilateral ptosis, diver-
gent strabismus, hypertelorism, low nasal bridge, 
and status after repair of right cleft lip.
Figure 2. Brain MR imaging of the patient at age 
2 years. 
(A) sagittal T1-weighted gradient echo image 
shows extensive left frontal PMG (arrows) and 
dilated lateral ventricle, (B) transverse T1-weighted 
gradient echo image shows heterotopia on 
ventricular wall (arrow), left frontal PMG, and PMG 
in the right medial anterior part of frontal lobe, 
(C) sagittal T1-weighted gradient echo image 
shows absence of corpus callosum. (D) transverse 
T2-weighted image showing PMG and heterotopia 
(arrow).
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MOLECULAR STUDIES
Routine cytogenetic analysis showed a normal male karyotype (46,XY), and subse-
quent genomic analysis by Affymetrix 6.0 K SNP array showed no pathogenic copy 
number variants. Sequencing of the FLNA gene was normal. With sequencing of the 
ARX gene, a 6- basepair insertion (335ins6, exon 2) was identified, which is expected to 
lead to a two alanine residue elongation of the first polyalanine tract. The boy’s mother, 
who is clinically unaffected, was found to be a heterozygous carrier of this insertion.
DISCUSSION
The combination of callosal agenesis and infantile spasms prompted ARX analysis in 
our patient, and a pathogenic mutation was identified. Interestingly, this boy also has 
PMG and PVNH, not been reported previously in ARX. This combination of findings may 
be coincidental in this boy, but could also be a manifestation of the ARX mutation.
The ARX gene encodes for 4 polyalanine tracts. Around 60% of known mutations in ARX 
are GCG repeat-encoded polyalanine tract expansions, and in 17 of 97 reported cases 
the first polyalanine tract is expanded, as in our patient.2 The 335ins6 mutation (under 
different nomenclature; c304ins(GCG)2), causes nonsyndromic X-linked mental retarda-
tion1, however, no data on brain imaging of these patients were presented. Another 
mutation of the first polyalanine tract, the c.304ins(GCG)7 mutation, has been reported 
in several phenotypes including NSID, Partington syndrome and X-linked infantile 
spasms.2,8 The role of the polyalanine tracts in the ARX protein is not well understood. 
Some authors have reported aggregation of the protein in the cytoplasm or nucleus 
in polyalanine expansion mutations.2,9 It has been suggested that the severity of the 
clinical phenotype may reflect increasing length of the expansion 10-12, however, others 
have reported great intra- and interfamilial variability.4,13,14
PMG and PVNH are considered malformations of cortical development (MCD) 15 which 
are caused by failure of neurons to correctly migrate from the subventricular zone 
and to organize during fetal development. Evident asymmetric PMG was described 
in 22q11 microdeletion syndrome and TUBB2B mutations but the cause of PMG is 
heterogenous, genetic and non-genetic.16,17 Lissencephaly, another form of MCD, is, in 
combination with ambiguous genitalia (XLAG), a well-recognized disorder due to ARX 
mutations. The role of ARX in neuronal migration has been studied; and in the brain of 
an ARX patient, clusters of immature neurons were found in the white matter 18; these 
authors hypothesized that ARX is necessary for the correct tangential migration of pre-
plate GABAergic interneurons derived from the lateral ganglionic eminences. Silencing 
of ARX expression in neural progenitors causes failure of cells to migrate to the cortical 
plate.19 Arx mutant mice show reduced neuronal migration out of the subventricular 
zone in utero, leading to ectopic periventricular accumulation of neurons 20, which 
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mimics the human PVNH phenotype. Both PMG and PVNH are not an indication 
for ARX screening and there are no studies systematically screening MCD (except 
lissencephaly) patients for ARX mutations. It would be of interest to perform analysis of 
the ARX gene in more patients with MCD to determine the significance of our finding. 
Over 1,000 targets of Arx have been identified 21, and recently, an 8 alanine expansion 
of the first polyalanine tract of Arx was shown to prevent repression of a subset of 
Arx targets.22 We hypothesize that genetic variations of ARX targets can contribute to 
the variable phenotype of ARX mutations and possibly for the unique aspects of our 
patient, already suggested for other genes involved in cortical development.23
Cleft lip and palate is an uncommon finding in ARX patients, but was reported once.24 
This patient also presented with hypertelorism, mental retardation, agenesis of corpus 
callosum, transsphenoidal encephalocele, and partial anterior hypopituitarism. This 
phenotype overlaps partly with that of our patient and also shows resemblance to 
frontonasal dysgenesis. A group of aristaless-like homeobox genes (ALX) genes is 
known to cause “frontonasal dysplasia”. Mutations in ALX3 cause frontorhiny 25 and 
isolated clefting 26. Mutations in ALX4 cause “frontonasal dysplasia” associated with 
alopecia and genital abnormalities.27 Recently, ALX1 mutations were found in patients 
with a severe form of autosomal recessive “frontonasal dysplasia”, with microphthalmia 
and facial clefting.28 Post-mortem brain studies of two affected fetuses showed corpus 
callosum agenesis, cerebellar hypoplasia and neuronal heterotopia of the pons in one.
In conclusion, we report a unique presentation of an ARX mutation associated with 
infantile spasms, PMG, PVNH, and cleft lip/palate. Screening of the ARX gene in a 
cohort of MCD patients with this combination would clarify the significance of our find-
ing. The broad phenotype and inter/intra familial variability observed in ARX mutations 
suggests that other contributing factors, either genetic or environmental, are involved 
in determination of the phenotype. Identifying the genetic factors among these, e.g. 
by exome sequencing, in the future will be important for adequate counselling of 
families with potentially high recurrence risk, for adequate therapy, and for further 
understanding of brain development.
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ABSTRACT
Mutations in FLNA (Filamin A, OMIM 300017) cause X-linked periventricular nodular 
heterotopia (XL-PNH). XL-PNH-associated mutations are considered lethal in 
hemizygous males. However, a few males with unusual mutations (including distal 
truncating and hypomorphic missense mutations), and somatic mosaicism have been 
reported to survive past infancy. Two brothers had an atypical presentation with 
failure to thrive and distinct facial appearance including hypertelorism. Evaluations 
of these brothers and their affected cousin showed systemic involvement including 
severe intestinal malfunction, malrotation, congenital short bowel, PNH, pyloric 
stenosis, wandering spleen, patent ductus arteriosus, atrial septal defect, inguinal 
hernia, and vesicoureteral reflux. The unanticipated finding of PNH led to FLNA testing 
and subsequent identification of a novel no-stop FLNA mutation (c.7941_7942delCT, 
p.(*2648Serext*100)). Western blotting and qRT-PCR of patients’ fibroblasts showed 
diminished levels of protein and mRNA. This FLNA mutation, the most distal reported 
so far, causes in females classical XL-PNH, but in males an unusual, multi-organ 
phenotype, providing a unique insight into the FLNA-associated phenotypes.
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INTRODUCTION
Mutations in FLNA (Filamin A, OMIM 300017, Xq28) cause several allelic X-linked 
disorders, including periventricular nodular heterotopia (XL-PNH), skeletal syndromes 
(e.g. Melnick-Needles syndrome), cardiac valvular dystrophy, chronic idiopathic 
intestinal pseudo-obstruction, FG syndrome, and terminal osseous dysplasia.1-3 Filamin 
A is widely expressed during development and has an important function in actin 
cytoskeletal organisation and cell signalling.4 In a study of PNH patients, FLNA muta-
tions were found in 83% of familial and 19% of sporadic cases.5 Genotype-phenotype 
correlations exists, and most of PNH patients are females with protein-truncating 
mutations, which are lethal in males. Rare cases of surviving males have been reported, 
and they usually presented with seizures and/or PNH 5-10 or (isolated) gastro-intestinal 
symptoms.11, 12 In contrast to the disruptive mutations in females, males were mosaic 
for the mutation or had missense, splice site, or distal truncating mutations.3, 5, 8, 13 These 
observations in males point to the obligatory presence of filamin A during human 
embryonic development.1
Here, we present a family where in 3 males and 4 females a novel no-stop FLNA muta-
tion (c.7941_7942delCT, p.(*2648Serext*100)) was identified. The family was originally 
referred because of failure to thrive and facial appearance in the affected males. Their 
extensive medical history, with unusual multi-systemic presentation, provides a unique 
insight into the FLNA-associated phenotypes.
CLINICAL REPORTS
A pedigree of the family is provided in Figure 1. Informed consent for participation in 
this study was obtained from all patients, according to the local IRB requirements.
The male propositus (III-1)was born at term as the first child of non-consanguineous 
Dutch parents. His birth weight was 3200 g (-1 SD). Neonatally, he underwent surgery 
for pyloric stenosis. Thereafter unexplained feeding difficulties required gastric 
tube feeding till age 7 months. Evaluation at 2 months, showed a malnourished, 
normocephalic (0 SD) and hyperteloric (ICD +2 SD) boy who had orbital fullness, a low 
nasal bridge, broad nasal base, broad mouth, micrognathia, left ear pit, narrow chest, 
V-shaped sacral dimple, crowded toes (Fig. 2A), an inguinal hernia and a persistent 
ductus arteriosus (PDA). Appearance became more normal with age (Fig. 2D). He 
had always had a tendency toward constipation, but from age 4 years, he developed 
progressive abdominal pain and flatulence. Celiac disease was excluded by duodenal 
biopsies. At age 6, he was diagnosed with intestinal malrotation and a short small 
bowel, estimated to be 1/3 of normal length. On a medium chain triglycerides (MCT) 
diet episodes of abdominal pain and flatulence decreased. Brain MRI at 4 years showed 
bilateral PNH, partial agenesis of the corpus callosum and a retrocerebellar cyst. A 
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24-hour EEG registered epileptic activity in the frontal lobes during sleep, although he 
never had overt seizures. His development is normal.
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Figure 1. 
(A) Pedigree. Black boxes represent affected males, dotted circles represent heterozygous females. (B) 
Sanger sequencing results showing wild type sequence, hemizygous male (patient III-1) and heterozy-
gous female (patient II-2). Arrow points to first position of the CT deletion (c.7941). (C) Result of qRT-PCR 
showing FLNA expression (normalized to COPS5 expression) in fibroblast cell lines from patients III-2 (2) 
, III-1 (3), and II-1 (4); and from four healthy control individuals (1=male, 5=male, 6=female, 7= female). 
Primers were designed against exon 2-3 (FLNA1) and exon 42-43 (FLNA2).Expression of FLNA is signifi-
cantly lowered in the patients versus controls. CLK2 expression (housekeeping gene) is normal in all cell 
lines. (D) Western blot analysis in fibroblasts using FLNA monoclonal antibodies (Abnova, clone 4E10-
1B2, diluted 1:1000) showing lowered FLNA expression in male patients (III:1 and III:2) compared to their 
mother (II-1) and two controls.
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His younger brother (III-2) was born at term with a weight 3715 g (0 SD). Neonatally 
he was diagnosed with vesicoureteral reflux (VUR), a mildly dysplastic mitral valve, 
and a PDA. He suffered from recurrent upper respiratory tract infections and severe 
constipation. Hirschsprung disease was excluded by suction rectal biopsy. At age 
6 months he presented with colitis due to severe cow’s milk protein intolerance, 
symptoms improved with a diet. Physical examination showed a prominent forehead, 
hypertelorism (ICD >2SD), orbital fullness, a short nose with anteverted nares, low-set 
ears, large mouth (rectangular-shaped when crying), crowded toes, deep plantar 
creases (Fig. 2G-H), longitudinal sacral dimple, and mild pectus excavatum. Hypotonia, 
drooling, and a mildly delayed motor development were noted. Appearance became 
more normal with age (Fig. 2B, E). Brain MRI at age 21 months demonstrated bilateral 
PNH and a retrocerebellar cyst (Fig. 2J, K). He never had seizures and attends regular 
education. At age 4 he presented acutely with vomiting and upper abdominal pain, 
peristaltic sounds were indicative of ileus, imaging (contrast radiographs and MRI) 
showed signs of gastro- intestinal obstruction. On laparotomy, the terminal ileum 
was distended over a distance of 10 cm, without functional obstruction. Two months 
later he experienced a similar episode which responded well to conservative therapy. 
An upper gastrointestinal contrast study showed a short small bowel, estimated 
1/3 of normal. He also responded well to a MCT diet. He presented again with acute 
abdominal pain at age 4.5 years and abdominal ultrasound and CT imaging showed an 
enlarged and dislocated (“wandering”) spleen and multiple accessory spleens (Fig. 2I). 
Splenopexy was performed successfully.
Their mother (II-1) is healthy. Results of cardiac evaluation (ECG and cardiac ultrasound) 
were normal.
The proband’s cousin (III-9) was born at 38 weeks, weighing 2865 g (-1 SD). During 
pregnancy his mother (II-4) was on carbamazepine therapy. Feeding difficulties were 
present from birth and at day 7 he was admitted because of bilious vomiting, diarrhea, 
and weight loss, requiring tube feeding. Examination (Fig. 2C) showed a malnourished 
infant with a mildly turricephalic head shape, prominent forehead creases, arched 
eyebrows, hypertelorism, almond-shaped eyes, a low nasal bridge, anteversion of 
the nares, broad mouth (rectangular-shaped when crying), abnormal palmar creases, 
sacral dimple, and a left inguinal hernia. A diagnosis of congenital short bowel and 
malrotation was made. Shortly thereafter, he deteriorated with progressive vomiting. 
At laparotomy a malrotated, distended but vital intestine was seen, most likely due to 
a resolved volvulus. He underwent a Ladd’s procedure but feeding problems persisted 
thereafter with frequent vomiting. At 10 weeks a jejunostomy and gastrostomy were 
placed and currently at age 5 months he is only partly tolerating enteric feeding and 
needs additional parenteral nutrition. Jejunal full thickness biopsies showed absence 
of FLNA immunostaining, without evident structural abnormalities (revised by R. Kapur, 
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Seattle Children’s Hospital). He experienced 2 urinary tract infections. Brain MRI at 2 
weeks of age showed PNH, hypoplastic cerebellum and vermis. He was diagnosed with 
an atrial septal defect (ASD) II. He has frequent episodes of tachypnea with oxygen 
need, lung CT imaging at age 5 weeks suggested presence of bronchomalacia.
His mother (II-4) has had three miscarriages. Her chromosomes and those of her 
husband were normal. She presented with seizures during her fourth pregnancy and 
subsequently PNH was identified on brain MRI. She has hypertelorism, and prolaps of 
the mitral valve with mild insufficiency.
The proband’s maternal aunt (II-2) suffers from mild constipation and uses a SSRI for 
depression and anxiety. She suffers from joint pains due to “loose ligaments”. As a child 
she had splint therapy because of congenital hip dysplasia. At age 30, she underwent 
repair of an umbilical hernia. She has downslanting palpebral fissures and small, low-
set ears. She complains of palpitations, however results of cardiac examination were 
normal. A common trunk of the truncus brachiocephalica and the left carotid artery 
was noted. Brain MRI showed PNH and retrocerebellar cyst (Fig. 2L).
The maternal grandmother (I:2) has an uterus bicornus and has suffered from depres-
sive episodes. Cardiac status was normal. She has mild hypertelorism.
LABORATORY INVESTIGATIONS
Patients III-1 and III-2 both have a normal male karyotype (46,XY). In III-2 results of a 
telomeric screen, (MLPA MRC Holland, SALSA P036C and P070), FISH analysis of the 
22q11 region and routine metabolic investigations were normal. Sanger sequencing 
of FLNA (reference sequence NM_01110556.1) showed a novel two base-pair deletion 
in exon 48; c.7941_7942delCT, p.(*2648Serext*100)), affecting the stop codon. This 
no-stop variant is predicted to elongate the coding RNA and create a novel stop 
codon in the polyadenylation signal of the 3´UTR. Subsequent targeted testing led 
to identification of this variant in their mother, grandmother, two maternal aunts and 
their clinically affected cousin (Fig. 1A, B). Skin fibroblast cell lines were obtained from 
patients III-1 and III-2 and their mother, II-1. Western blot using FLNA monoclonal 
antibodies (Abnova, clone 4E10-1B2, diluted 1:1000) showed diminished protein levels 
in fibroblast homogenates from the brothers, compared to their mother’s and two 
independent control cell lines (confirmed in triplicate) (Fig. 1D). QRT-PCR primers were 
designed against exon 2-3 (Ensembl FLNA_002, forward CATCAAACTGGTGTCCATCGA, 
reverse GGAGATGGAGTAGTGCAGGATCA) and exon 42-43 (forward TCTTTTGAG-
GACCGCAAGGA, reverse CCTCGTTGAACTTGACTGAGACTTC). Expression of mRNA 
was downregulated in both patients and their mother compared to three unrelated 
controls, normalized to COPS5 expression (Fig. 1C).
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DISCUSSION
We describe three boys with a novel FLNA variant who have an unusual non-lethal 
phenotype and atypical presentation with failure to thrive and minor facial anomalies. 
On examination they had extensive and variable multi-organ involvement including 
congenital short bowel with malrotation, “wandering spleen”, PNH, PDA, and urinary 
tract abnormalities. Only one of the affected females had presented with seizures and 
PNH, the others were ascertained through affected relatives. The unanticipated finding 
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Figure 2. 
(A-F) facial appearance of patients. (A) patient III-1, age 2 months with hypertelorism, orbital fullness, 
broad nasal base, and broad mouth (B) patient III-2, age 3.5 months, showing hypertelorism, orbital full-
ness, anteverted nares, rectangular-shaped mouth. (C) patient III-9, age 4 months, with hypertelorism, 
almond-shaped eyes, infra-orbital creases, low nasal bridge, and anteverted nares. (D) patient III-1, age 7. 
E: patient III-2, age 4. (F) sisters in childhood, only individual II:3 does not carry the mutation. (G, H) foot of 
patient III-2 with crowded toes and deep plantar creases. (I) Abdominal CT-scan image of patient III-2, ar-
row points to dislocated spleen. (J-L) brain MRI, T2-weighted images. (J) patient III-2 transverse view, note 
PNH along frontal horns of lateral ventricles. (K) patient III-2 transversal view shows retrocerebellar cyst. (L) 
patient II-2, showing PNH along the walls of the lateral ventricles.
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of PNH in the two brothers led to identification of the c.7941_7942delCT no-stop 
variant. Although variable congenital malformations are associated with FLNA muta-
tions, PNH seems to be the most constant finding and therefore provides a valuable 
clue to diagnosis in these patients. PNH has occurred in females with classic XL-PNH, 
with MNS-like facial appearance 14, personal observation and with an Ehlers-Danlos-like joint 
hypermobility syndrome 15, 16, and in rare surviving males (summarized in Table 1). 
Brain MRI is not routinely performed in neurologically normal patients presenting 
with congenital abnormalities, therefore the frequency of FLNA mutations might be 
underestimated. Table 1, summarizing the phenotypes of surviving males, presents 
additional symptoms which might lead to consideration of FLNA testing in males. Feed-
ing problems, severe constipation and/or intestinal pseudoobstruction are frequent 
and 5 other patients have been diagnosed with congenital short bowel.11, 12, 17 The latter 
is a rare anomaly, and only one other gene for congenital short bowel syndrome, CLMP, 
is known to date.18 FLNA is a second gene to consider in the differential diagnosis, 
especially in males presenting with additional findings outside the gastrointestinal 
tract. Cardiovascular anomalies are also common, and a number of males have been 
described with familial isolated polyvalvular cardiac disease.19, 20 Seldomly, the face is 
described, but this proved to be of diagnostic value in this family.
Although the FLNA mutations in surviving males are non-recurrent, all are relatively 
mild (e.g. non-truncating or mosaic). The frameshift induced by the c.7941_7942delCT 
deletion disrupts the original stopcodon, and creates a novel stopcodon 100 amino 
acids downstream in the 3´UTR polyadenylation signal. This might lead to increased 
mRNA degradation due to lack of a protective polyA tail, which is supported by the 
lowered expression we observed in the patients with qRT-PCR experiments. As these 
males present with a non-lethal phenotype, and Western blot shows residual protein 
levels, we hypothesize that a small amount of RNA escapes degradation and leads to 
low levels of functional protein.
Originally, gastro-intestinal features in FLNA patients were considered due to impaired 
gastrointestinal motility because of inadequate migration of neurons to the bowel 
during embryonic development 11. However, recently the neurogenic hypothesis was 
doubted and in five male patients with FLNA-related X-linked pseudo-obstruction 
abnormal layering of the muscularis propria was shown, without abnormalities of the 
enteric nervous system.12 Smooth muscle dysfunction might be an explanation for the 
frequently observed PDA in FLNA patients and the pyloric stenosis in patient III-2, yet 
jejunal biopsies from patient III-9 did not show evident smooth muscle abnormalities.
Filamin A has a wide range of functions, and this family shows that its presence is es-
sential for proper development of the gastro-intestinal, cardiovascular, genito-urinary 
and central nervous system. Clinicians should be aware of the differential diagnosis 
of acute abdomen in FLNA patients, which can include intestinal pseudoobstruction, 
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malrotation, volvulus, and wandering spleen, whilst chronic abdominal complaints 
and failure to thrive can be due to a short bowel. The findings in this family together 
with a few prior reports emphasize the high frequency of gastrointestinal symptoms 
in these patients, and as this family shows, one diagnosis does not exclude the other. 
Due to its variable presentation, the prevalence of FLNA mutations might very well be 
underestimated. Testing should be considered in patients presenting with a wide range 
of symptoms, and this report adds wandering spleen to its presentation. A proper 
diagnosis makes adequate monitoring of all involved organs possible and informs 
families of recurrence risks. We suggest a thorough work up of the different organ 
systems in each (male) patient, including diagnostic workup and careful monitoring of 
gastrointestinal complaints, a renal ultrasound, and a cardiac examination.
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ABSTRACT
We present a neurodegenerative disorder starting in early childhood of two brothers 
consisting of severe progressive polyneuropathy, severe progressive cerebellar 
atrophy, microcephaly, mild epilepsy and intellectual disability. The cause of this rare 
syndrome was found to be a homozygous mutation (c.1250_1266dup, resulting in a 
frameshift p.Thr424GlyfsX48) in PNKP, identified by applying homozygosity mapping 
and whole genome sequencing. Mutations in PNKP have previously been associated 
with a syndrome of primary microcephaly and seizures (MCSZ syndrome, MIM 613402), 
but not with a neurodegenerative disorder. PNKP is a dual function enzyme with a 
key role in different pathways of DNA damage repair. DNA repair disorders can result 
in accelerated cell death, leading to underdevelopment and neurodegeneration. In 
skin fibroblasts from both affected individuals we show increased susceptibility to 
apoptosis under stress conditions and reduced PNKP expression. PNKP is known to 
interact with DNA repair proteins involved in the onset of polyneuropathy and cerebel-
lar degeneration, therefore our findings explain this novel phenotype.
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INTRODUCTION
From the first identification of the basis of mendelian disorders using whole exome 
sequencing (WES) 1 and whole genome sequencing (WGS) 2, 3 these techniques have 
rapidly emerged as effective methods in finding disease-causing mutations. In con-
sanguineous pedigrees this can be combined with homozygosity mapping for rapid 
candidate gene filtering.4 Two siblings from a Dutch isolated population presented to 
our clinic with a rare combination of features starting in early childhood consisting of 
ataxia caused by progressive cerebellar atrophy, progressive debilitating polyneuropa-
thy, microcephaly, severe intellectual disability (ID) and mild epilepsy. No ocular signs 
or involvement of other organs were present. No known disorder was compatible with 
this phenotype (including known DNA repair disorders and hereditary neuropathies), 
extensive metabolic work-up was normal. The MRI patterns were not typical for known 
cerebellar ataxia with polyneuropathy syndromes, such as infantile neuroaxonal 
dystrophy or neuroacanthocytosis.
Despite multiple expert opinions and laboratory studies we were unable to establish a 
definitive clinical diagnosis. We therefore pursued a genotype-first approach and chose 
a combination of homozygosity mapping and whole genome sequencing approach in 
order to minimize the chance of missing known and putative pathogenic mutation(s) 
in both coding regions and splice sites.5 The same strategy has been successfully 
used to screen all known and identify new hereditary motor and sensory neuropathy 
(HMSN) genes.2 To our surprise we identified a homozygous mutation in PNKP (MIM 
605610) in both affected siblings by WGS and confirmed the disease locus with 
homozygosity mapping. Mutations in PNKP (polynucleotide kinase 3`-phosphatase) 
have been described in an autosomal recessive disorder characterized by micro-
cephaly, seizures and developmental delay (MCSZ, one of the early infantile epileptic 
encephalopathies, EIEE10, MIM 613402).6 The MCSZ patients are phenotypically very 
different to the patients described, who did not show any clinical progression, or any 
neurodegenerative symptoms. Additional studies in patient cells indicate a role of 
increased apoptosis in the pathogenesis of this novel degenerative phenotype.
CLINICAL REPORTS
The parents of our patients are healthy and originate from an isolated community in 
the southwest of the Netherlands. Genealogical studies of the family pedigree showed 
a loop of consanguinity (Fig. 1A).
Patient 1 was born at term with microcephaly (occipito-frontal circumference, OFC 
-3.25 SD), and weight and length at -1 SD. He had developmental delay, at 15 months 
he was able to take a few supported steps, and say ‘daddy’ and ‘mama’. At this age his 
OFC was -5.7 SD. At 23 months he walked independently, with a broad based ataxic 
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gait. He had brisk tendon reflexes. He presented with a series of febrile seizures at 
2.5 years, and experienced occasional seizures, mostly febrile, thereafter. His global 
development was compatible with 17 months at age 4.5 years (Bayley scale of develop-
ment). The boy was hyperactive and always had an extreme happy behaviour. The 
diagnosis Angelman syndrome was considered, but DNA testing was negative. At age 
9 he was a restless boy with severe progressive microcephaly (-6 SD), short stature (-4 
SD), ataxic gait, speaking 5 to 10 words. A brain MRI at age 16 showed severe cerebellar 
atrophy (Fig. 2, A-C), while a CT made at the age of 10 months showed no atrophy of 
the cerebellum at all.
patient 1
A
B
patient 2
144 155 166 177 188 199
GAAGCAAGGGAAACGGGTCGCCATCGACAACGGGTCGCCATCGACAACACAAACCCAGACGCCG
wt
wt / wt
wt
Figure 1. 
(A) Pedigree of the family showing common ancestor couple and the link to a possibly third affected 
family member. PNKP genotype is shown below individuals: *= 1250_1266 dup, wt= “wild type” PNKP 
sequence, black boxes represent affected persons. (B) Sanger sequencing results of PNKP in patient 2, the 
sequence present in duplo is shaded in pink and yellow.
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A slow deterioration of motor skills became evident, and he became wheelchair bound 
at age thirteen (see supplemental video). Motor function further deteriorated over 
the next few years, mostly as the consequence of progressive signs of the peripheral 
neuropathy, i.e. paresis of arms and legs accompanied by hypotonia, muscular atrophy, 
loss of the initially brisk tendon reflexes, and the development of contractures. A 
progressive severe motor and sensory demyelinating polyneuropathy with axonal 
degeneration was shown on EMG at age 11 and 16 (Tables 1 and 2). In contrast to 
the motor deterioration, cognitive functions and speech performance remained 
stable, while the epilepsy improved. He retained a happy demeanour, but had temper 
tantrums in adolescence. He died of pneumonia at 25 years.
Patient 2, the younger brother of patient 1, was born at term with birth weight at +0.5 
SD, length at -0.25 SD, and OFC at -1.5 SD. At 3 months microcephaly (-3.5 SD) and 
developmental delay were noted. His first seizure occurred at 12 months. He walked 
independently at 18 months and showed also hyperactive and happy behaviour. At 
five years he developed strabismus and papilloedema consistent with raised intracra-
nial pressure and a ventriculo-peritoneal shunt was placed. He slowly lost his ability 
to walk, and started using a wheel chair from age 7 (supplemental video). At age 14 
his OFC was -4.75 SD, and he was a hyperactive boy who could speak about 10 words. 
EMG at age 10 and 16 showed demyelinating polyneuropathy (Tables 1 and 2). Brain 
MRI at age 15 months showed enlarged lateral ventricles and thin corpus callosum 
(Fig. 2, D-F), and at age 9 and 18 years, after placement of the VP drain, showed a 
severe progressive cerebellar atrophy, and mild cerebral atrophy (Fig. 2, G-L). Seizures 
occurred 3-4 times a year while on carbamazepine therapy, but later on the frequency 
decreased. No eye problems, skin rash or susceptibility to infection were ever observed 
in the brothers.
A second-degree cousin of the father (Fig. 1A) had a similarly affected son who died 
around 30 years of age of a progressive neurological disease. No medical records are 
available. He had a small head, seizures and had lost the ability to walk.
Metabolic investigations including lactate, vitamin A and E, very long chain fatty acids, 
sialotransferrin isoforms, erythrocyte and leukocyte morphology, lysosomal enzymes, 
urine organic acids, mucopolysaccharides and amino acids, and CSF neurotransmitters 
were normal in both brothers. Transcription-coupled nucleotide excision repair after 
UV treatment (diagnostic test for Cockayne syndrome) and inhibition of DNA synthesis 
after X-ray irradiation (diagnostic test for ataxia-telangiectasia) were normal in patient 
fibroblasts (see below).
A video of patient 1 and 2 at different ages showing ataxia and progressive deteriora-
tion is included in the supplemental data (with consent of the family).
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Table 1. Nerve conduction studies
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Patient 1
(11 years) Motor:
R ant tib EDB 10.4 72 0.4 0.6
R median APB 3.5 41 5.0 4.5
Patient 1
(16 years) R ant tib EDB 0
R post tib AH 0
L post tib AH 0
R median APB 5.3 34 4.5 2.1
Sensory:
L sural 0
R median (digit 3) 0
Patient 2
(11 years) Motor:
R ant tib EDB 0 0
R post tib AH 6.5 34 2.8 1.5
L post tib AH 4.9 37 2.7 2.4
Sensory:
L sural nerve 0
Patient 2
(16 years) Motor:
R ulnar nerve ADM 4.4 31 0.7 0.8
R post tib Soleus 0
L post tib AH 0
Sensory:
R sural nerve 0
R median (digit 3) 0
Nerve conduction velocity (NCV) and distal motor latency (DML) values for patients 1 and 2 show slowing 
and loss of conduction in motor and sensory nerves, and conduction block consistent with a severe mixed 
demyelinating/axonal sensorimotor polyneuropathy. Normal values: NCV > 50 m/s in the arms, > 40 m/s 
in the legs; compound motor action potential (CMAP) extensor digitorum brevis (EDB) > 5 mV, CMAP 
muscles hand > 10 mV. ADM abductor digiti minimi, AH abductor hallucis, ant tib anterior tibial nerve, 
APB abductor pollicis brevis, L left side, post tib posterior tibial nerve, R right side (R), SNAP sensory nerve 
action potential.
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MATERIALS AND METHODS
Patient material and informed consent
All the family members and legal patient guardians provided written informed consent 
for participation in the study, which is embedded in a broader study of the cause of 
brain malformation at the Erasmus MC.
SNP arrays
500 ng of total genomic DNA extracted from peripheral leucocytes of the two affected 
brothers and their unaffected sister was hybridized to Genome-Wide Human SNP Array 
6.0 according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA). Affymetrix 
Genotyping Console (GTC4.1.0) was used for genotyping and both GTC4.1.0 and CNAG 
v3.3.0.1 Beta were used for regions of homozygosity (ROH) analysis as well as copy 
number analysis.7
Whole genome sequencing
DNA from the mother and two affected sons was extracted from peripheral leucocytes 
(mother) and fibroblast cell lines (sons) and sent to Complete Genomics (Mountain 
View, US), for whole genome sequencing.8 This technique was preferred above exome 
sequencing in order to minimize the chance of missing the mutations by exon captur-
ing techniques.9
Reads were mapped to the National Center for Biotechnology Information (NCBI) 
reference genome, build 36. Analysis of the whole genome sequencing data was done 
using CGA tools version 1.3.0 and TIBCO Spotfire version 3.3.1. The initial analysis was 
restricted to nonsynonymous variants, variants disrupting the acceptor or donor splice 
Table 2. Needle EMG results
Muscle FP PSW Maximal pattern Polyphasic MUAP
Patient 1
(16 years) L TA + + 0
L Q + - mixed +
Patient 2
(11 years) L TA - - mixed -
Patient 2
(16 years) R TA ++ - 0
R FR ++ +++ 0
R BB - - mixed +
Needle EMG in both patients shows fibrillations (FP), positive sharp waves (PSW), and polyphasic motor 
unit action potentials (MUAP) consistent with denervation.
BB biceps brachii, FR femoris rectus, L left side, Q quadriceps, R right side, TA tibialis anterior.
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site or small insertions or deletions (up to approximately 50 bp) in the homozygous 
area that were fully called and were not present in dbSNP129, or in data from the 1000 
genome database and Exome variant sever (Washington university), or in 100 control 
samples from our in-house database (HuVariome). Additionally, variants should follow 
the expected autosomal homozygous recessive inheritance pattern. When this analysis 
did not lead to a result, the stringency of the filtering was lowered by allowing no-calls 
or half-calls at potential variant positions, as long as one of the family members 
showed a variant on at least one allele. As a compound heterozygous recessive or 
X-linked inheritance could not be excluded by the pedigree of this family, we also 
performed analyses for these inheritance models.
Sanger sequencing
Verification of the mutation was performed by Sanger sequencing of exon 14 of the 
PNKP gene (RefSeq NG_027717) on DNA isolated from peripheral leucocytes. PCR 
amplification reactions were performed and products were purified with ExoSAP-IT 
(USB). Direct sequencing of both strands was performed using Big Dye Terminator 
chemistry ver. 3.1 (Applied Biosystems). DNA fragment analysis was performed using 
capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems) and the 
software package Seqscape (Applied Biosystems, version 2.1). Primer sequences are 
available upon request.
DNA repair and apoptosis studies
In cultured skin fibroblasts from patient 1 and 2, transcription-coupled nucleotide exci-
sion repair after UV treatment was used as diagnostic test for Xeroderma pigmentosum 
and Cockayne syndrome as described and resistance to inhibition of DNA synthesis 
after X-ray irradiation (cell cycle arrest) was used as a diagnostic test for mutations in 
the ATM pathway (ataxia-telangiectasia and Nijmegen breakage syndrome).10-12
Using cultured skin fibroblasts from both patients bearing the homozygous PNKP 
mutation, and 5 healthy control cells lines, we tested for susceptibility to apoptosis. In 
order to detect apoptosis the cells were stained with the FlicaTM (Fluorescent-Labeled 
Inhibitor of Caspases) apoptosis multi-caspase detection kit (Immunochemistry Tech-
nologies, LLC), which makes use of an inhibitor sequence of active caspases and was 
performed according to the manufacturer instructions. Fluorescent cells were scored 
(as a percentage of apoptotic fibroblasts) before and after stress induction by 24 hours 
serum deprivation and then a further 24 hours exposure to 5 mM dithiothreitol (DTT) 
by two blinded investigators. Necrosis versus apoptosis was tested by vital staining 
exclusion with propidium iodide. The experiment was repeated three times and each 
time performed in triplicate.
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Figure 2. 
MRI imaging of patient 1 (A-C) and patient 2 (D-L). First two columns show transversal T2-weighted im-
ages, the third column shows sagittal T1-weighted images. (A-C) patient 1 age 16 years, microcephaly, 
generalized atrophy, enlarged ventricles, and severe cerebellar atrophy. (D-F) patient 2 age 15 months, 
mild generalized atrophy, enlarged lateral ventricles and thin corpus callosum. (G-I) age 9 years, and (J-L) 
age 18 years, show decrease of lateral ventricle sizes after placement of VP-drain, severe and progressive 
cerebellar atrophy.
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quantitative PCR
Analysis of gene expression by qRT-PCR was carried out using a KAPA SYBRH FAST qPCR 
Kit (Kapa Biosystems) in the CFX96 Real-Time system (BioRad). Thermal cycling conditions 
were as follows: denaturing step (95˚C for 3 minutes), followed by 35 cycles of denaturing 
(95˚C for 5”), annealing and extension (60˚C for 30”). Fluorescence detection and data 
analysis were performed by BioRad CFX Manager 2.0. Experiments were performed in 
triplicate using as the reference GAPDH (MIM 138400) and ACTB (MIM 102630) for gene 
expression normalization.13 Primers are listed in supplemental Table S3.
RESULTS
SNP arrays and WGS
ROH analysis of the two affected brothers and an unaffected sister was performed in 
CNAG 3.3.0.1 Beta. Two regions of overlapping ROH were found in the two affected 
brothers and not in the unaffected sister on chromosome 11q23 (bp 117,449,498-
118,276,116, build 37) and chromosome 19q13 (bp 34,230,986-51,258,314, build 37). 
Considering the consanguinity loop and the size of the area (17 Mb), the region on 
chromosome 19q13 can be confidently considered identical by descent rather than 
identical by state and would putatively contain the genetic mutation (Fig. S1). The 
mapped whole genome sequence of the three samples (mother and two sons) varied 
between 183 and 192 Gb, resulting in a good average coverage between 66x and 
68x per genome (Table S1). Confident diploid calls could be made for approximately 
97% of the reference genome in all cases. On average, 3.75 million genetic variants 
were identified per sample, including single nucleotide variants and short insertions, 
deletions and substitutions up to ~50 bp.
Filtering for a homozygote recessive mutation present in both affected individuals was 
applied and after allowing no calls, variations in only 3 genes in the homozygous regions 
were found: ZNF285A, FCGRT and PNKP (Fig. S2). We excluded FCGRT as this encodes a 
protein only expressed in placental tissue and responsible for transferring IgG from mother 
to fetus therefore is not relevant to the phenotype. ZNF285A is 100% identical to human 
gene ZNF806 and ZNF678, it has no mouse ortholog which throws doubt onto the physi-
ological mechanism, and is in a cluster of more then 25 similar ZNF genes on chromosome 
19. Which makes it unlikely that this is the causative gene for this phenotype.
The PNKP variant was confirmed by Sanger sequencing, which showed an insertion of 
17 bp corresponding to a duplication in exon 14 of PNKP (c.1250_1266dup) resulting 
in a frameshift (p.Thr424GlyfsX48, PNKP-201 Ensembl database). This insertion is within 
the largest candidate ROH (Fig. S1 and Table S1). The PNKP gene was recently described 
in literature to be related to microcephaly, seizures and developmental delay (MCSZ) 
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syndrome and one of the mutations was the same variant that we identified in our 
family 6. Although heterozygous for the duplication, the mother was homozygous for 
the haplotype previously described. This confirms the association of the duplication 
with this haplotype in different ethnic backgrounds, and suggests this haplotype might 
predispose to the occurrence of the duplication, instead of being a founder effect. 
Analysis of WGS data for compound heterozygous and X-linked inheritance did not 
lead to any additional causative variants being found. We also specifically looked into 
genes known to be involved in neuropathy (Table S4) and found sufficient coverage 
and sequencing depth to confidently exclude a causative mutation.
qRT-PCR
In order to confirm the 17 bp duplication in exon 14 and to study its effect on PNKP expres-
sion we studied transcripts by qRT-PCR. Using primers against PNKP and designed over 
exon 3 and 4 and exon 15 and 16 we showed that the expression of PNKP was consistently 
decreased, however there was still expression of mRNA for PNKP in the homozygous state 
(Fig. S3). These results support the effect of the mutation as a loss of PNKP function.
Apoptosis studies
One of the effects of DNA damage is that, due to overall cell stress, cells have an 
increased susceptibility to undergo apoptosis. It has also been hypothesized that 
abnormal apoptosis is the pathogenic mechanism leading to microcephaly in MCSZ 
6. Cultured skin fibroblasts from both patients had indeed a significantly increased 
tendency to undergo apoptosis (Student’s unpaired t-test p<0.0001) when under stress 
conditions in comparison to 5 control cell lines (Fig. 3).
Apoptosis in DTT treated fibroblasts
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Figure 3. Patient 1 and patient 2 fibroblasts have 
an increased tendency to undergo apoptosis when 
treated with 5mM DTT in comparison to 5 control 
cell lines, each experiment involved testing 5 con-
trol cell lines and 2 patient cell lines on 3 separate 
occasions. (p<0.001, unpaired t-test, SPSS v17.0). 
Rates are shown as a mean of 3 experiments (+/- 
SEM).
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DISCUSSION
We successfully applied WGS to identify the disease causing PNKP mutations in two 
brothers with a novel phenotype consisting of progressive cerebellar atrophy, severe 
polyneuropathy, microcephaly, and severe ID. There were occasional seizures, but no 
history of early infantile epileptic encephalopathy.
The same 17 bp duplication in exon 14 (c.1250_1266dup, resulting in a frame shift 
Thr424GlyfsX48) in PNKP in homozygous and compound heterozygous state has been 
identified in patients with a different syndrome (MCSZ/EIEE10, microcephaly, intrac-
table seizures and developmental delay syndrome).6 The published three patients who 
were homozygous for this mutation within an identical haplotype were not described 
as having progressive neurodegeneration. However, our patients clearly showed 
progressive disease in childhood, with loss of motor milestones (supplemental video), 
development of severe neuropathy and cerebellar atrophy. The MCSZ syndrome was 
not considered in our patients because of these symptoms. The extensive diagnostic 
investigations, the combined autozygosity mapping and WGS approach makes very 
unlikely that in this family we missed another genetic mutation accounting for the 
disorder.
PNKP is a dual function protein that has a polynucleotide 3’phosphatase and a poly-
nucleotide 5` hydroxylkinase domain and has an important role in repair of both single 
strand breaks (SSB) and double-strand breaks (DSB).14, 15 Fibroblast cell lines from our 
PNKP patients showed an increased tendency to go into apoptosis, supporting a role 
of apoptosis in the pathogenesis. Our observations suggest that stress placed on the 
cell by the DNA repair defect causes insufficient proliferation and cell death. Increased 
apoptosis was shown in mouse neuronal precursors and differentiated neurons with 
reduced Pnkp levels.6
We looked at PNKP’s interacting partners using STRING analysis, which combines 
information from different sources to identify known and putative protein interactions 
(Fig. 4). This shows interaction with known neurodegenerative disease-associated 
proteins (Fig. 4). Mutations in TDP1 cause autosomal recessive spinocerebellar ataxia 
with axonal neuropathy (SCAN1, MIM 607250) 16, and this has led to the previous 
suggestion that PNKP could be a gene for SCAN 17. APTX mutations cause ataxia-
oculomotor apraxia type 1 (AOA1, MIM 606350). PNKP, TDP1, and APTX defects all 
lead to abnormal SSB repair, which provides experimental evidence for a common 
mechanism of neurodegeneration.18
Severe microcephaly is observed in the autosomal recessive primary microcephaly 
syndromes (MCPH). One of the genes involved in this disorder, MCPH1, links the MCPH 
genes to DNA repair by activating ATM and ATR (respectively associated with ataxia-
telangiectasia and Seckel syndrome) 14, 19, which in turn phosphorylate and activate 
PNKP.
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Figure 4. STRING analysis showing PNKP interactions between known proteins which are encoded by 
genes associated with primary microcephaly syndromes (red filled circles), DNA repair disorders (green 
filled circles), proteins not yet associated with human neurological disease (candidate genes, blue filled cir-
cles). The blue line between the proteins indicate known interactions and the thickness of the line is repre-
sentative of the confidence of evidence (the thicker the line, the more evidence to support the interaction).
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In the DSB repair, which is particularly important in dividing cells during development, 
PNKP directly interacts with the scaffold XRCC4 and activates LIG4. LIG4 mutations 
cause immunodeficiency with microcephaly (MIM 606593).19, 20 DNA ligase 4 -/- mice 
show increased apoptosis throughout the nervous system and die in the embryonic 
period. Lig4 conditional KO mice (Lig4 Nes-Cre) have a pronounced microcephaly and 
show increased apoptosis from E13.5, peaking at E15.21 This apoptosis is apparently 
mediated by the intact pro-apoptotic function of ATM in Lig4 mutants.22 Microcephaly 
due to increased apoptosis of neuroprogenitors during embryonic development has 
been shown by our group in a syndrome with congenital microcephaly and diabetes.23
Therefore, the function and interactions of PNKP supports a role in the neurodegenera-
tive phenotype as well as microcephaly, possibly by increased apoptosis.
In conclusion, we have described a neurodegenerative phenotype not previously 
described with PNKP mutations and used a combined approach of autozygosity 
mapping and whole genome sequencing as a valuable tool for diagnosis.
Supplementary information is available online at the Neurogenetics website.
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Sir,
We read with great interest the review by Reynolds and Stewart in the January 
issue reviewing three neurological disorders associated with defective single strand 
break repair: ataxia oculomotor apraxia 1 (AOA1), spinocerebellar ataxia with axonal 
neuropathy 1 (SCAN1) and microcephaly, early-onset, intractable seizures and devel-
opmental delay (MCSZ) syndrome.1 The authors discuss in detail the clinical features 
and underlying pathologic mechanisms. We noted that they focus on the differences in 
clinical presentation between AOA1, SCAN1 and MCSZ syndrome; the first two having 
progressive cerebellar ataxia as a major symptom, and the latter retaining normal brain 
structures and lacking sign of neurodegeneration or ataxia. They hypothesize that the 
hypomorphic nature of the mutation with preservation of DNA 3’ phosphatase activity 
of PNKP leads to this attenuated phenotype.
Indeed, the individuals described in the first report of MCSZ syndrome lack cerebellar 
symptoms.2 However our group recently published clinical details of two brothers with 
PNKP mutation who, besides the congenital microcephaly, presented in early child-
hood with a neurodegenerative disorder consisting of progressive cerebellar ataxia 
and severe polyneuropathy leading to loss of motor milestones, wheel chair depen-
dence, and in one, premature death at age 25 years.3 Intensive investigations including 
repeated brain imaging and EMGs showed progressive cerebellar atrophy and severe 
mixed demyelinating/axonal sensorimotor polyneuropathy (Fig. 1). In addition they 
had mild epilepsy, not meeting criteria for early infantile epileptic encephalopathy, and 
moderate/severe intellectual disability). Through homozygosity mapping and whole 
genome sequencing a homozygous mutation (c.1250_1266dup resulting in a frame-
shift p.Thr424GlyfsX48) in PNKP was identified. This is exactly the same homozygous 
duplication already described in the 3 patients with MCSZ syndrome who did not show 
any evidence of neurodegeneration.2 In light of the knowledge about the PNKP func-
tion we can fully explain the phenotype of our patients and agree with the prediction 
that this protein plays a major role in development of the CNS and in maintenance of 
normal functions of both CNS and PNS throughout life.
PNKP is a dual function enzyme which functions in both single strand and double 
strand break repair. PNKP directly interacts with TDP1, associated with SCAN1, and this 
has led to the previous suggestion that PNKP could be a candidate gene for spino-
cerebellar ataxia with neuropathy.4 PNKP is involved in single strand break (SSB) DNA 
repair by binding to a scaffold provided by XRCC1 and processing the repaired strands 
for the DNA ligase LIG3.5 Interestingly, XRCC1 knock-out mice show loss of cerebellar 
purkinje cells, ataxia and seizures.6
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PNKP is also involved in double strand base repair and directly interacts with XRCC4 to 
activate LIG4. Conditional knock-out mice (Lig4 Nes-Cres) show microcephaly and have 
increased apoptosis in the brain at E23.5-E15.7
There is therefore sufficient knowledge to support and to expect the presentation of 
microcephaly, cerebellar ataxia and polyneuropathy, which we observed in case of 
PNKP mutation.
We showed in patient-derived fibroblasts harbouring the PNKP duplication an in-
creased tendency to undergo apoptosis, thus supporting the theory that their micro-
cephaly is caused by an increased apoptosis in neuronal precursors with unrepaired 
DNA breaks. We hypothesize that PNKP’s dual function in single and double strand 
break explains the combination of cerebellar atrophy and microcephaly.
It is not clear at the moment why the neurodegenerative symptoms were not present 
in the early description of the same PNKP mutation, but this is very interesting to 
address in future studies, particularly whether additional genetic, epigenetic or 
environmental factors contribute to this variability, as some of these could be modifi-
able and amenable to intervention.
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Figure 1. Brain sagittal T1 magnetic resonance imaging of one of the brothers (A), age 16, showing micro-
cephaly and profound cerebellar atrophy compared to age-matched control (B).
167Neurodegeneration and PNKP mutation (2)
Ch
ap
te
r 3
.6
REFERENCES
 1. Reynolds JJ, Stewart GS. A single strand that links multiple neuropathologies in human disease. 
Brain : a journal of neurology. 2013;136(Pt 1):14-27. Epub 2013/02/01.
 2. Shen J, Gilmore EC, Marshall CA, Haddadin M, Reynolds JJ, Eyaid W, et al. Mutations in PNKP 
cause microcephaly, seizures and defects in DNA repair. Nat Genet. 2010;42(3):245-9. Epub 
2010/02/02.
 3. Poulton C, Oegema R, Heijsman D, Hoogeboom J, Schot R, Stroink H, et al. Progressive cerebellar 
atrophy and polyneuropathy: expanding the spectrum of PNKP mutations. Neurogenetics. 
2013;14(1):43-51. Epub 2012/12/12.
 4. Plo I, Liao ZY, Barcelo JM, Kohlhagen G, Caldecott KW, Weinfeld M, et al. Association of XRCC1 
and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA 
lesions. DNA Repair (Amst). 2003;2(10):1087-100. Epub 2003/09/19.
 5. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet. 2008;9(8):619-31. 
Epub 2008/07/16.
 6. Lee Y, Katyal S, Li Y, El-Khamisy SF, Russell HR, Caldecott KW, et al. The genesis of cerebellar 
interneurons and the prevention of neural DNA damage require XRCC1. Nat Neurosci. 
2009;12(8):973-80. Epub 2009/07/28.
 7. Gatz SA, Ju L, Gruber R, Hoffmann E, Carr AM, Wang ZQ, et al. Requirement for DNA ligase IV 
during embryonic neuronal development. J Neurosci. 2011;31(27):10088-100. Epub 2011/07/08.

Chapter 4
New gene and mechanism

Chapter 4.1
Human INTS8 mutations link brain 
development and transcriptome integrity 
to the Integrator complex
Renske Oegema*, David Baillat*, Daphne Heijsman, Rachel Schot, Sima 
Kheradmand Kia, A. Jeannette M. Hoogeboom , Zheng Xia, Wei Li, Matteo 
Cesaroni, Maarten H. Lequin7, Cathryn J. Poulton, William B. Dobyns, 
Irenaeus F.M. de Coo, Frans W.Verheijen, Andreas Kremer, Peter J. van 
der Spek, Rob Willemsen, Adriana I. Iglesias, Leontine van Unen, Eric J. 
Wagner^, Maarten Fornerod^, Grazia M.S. Mancini
*,^ these authors contributed equally to the manuscript
Manuscript submitted
172 Chapter 4.1
ABSTRACT
Integrator (INT) is an RNA polymerase II (RNAPII)-associated complex that was recently 
identified to have a broad role in both RNA processing and transcription regulation. 
Despite the size of INT (>14 subunits), no germline mutations causing human disease 
in any subunit have been reported. Here, we show that Integrator Complex Subunit 8 
gene (INTS8) mutation causes a rare human neurodevelopmental syndrome. Patient 
cells display significant disruptions in gene expression and RNA processing, while 
depletion of INTS8 in zebrafish embryos lead to prominent underdevelopment of the 
head. Therefore, our results point to an evolutionary conserved requirement of INT in 
brain development.
173Integrator complex subunit 8 (INTS8) mutations
Ch
ap
te
r 4
.1
INTRODUCTION
The Integrator complex (INT) associates with the C-terminal domain of the largest 
subunit of the RNA polymerase II (RNAPII). It was first discovered to mediate the co-
transcriptional 3’-end processing of the U-rich small nuclear RNAs (UsnRNAs), the RNA 
components of the spliceosome.1, 2 Recently, the scope of INT function has broadened 
through the discoveries of a general role in RNAPII promoter proximal pause-release 
and in the processing of enhancer RNAs.3-7 INT consists of at least 14 subunits and is 
phylogenetically conserved among metazoans.1, 8 To the exception of INT subunits 
INTS9 and INTS11, that are paralogues of the cleavage and polyadenylation specific-
ity factor (CPSF) subunits CPSF100 and CPSF73 respectively, and which form the 
endonuclease factor responsible for cleavage of pre-mRNA 9, 10, the other INT subunits 
bear no homology to any RNA processing machinery or transcriptional regulators that 
would allow a predictable function within the complex.11 Although animal studies 
suggest an evolutionary conserved requirement of INT subunits for normal embryonic 
development 12-17, human INT germline mutations have not been linked to any disease.
Mutations in U snRNA have been previously linked to splicing alterations leading to 
brain disorders. For example, mutations in the mouse Rnu2-8, coding for U2 snRNA, 
results in cerebellar degeneration 18 and U4atac mutations in humans result in extreme 
microcephaly.19 Besides its role in UsnRNA 3’-end processing, recent studies identified 
INT as a regulator of gene expression through RNAPII-dependent transcriptional 
initiation, pause-release and elongation.3, 5, 6 Promoter-proximal pausing affects up 
to 40% of the genes and is particularly important during development.20, 21 Paused 
RNAPII is preferentially encountered at developmentally-regulated genes where it can 
orchestrate the synchronous gene activation necessary for pattern formation.22-25 This 
process is particularly important during neuronal development, synapse plasticity 
and maturation.26-28 Given the established function for INT in UsnRNA biogenesis and 
RNAPII pause-release it would be predicted that reduced INT activity could disrupt 
normal human neurodevelopment. Here, we demonstrate for the first time that muta-
tion in the Integrator Complex Subunit 8 gene (INTS8) causes a rare neurodevelopmental 
syndrome through loss of INT integrity and function leading to broad transcriptome 
alterations.
RESULTS AND DISCUSSION
Three siblings presented with a distinct and recognizable neurodevelopmental 
syndrome. In summary, they had severe intellectual disability, spastic tetraplegia, 
epilepsy, microcephaly, and cerebral blindness (Fig. 1A and see clinical reports in 
supplement). Brain imaging showed periventricular nodular heterotopia (PNH) and 
cerebellar hypoplasia (Fig. 1B, S1). Whole genome sequencing (WGS) using DNA from 
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six family members identified bi-allelic mutations in the Integrator Complex subunit 8 
gene (INTS8) in the affected siblings (Table S1). The first mutation is a nine-base-pair 
deletion leading to the deletion of three amino acids (c.2917_2925del, p.Glu972_Leu-
974del; simplified as INTS8ΔEVL), while the second mutation is a predicted missense 
mutation (c.893A>G, p.Asp298Gly). The mutations and their segregation in the family 
were confirmed by Sanger sequencing (Fig. 1C, 1D). INTS8 is a 995-amino-acid protein, 
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Figure 1. Biallelic INTS8 mutations in a family with a severe neurodevelopmental syndrome. 
(A) Pedigree of the extended family; filled symbols represent affected individuals. Below each individual 
the INTS8 alleles (WT= wild type) are shown. (B, upper panel) magnetic resonance imaging (MRI) of af-
fected individual III-2 showing cerebellar hypoplasia (left, arrow) and periventricular nodular heterotopia 
(right, arrows). (B, lower panel) normal MRI from unaffected individual for comparison. (C,D) Electrophe-
rograms from Sanger sequencing of INTS8 wild type and mutant alleles. (E) Graphical depiction of INTS8 
including the four tetratricopeptide (TPR) motifs (blue blocks), the patient mutations and in the lower 
panel the conservation of the affected amino acids residues.
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containing four predicted tetratricopeptide (TPR) motifs, which are versatile protein-
protein interaction domains. Both mutations reside in conserved regions of the protein 
and INTS8ΔEVL is located at the C-terminus of the TPR4 domain in a predicted alpha 
helix (Fig. 1E). In spite of sequencing INTS8 in 25 PNH patients and 266 other patients 
with brain malformations, we did not observe additional bi-allelic INTS8 mutations, 
which suggests that this is a gene with a very low mutational rate. This is supported by 
the high combined annotation dependent depletion (CADD) score of the mutations 
(Table S2).29
To study whether and how these mutations affect INTS8 expression we obtained 
primary fibroblasts from the three affected siblings and their unaffected brother, who is 
heterozygous only for the INTS8ΔEVL mutations. qRT-PCR indicates that INTS8 expres-
sion is reduced in patient cells (~50% reduction) suggesting that one of the INTS8 
genes is not expressed (Fig. 2A). To confirm this, we designed an amplicon incapable of 
amplifying the INTS8ΔEVL allele and found that the expression of the INTS8 c.893A>G 
allele is almost undetectable in patients (Fig. 2A).
Close analysis of known INTS8 transcripts in the NCBI RefSeq database indicates 
that the INTS8 c.893A>G mutation is located at position +1 of an exon (exon 8) of an 
annotated alternative 3¢ splice site used by isoform NR_073445.1 (variant 3, Fig. 2B). 
This variant is predicted to generate a premature stop codon within exon 8 and to be 
subjected to rapid degradation through nonsense mediated decay (NMD). To test the 
impact of c.893A>G on exon 8 splicing, we designed an INTS8-GFP minigene-reporter 
construct (Fig. 2C). Wild-type-INTS8 minigenes transfected into HeLa or HEK293T 
cells generated two distinct exon inclusion products (Fig. 2D), confirmed by Sanger 
sequencing to be variants 1 and 3 (not shown). Strikingly, introduction of the single 
base c.893A>G mutation into the INTS8 reporter was sufficient to completely change 
the splicing of exon 8 such that the distal 3¢ splice site used in the INTS8 variant 3 
was now exclusively utilized (Fig. 2D). Cloning and sequencing of this single spliced 
product confirmed the predicted exon junction (Fig. S3A). Both endogenous isoforms 
can be detected in HeLa cells but variant 3 constitutes only 6% of total cellular INTS8 
mRNA (Fig. S3B and S3C). Treatment in HeLa or HEK293T cells with puromycin or 
cycloheximide increased variant 3 RNA levels to 43% and 34%, respectively (Fig. S3C), 
supporting the model that variant 3 is subject to NMD.30 In patient cells, baseline levels 
of INTS8 variant 3 also increased after mRNA stabilization (Fig. S3D). Collectively, these 
results show that the c.893A>G mutation dramatically alters the splicing of INTS8 exon 
8, producing a premature stop codon and an unstable transcript.
As the c.893A>G allele produces an unstable mRNA, we deduced that the mutant 
INTS8ΔEVL is the preponderant protein expressed as suggested by the levels of mRNA 
expression in patient cells (Fig 2A, middle panel). Further, we could detect comparable 
levels and nuclear localization of INTS8ΔEVL protein in patient cells suggesting that 
176 Chapter 4.1
removal of these three amino acids does not overtly impact protein folding and 
accumulation (Fig S4, S5 and S6). Therefore, we investigated whether the INTS8ΔEVL 
protein could impact INTS8 interaction with the other subunits in the complex. To 
that end, we established HEK293T cells stably expressing wild-type (WT) or mutant 
(ΔEVL) INTS8 bearing an N-terminal 3XFLAG tag and purified the associated INT using 
anti-FLAG affinity resin. While WT and mutant INTS8-associated peptides showed a 
very similar pattern by SDS-PAGE (Fig. S7). Probing for the presence of specific INT 
subunits revealed differential association with the two proteins. The ΔEVL-FLAG-INTS8 
eluates contained nearly undetectable amounts of INTS1,-12 and RPB1, reduced 
levels of associated INTS4,-9,-11, but similar levels of endogenous INTS5 and INTS3, 
compared to WT-FLAG-INTS8 (Fig. 2E). Thus, the ΔEVL mutation appears to impact the 
ability of INTS8 to associate with other members of the INT complex. In patient cells we 
found reduced levels of INTS4, INTS9, and INTS11 and normal levels of INTS3 (Fig. 2F) 
suggesting that the reduced association of INTS8 with other members of INT leads to 
an overall loss in INT integrity and stability of some of its subunits. Consistent with this 
observation, we measured slight but significantly elevated amounts of misprocessed 
snRNA in patient cells (Fig. 2G), although total snRNA levels did not significantly differ 
between patient and control cells (Fig. S8). Taken together, these results indicate that in 
patient cells, there is both a reduction in integrity and function of INT.
To investigate the extent of INTS8 dysfunction on transcription and splicing, we 
conducted both exon array analysis and RNA-seq on patient cells relative to controls. 
Differential gene expression (DGE) data from exon arrays performed on fibroblasts 
showed a large number of significantly dysregulated genes in the patients’ vs. control 
cells (n=682; p<0.02, Table S3). To confirm results attained by exon array and to further 
explore a genome-wide effect on splicing we subjected poly(A) mRNA fractions from 
patient III-2 and III-4 and 2 controls to high depth RNAseq analysis (~65-fold average 
coverage, Table S4). We found an even larger number of genes (N=3,002; p< 0.02) that 
were significantly up- or downregulated in patient cells vs. control cells (Table S5). We 
validated 17 of these potential target genes by qRT-PCR (Fig. 3A,3B, S9). Comparison 
of DGE data between exon arrays (3x3 design) and RNAseq (2x2 design) showed a 
correlation coefficient of 0.66 between the two data sets (Fig. 3C) and, interestingly, 
that a majority of the genes that are significantly dysregulated in both datasets (N=82) 
are expressed in the CNS (Table S6).
In addition to transcriptional deregulation, we also detected significant splicing 
changes in 215 genes (p<0.01, 292 total events, Table S7) and confirmed the INTS8 
alternative splicing induced by the c. 893A>G mutation in patient cells. The vast 
majority of affected splicing events are skipped exons (65%) and mutually exclusive 
exons (19%, Fig. 3D). We selected five alternatively spliced genes and confirmed the 
corresponding splicing changes (Fig. 3E, 3F, S10). In mammals, it is estimated that 90% 
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of protein-coding genes are subject to alternative splicing (AS) and that the brain in 
particular relies heavily on AS to regulate neuronal development.31-33 Among the AS 
genes, the SPTAN1 gene is particularly interesting because in patient cells, exon 37 of 
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Figure 2. Effect of the INTS8 mutations. 
(A) qRT-PCR on fibroblast-derived RNA of the patients (III-2, III-3, III-4), their unaffected sibling (III-1), and 
two control cell lines (C1, C2), normalized for GAPDH expression. Expression of the c.893A>G allele vs. wild 
type was measured using a primer designed at the c.2917-2925del (INTS8 non-DEVL allele). (B) Schematic 
overview of INTS8 genomic and protein sequence. The c.893A>G mutation is present at the start of the 
exon8 of transcript variant 3 that contains a premature stop codon. (C) Schematic of the GFP-minigene 
reporter construct used to evaluate the effect of the c.893A>G mutation on INTS8 exon 8 splicing pattern. 
(D) RT-PCR analysis of RNA isolated from HeLa (lanes 1-3) or HEK293T cells (lanes 4-6) transfected with the 
GFP-minigene constructs. The empty reporter (GFP) is used as a control. (E) Western blot analysis of flag-
affinity eluates from HEK293T stable lines expressing 3xFlag-tagged INTS8 wild type (WT) or INTS8DEVL. 
(F) Western blots on total cell extracts from patient and control primary fibroblasts. (G) qRT-PCR showing 
normalized expression of misprocessed U1, U2 and U4 snRNAs in total RNA extracted from patient III-2 
and III-4 fibroblasts compared to two controls.
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the gene is exclusively skipped. SPTAN1-deficient patients share many features with 
the INTS8 patients as they present with severe intellectual disability, no visual tracking, 
epilepsy and spastic tetraplegia and brain imaging shows cerebellar hypoplasia, 
acquired microcephaly and hypomyelination.34 Interestingly, the skipped exon (exon 
37) is normally specific to brain and muscle tissues and codes for a predicted protein-
protein interaction motif suggesting a potential loss of function in INTS8 patients.35-37 
Altogether, these results indicate that INT-deficient patient cells contain global 
transcriptome perturbations manifesting as both altered splicing patterns and gene 
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Figure 3. Dysregulated transcriptome in patient cells. 
(A, B) qRT-PCR validation of gene expression variation in patient cells for NPTX1 and OSR2 mRNAs. (C) Cor-
relation analysis of DGE data from exon arrays (X axis) and RNAseq (Y axis). (D) Pie chart representing the 
different types of AS detected in patient cells vs control in RNA-seq data (n=215, p<0.01, 292 total events). 
(E, F) Experimental verification by RT-PCR of the splicing changes associated with INTS8 mutations for 
ADAM15 (E) and ATL3 (F) mRNAs.
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expression, which are supported by INT’s emerging role in both UsnRNA processing 
and transcription regulation.
In view of the severe developmental brain defects observed in the patients, and 
the peak of INTS8 expression in the human and mouse fetal brain (Fig. S11, S12), 
we studied the effect of INTS8 depletion in zebrafish embryos using a morpholino 
antisense oligonucleotide (MO) approach directed against the zebrafish homolog of 
human INTS8 (NP_001018592.2, Text S1). We designed two splice-blocking MO against 
ints8, MO1 and MO2, and both were able to down-regulate ints8 mRNAs levels by more 
than 90% (Fig. S13, S14). The MO1 morphants showed severe developmental defects 
detectable as early as one day post fertilization (dpf ) and readily visible at 2 dpf. 
Notably, ints8 morphants presented central nervous system defects characterized by a 
smaller and structurally abnormal brain compared to wild type (Fig. 4A-F). In addition, 
they had near-absent pigmentation, underdevelopment of the eye, swelling of the 
yolk sac, and pericardial edema. Not only were the effects visible at relatively low MO 
doses, but we also observed a dose-dependent response from 2 to 8 ng (Fig. 4B-D). 
Morphants developed microcephaly as their head size was significantly smaller in 4 
ng and 8 ng morphants compared to uninjected embryos (Fig. 4G). More importantly, 
we found that the head size/body length ratio was also significantly smaller in the 
morphants (Fig. 4H). This suggests that there is a specific effect of ints8 depletion on 
head development independent from an overall developmental growth defect. To rule 
out the possibility that the observed developmental defects were caused by off-target 
p53-mediated apoptosis 38, we co-injected MO1 with p53-MO. The phenotype of 
these morphants did not differ from that observed in the MO1 morphants (Fig. S15). 
Injections with MO2 replicated the MO1 phenotype, as these morphants also had 
significantly smaller heads and smaller head size/ length ratio (Fig. S16). Altogether 
these results indicate that ints8 expression is required in the developing zebrafish brain 
and that its depletion causes microcephaly, as we also observed in patients.
Our study provides the first evidence for an evolutionary conserved requirement of 
INTS8 and crucial role of INT during human brain development. INTS8 is essential for 
the structural and functional integrity of INT, and mutated INTS8 causes increased U 
snRNA misprocessing, increased AS events and altered gene expression, confirming a 
central INT role in transcriptional regulation.
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MATERIALS AND METHODS
Subject recruitment
All study participants or their legal caretakers gave written informed consent to 
participate in this study, and for publication of images, according to Erasmus MC 
institutional review board requirements (protocol METC-2011253, METC-2012387).
A  uninjected WT
C ints8 MO1 4 ng D ints8 MO1 8 ng
B ints8 MO1 2 ng
F
E
** **
** ** uninjected WT
ints8 MO1 2 ng
G H
Figure 4. Underdevelopment of the head in ints8 zebrafish morphants. 
(A-D) Close view of zebrafish embryos at 2 dpf treated with increasing ints8 MO1 doses (WT= uninjected). 
(E, F) Representative pictures of histology sections of uninjected WT and embryos injected with 2ng MO1 
at 2 dpf. (G) Comparison of head size at 3 dpf between WT and embryos treated with 4 and 8 ng of ints8 
MO1 (n=40, ** p=<0.001, Kruskal-Wallis). (H) Comparison of head size/body length ratio at 3 dpf between 
WT and embryos treated with 4 and 8 ng of ints8 MO1 (n=40, ** p=<0.001, Kruskal-Wallis).
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Whole genome and Sanger sequencing
Whole-genome sequencing (WGS) using DNA from the four siblings and their parents 
was performed using the Complete Genomics platform (Mountain View, US), details are 
provided in File S1. Data are deposited internally at the Erasmus MC to acknowledge 
the privacy of the family.
qRT-PCR of endogenous INTS8
Quantitative (q)RT-PCR of RNA extracted from cultured fibroblasts of the affected 
siblings, their unaffected brother, and two control cell lines was carried out using a 
KAPA SYBR FAST qPCR Kit (Kapa Biosystems) in the CFX96 Real-Time system (BioRad), 
details are provided in Supplemental Methods.
qRT-PCR of misprocessed UsnRNA and Integrator target gene expression in 
primary fibroblasts
qRT-PCR was performed using RNA from cultured fibroblasts on a Stratagene Mx3000P 
real-time PCR system (Agilent) using the KAPA SYBR FAST qPCR Kit (Kapa Biosystems) 
according to manufacturer’s instructions, details are provided in Supplemental 
Methods.
Splicing assays
Exon 8 and flanking intronic sequences of human INTS8 gene were amplified from 
HEK293T genomic DNA by PCR (primers in Supplemental Methods). The amplicon 
was cloned into the pGint vector 39 using BamHI and SalI restriction sites. The A893G 
mutation was introduced by site directed mutagenesis (primers in Supplemental 
Methods). The resulting constructs were transfected in HEK293T and HeLa cells using 
Lipofectamine2000 (Thermo Fisher). After 48h, total RNA was extracted, purified and 
used to generate cDNA. PCR amplification of the corresponding splicing product was 
performed. For detection and quantification, oligonucleotides were 5’ radiolabeled 
using 32P-gATP and T4 Polynucleotide Kinase (Thermo Fisher) and added in a 1/10 ratio 
with unlabeled oligonucleotides. The corresponding PCR reactions were resolved onto 
a 6% non-denaturing acrylamide gel, fixed and dried. The gels were scanned using a 
storage phosphor screen and a Storm scanner (GE Healthcare) and quantified using 
ImageQuant software (GE Healthcare).
INTS8 stable cell lines and Flag-affinity purification
The human INTS8 cDNA was amplified by PCR from HeLa cell cDNA and the cor-
responding PCR product was cloned into a modified pCDNA6 plasmid containing an 
N-terminal 3XFlag tag using EcoRI and XhoI restriction sites. The EVL deletion was 
introduced by site directed mutagenesis. HEK293T cells were transfected with either 
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construct. Flag-affinity purification was performed as in 1 using nuclear extracts from 
approximately 109 cells. Integrator subunits in the eluate were detected by Western 
blot using the following antibodies: anti-FLAG M2 (Sigma), INTS1 (Bethyl, A300-361A), 
INTS3 (Bethyl, A302-050A), INTS4 (Bethyl, A301-296A), INTS5 (Abcam, ab74405), INTS9 
(Bethyl, A300-422A), INTS11 (Bethyl, A301-274A) and INTS12 (Proteintech, 16455-1-AP). 
Oligonucleotide sequences are listed in File S1.
Western blot of Integrator complex components
Cultured fibroblasts were used for western blots of INT components. Approximately 75 
μg of the clarified whole cell extract were separated on an 8% acrylamide SDS-PAGE 
gel. After transfer to a PVDF membrane, the presence of the different INT subunits was 
assessed by Western blot using the antibodies listed above.
Exon arrays
Six Affymetrix GeneChip Human Exon 1.0 arrays of RNA extracted from cultured 
fibroblasts of all three affected siblings and three age and sex-matched controls were 
rma normalized on transcript level using the R package (http://www.r-project.org). Top 
down- and upregulated genes with p values <0.02 were analyzed for enriched gene 
ontology terms (goterms_BP_all) using DAVID (medium stringency) to identify clusters 
with significant enrichment (enriched score ≥ 1.3). CEL file microarray data are available 
under GEO accession number GSE48849 (http://www.ncbi.nlm.nih.gov/geo/).
RNA-Seq analysis
Poly(A) mRNA fractions isolated from cultured fibroblasts from patient III-2, III-4, 
and two controls were subjected to RNA-Seq analysis. In order to detect even slight 
changes in splicing, we utilized high depth RNA sequencing (RNA-Seq, ~1.5 x 107 
reads). The resulting data was analysed using a recently developed pipeline specifically 
designed to monitor splicing efficiency.40 In addition, we analysed patient and control 
RNA-Seq data for differences in gene expression at steady state levels using EdgeR. 
Data are deposited in Gene Expression Omnibus (GSE76878).
Zebrafish ints8 morpholino design and microinjections
All zebrafish procedures and conditions were in accordance with the Dutch animal 
welfare legislation, details are provided in supp. Two Morpholino antisense oligo-
nucleotides (MO1 and MO2) predicting abnormal splicing were obtained from Gene 
Tools (Philomath, OR, USA). MO1 was designed against zebrafish ints8 targeting the 
intron 2 exon 3 donor site. The second morpholino (MO2) targets the exon 6 intron 7 
boundary. Indicated amounts of MOs solutions were injected into the yolk of one to 
two cells stage zebrafish embryos (Danio rerio,Tupfel long fin strain) using a pneumatic 
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picopump (World Precision Instruments, Berlin, Germany). In addition, a previously 
described MO against p53 was used to detect possible off-target effects due to activa-
tion of p53 expression.38 For measurements, pictures were taken with a Leica M165 
MC stereo microscope and Leica Application Suite v4.4.0 software. Measurements 
were made using the Fiji software (ImageJ 1.50a, http://imagej.nih.gov/ij). For body 
length, total distance from head to tail was measured. For head size, we measured the 
distance from head till the posterior part of the otic vesicle. The head size/body length 
ratio was calculated for each larva using Excel software. The Kruskal-Wallis test for 
non-parametric statistical testing of independent samples was performed using IBM 
SPSS software (v21).
Supplementary information is available online at http://cluster15.erasmusmc.nl/
oegema. Username oegema, password renske.
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GENERAL DISCUSSION
The main purpose of my research was to expand our knowledge regarding malforma-
tions of cortical development (MCD). Our studies provide novel data with respect to 
their presentation, classification and etiology. Although our knowledge on MCD has 
expanded substantially, we have also learned that MCD are far more diverse on the 
clinical and genetic level than we had ever anticipated.
This general discussion will highlight my most important findings and place them in 
the context of the current knowledge on cortical development. It starts with a discus-
sion of the phenotypic heterogeneity and the importance of thorough phenotyping. 
Next, I will show that this heterogeneity is also present at the genetic level, but at 
the cellular level many MCD-associated genes can be linked to similar underlying 
pathways. Regulation of gene expression is presented as a novel mechanism. Finally , 
the future perspectives and challenges in diagnostics and research will be discussed.
MCD PHENOTYPING
For many rare disorders, knowledge on the full clinical spectrum and/or the molecular 
background is lacking, therefore the individuals described in this thesis were carefully 
phenotyped. We showed that this can lead to a clinical diagnosis, targeted identifica-
tion of the molecular cause, or expansion of the phenotype associated with a known 
gene. The latter will provide better counseling of the affected families on the prognosis 
of their disorder and the possibility to anticipate on specific symptoms.
Imaging-based diagnosis
Chapter 2.1 showed that regarding subcortical heterotopia the current MCD classifica-
tion is not comprehensive and many subtypes exist. Also it showed that an imaging-
based diagnosis can be very helpful in predicting the likelihood of a genetic etiology 
with high recurrence risk or rather a sporadic occurrence.
Chapter 2.2 illustrates the emerging importance of tubulinopathies, e.g. disorders 
caused by a mutation in a tubulin gene. Likely, any clinician involved in the care 
of MCD patients will encounter tubulinopathy patients. The first studies screening 
tubulin genes in large cohorts of MCD patients has yielded a mutation detection rate 
of 1-10%.1-4 Although the phenotypic spectrum is extremely broad, including micro-
cephaly, lissencephaly, pachygyria, polymicrogyria and simplified gyral pattern, it has 
become evident that tubulinopathies share a complex but recognizable brain imaging 
pattern. Often the corpus callosum is agenetic or hypogenetic, the basal ganglia are 
dysmorphic with absence of the internal capsule, and the brain stem and cerebellum 
are hypoplastic and dysplastic (Fig. 1). A recent study has shown that selecting MCD 
patients for these additional abnormalities substantially increased the mutation 
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detection rate, up to 42% for TUBA1A. 5 We show in Chapter 2.2 that a distinct cerebel-
lar dysplasia is highly predictive of finding tubulin mutations, as we found mutations in 
7 out of 9 tested patients. None of the scans of these patients were classified as MCD, 
although re-review showed a clearly abnormal gyral pattern. This pattern, however, did 
not classify as either polymicrogyria, pachygyria or simplified gyral pattern. Instead, 
the cortical thickness was near-normal, but the gyri were irregular in size and in depth. 
As nomenclature was lacking, we proposed the term dysgyria. This term has also been 
adopted by the Barkovich group.6 Also, a feature which had been noted by others, but 
had not received much attention, is the marked asymmetry of the abnormalities.
Phenotypic expansion
An imaging diagnosis and a syndrome diagnosis can be complementary to each other 
and the clinical geneticist plays an essential role in this by carrying out a thorough 
dysmorphology exam in every child with MCD. This is illustrated in Chapter 3.1, where 
we expanded the clinical spectrum of KBG syndrome with PNH. The MCD itself did not 
offer a clue to the diagnosis in this child, as PNH were, at this time, never described in 
patients with KBG syndrome. Similarly, in chapter 3.3, we described for the first time, 
PNH and polymicrogyria in a patient with a known ARX mutation. The finding of MCD 
in this boy eventually led to successful epilepsy surgery. This illustrates how clinical 
observations remain essential, even in the background of a molecular diagnosis.
The proband from the family described in chapter 3.4 had extensive multi-organ 
involvement, but not until the finding of PNH this led to the identification of the 
FLNA mutation. We show through our study and extensive literature review that the 
common assumption that FLNA mutations are embryonically lethal in males is untrue. 
Moreover, these males commonly present with multi-organ involvement and the 
gastro-intestinal symptoms in particular can be debilitating. The symptoms associated 
A B C D
Figure 1. Typical MR imaging abnormalities observed in tubulinopathies 
(all T1 weighted). (A) Agenesis of the corpus callosum in patient with TUBA1A c.410T>A. (B) Pachygyria 
with an asymmetric gyral pattern in patient with TUBA1A c.1265G>A. (C) Asymmetric dysmorphic basal 
ganglia and thalami with fusion of the caudate and putamen in patient with TUBB3 c.1070C>T. Also note 
the normal cortical thickness , with irregular sulcal depth, especially evident in the frontal lobes (dysgyria). 
(D) Asymmetric cerebellar hypoplasia (TUBA1A c.1265G>A).
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with FLNA mutations are extremely variable, even within the same family. For example, 
we observed severe respiratory disease in one affected boy, but not in his two cousins. 
Similar observations have been made in other families.7,8 Future studies should aim at 
identifying possible modifying factors, genetic or environmental, as these might offer 
clues to therapeutic interventions.
In chapter 3.5 we expanded the phenotype associated with a known mutation in PNKP 
with severe neurodegeneration. Our finding should therefore change the counseling 
on prognosis and the clinical care for patients with PNKP mutations. The finding of 
neurodegenerative features has been confirmed in a subsequent Portuguese study, 
where PNKP was found to be a major gene associated with autosomal recessive dysto-
nia, ataxia and oculomotor apraxia.9 As we have observed an increased susceptibility 
to undergo apoptosis in patient cells , one could hypothesize that the microcephaly 
and seizures are due to increased apoptosis in the brain. A similar mechanism has 
been proposed for the microcephaly, epilepsy, and diabetes syndrome.10 Of note, 
the Portuguese patients did not have microcephaly nor seizures, and therefore the 
susceptibility to apoptosis might depend on the genotype, or on an additional event 
triggering the onset of apoptosis.
In conclusion, mutations in the same gene can cause extreme phenotypic variability, 
and, vice-versa, MCD are caused by mutations in many different genes.
Future perspectives
Ultra-high field 7T MRI has already proved its superiority in diagnosing polymicrogyria, 
focal cortical dysplasia type IIb, and subcortical heterotopia in small cohorts.11-13 This 
highly detailed imaging with a microscopic resolution enables visualization of small 
anatomic structures not previously appreciated at lower fields, and therefore more 
accurate identification of the location and extent of the malformation.11 Several other 
technical advances also aid to provide more detailed and accurate imaging, adding 
valuable information on prognosis and when planning epilepsy surgery.14,15 These 
novel techniques need experienced neuroradiologists to interpret and classify the 
imaging data, acting in close collaboration with neurologists and clinical geneticists. 
Clinical geneticists in particular are trained in pattern recognition by incorporating all 
the typical features of a patient, and a dysmorphologist eye on the brain scan could 
prove essential in this process. Clinical geneticists also serve as a bridge between the 
laboratory and the clinic.
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MOLECULAR MECHANISMS
Subcortical heterotopia
A subset of rare forms of subcortical heterotopia has been shown to be caused by 
genetic mutations (discussed below). However, it is striking that for the large majority 
of subcortical heterotopia, especially the deeply infolded and the curvilinear subtypes, 
the molecular basis is unknown. We hypothesize that those are caused by either de 
novo mutations, possibly mosaic or somatic, vascular disruptive events or by a complex 
interplay of genetic and environmental factors. Vascular disruptive events have already 
been associated with the occurrence of schizencephaly and polymicrogyria.16,17 A 
complex etiology is also observed in families with cerebrovascular disease (and also 
rare instances of schizencephaly, polymicrogyria and cortical dysplasia) due to COL4A1 
mutations; the penetrance is low and modifying factors are required for developing 
disease.18 Epilepsy is a major, but potentially treatable complication of subcortical het-
erotopia and recent studies have shown that the underlying etiology of epilepsy can 
affect therapy outcome.19 For epilepsies with a possible genetic basis, efforts should be 
made to identify its cause paving the way for individualized treatment. MCD is a major 
cause of epilepsy, as several studies have shown that MCD is found in 25% of pediatric 
partial seizures, 5-15% of adult epilepsy, and 20-40% of therapy-resistant epilepsy.20-23 
A large-scale sequencing effort, preferably in affected brain tissue, is needed to answer 
questions regarding etiology and to identify potential targets for therapy.
Periventricular nodular heterotopia
Although mutations in FLNA are the most frequent cause of PNH, its etiology is far 
more complex. This is demonstrated by the findings in our study cohort and is also 
illustrated by Table 1 in Chapter 1, which list many genes and chromosomal aberrations 
that have been associated with PNH, many only in sporadic reports. FLNA encodes 
an important regulator of the actin cytoskeleton, which is connected to the plasma 
membrane through integrins, hence to the extra-cellular matrix. The discovery that 
the majority of X-linked PNH can be explained by mutations in FLNA has led to the 
hypothesis that PNH are the result of an intrinsic defect in migration of the neuronal 
progenitor cell.24 This was supported by the earlier finding that melanoma cell lines 
lacking FLNA show defective motility.25 However, in the majority of patients, the cortex 
is normally or near-normally developed. This suggests that neuronal progenitors 
harbouring pathogenic mutations can successfully complete migration. Moreover, 
FLNA has a wide range of functions and dozens of interacting partners.26 More recent 
studies have emphasized an important role for the radial glial cell in the pathogenesis 
of PNH.27 Brain pathology of deceased FLNA patients showed a disruption of the 
ependymal lining and diminished radial glia processes and these findings were 
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reproduced by Flna knockdown in developing rat brain.28 In addition, disruption of the 
radial glial scaffold in animal models leads to heterotopia.29,30
Other genes that have been definitely related to periventricular heterotopia are 
involved in subcellular vesicle trafficking (ARFGEF2)31 and the Hippo pathway, 
disturbance of which led to increased proliferation of early progenitors and a block 
in their subsequent differentiation (DCHS1, FAT4).32 Interestingly, FLNA has also been 
implicated in vesicle trafficking and it binds to the ARGEF2 encoded protein BIG2.33 It 
has been suggested that impairment of vesicle trafficking leads to loss of cell adhesion 
molecules and thus loss of ependymal integrity.33
In conclusion of the available data, PNH could be due to a subtle disturbance of 
intricate processes and a complex interplay of the migrating neuron and its supporting 
matrix. This disturbance could be caused by either one or a combination of defects 
in the connection to the ependymal lining, the cytoskeleton, the responsiveness to 
extracellular cues, the cell cycle, the polarity of the migrating progenitor or of the 
radial glial cell, neuronal adhesion and disassembly and premature differentiation.27,34-36 
Further studies are necessary to elucidate the full profile of this intriguing process. 
Animal models have provided great insights into neuronal migration, however they 
cannot always replicate the cortical malformations observed in humans.37,38 As mice 
lack a gyrencephalic cortex, other mammals, for example ferrets serve as better models 
of human brain development.39,40 Cerebral organoids offer a simplified model of early 
brain development, enabling the study of gene expression patterns and the effect 
of gene knockdowns on proliferation, migration, differentiation, and organisation of 
human neuronal cells.41,42
INTS8
A potential novel mechanism is highlighted by our discovery of INTS8 mutations in a 
syndromal form of PNH (chapter 4.1). This study represents the first identification of 
germline mutations in an Integrator Complex component and shows that this complex 
is required for brain development in both humans and zebrafish. The Integrator 
complex associates with RNA polymerase II and regulates snRNA processing, and 
transcriptional regulation of protein-coding genes through at least transcription 
initiation and RNA polymerase II pause release.43
We propose several mechanisms through which INTS8 mutations lead to this severe 
brain developmental disorder. Firstly, altered expression of one particular gene could 
cause the observed phenotype. Several dysregulated genes in patients cells can be 
related to early brain development by their function and/or expression profile (Ap-
pendix). Secondly, we showed that in patient cells many genes are alternatively spliced. 
This is in line with the role of the Integrator complex in the processing of snRNAs, 
major components of the spliceosome. Several studies have demonstrated that the 
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brain relies heavily on alternative splicing during neuronal development.44-46 This is 
supported by the finding that mutations in the splicing factor RNA-binding motif 
RBM10 cause abnormal mRNA splicing and intellectual disability, microcephaly, PNH, 
and cerebellar hypoplasia.47,48 Similarly, mutations in the minor spliceosome U4atac sn-
RNA gene in human results in splicing defects and cause microcephalic osteodysplastic 
primordial dwarfism.49,50 Thirdly, the development of the brain, more than that of any 
other organ, is finely tuned by RNA transcriptional and post-transcriptional processes.51 
It could be that this fine-tuning is disturbed leading to global transcriptome alterations 
in the developing brain. Studies in patient cells also support a broader disruption of 
both gene expression levels and alternative splicing. Finally, it has been shown that the 
lntegrator complex is required for ciliogenesis.52 SiRNA mediated depletion of several 
Integrator components led to a significantly decreased number of ciliated cells.52 It is 
unclear whether the Integrator complex is directly involved in ciliogenesis or that this 
is an indirect effect of the altered gene expression or RNA splicing. Because ciliogenesis 
is crucial during brain development (see below) we studied the cilia in patient cells by 
immunocytochemistry but observed no obvious structural abnormalities (F. Verheijen, 
unpublished data). This does not, however, exclude a more subtle effect of these or of 
other, currently unrecognized, INTS8 mutations on cilia structure or function.53,54
The importance of microtubule dynamics in MCD
Tubulinopathies
Many MCD, including heterotopia and microcephaly, the objects of this study, have a 
link to abnormalities of microtubules. The recent discoveries of mutations in alpha- and 
beta-tubulin encoding genes in MCD patients have greatly emphasized the importance 
of microtubule dynamics. Mutations causing MCD have now been identified in TUBA1A, 
TUBB2A, TUBB2B, TUBB3, and TUBB.55 In addition to the alpha- and beta-tubulins, 
mutations in many microtubule-associated genes cause MCD (Fig. 2). In Chapter 2.1 we 
show that mutations in EML1, encoding a microtubule-associated protein cause a rare 
syndrome characterized by ribbon-like subcortical heterotopia and megalencephaly.56 
This is one of the most rare types of SUBH and one of the few of which the genetic 
cause has been determined.
Microtubules are an important component of the cytoskeleton and in addition 
facilitate intracellular transport and nuclear movement, an essential process in cell mi-
gration. Microtubules are expressed in many cell types throughout the body. However, 
mutations in the above-mentioned genes primarily affect the nervous system. This is 
probably explained by the fact that microtubules are heterodimers build of alpha- and 
a beta-tubulin isotypes in a variable mixture, as each isotype has its specific temporo-
spatial expression pattern.57,58 Therefore, the composition of microtubules in neuronal 
cells differs greatly from that in non-neuronal cells.58
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Centrosome
The major microtubule-organizing center is the centrosome (Fig. 2). During cell 
division, the centrosome duplicates and forms the base of the mitotic spindle which 
separates the chromosomes. Mutations in many centrosomal components have been 
shown to cause primary microcephaly.59 This strengthened the concept that neuronal 
proliferation is the main process affected in these patients.60 Although per definition 
major structural brain abnormalities are absent in individuals with primary micro-
cephaly, very little brain imaging from this group has been published. Our observation 
of subcortical heterotopia in a girl with primary microcephaly due to CENPJ mutations 
was therefore surprising. However, careful literature study showed that MCD occurs in 
patients with microcephaly caused by KATNB1, WDR62, STIL, ASPM, and RTTN muta-
tions suggesting that brain malformations are more frequently observed in patients 
initially diagnosed as having primary microcephaly.54,61-64 Hence the original definition 
of primary microcephaly might become obsolete as there is a broad and continuous 
spectrum of associated brain abnormalities, similar to the microtubule-associated 
disorders.
Primary cilium
Microtubules form major building blocks for the primary cilium. This organelle pro-
trudes its axoneme from the cell surface and plays and important role in major cellular 
signalling pathways, including the Hedgehog and Wnt signaling pathways. The base 
of the primary cilium is the basal body, a structure derived from the centrioles. The 
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axoneme consists of a core of microtubule doublets.65 The significance of cilia function 
for brain development is evident from the spectrum of neurodevelopmental disorders 
associated with ciliopathies, e.g. Bardet-Biedl syndrome and Joubert syndrome. A 
growing number of studies point to an essential role of the primary cilium in mam-
malian corticogenesis 29,66-69, and we have observed several patients with MCD and 
defective ciliogenesis (53 and F. Verheijen and G. Mancini, unpublished data).
Microtubule – actin interactions
Another major cytoskeletal component, the actin network, also plays an important role 
in cortical development.70 Filamin A binds to and is an organizer of the actin cyto-
skeleton.71 Its importance is also supported by the recent identification of mutations 
in genes encoding actin components (ACTB and ACTG1) causing a syndromic form of 
lissencephaly.72 Accumulating evidence suggests that there is an important crosstalk 
between the microtubule and the actin neuronal networks.73 The microtubule-
associated protein doublecortin (DCX, figure 1) can be translocated to F-actin74, and 
interestingly, the centrosome can act as an organizer of the actin network.75 Several 
actin-related genes had an altered expression in INTS8 mutant cells, indicating another 
potential pathway through which the INTS8 mutations influenced brain development.
DYRK1A and brain development
We described a recognizable syndrome associated with chromosomal microdeletions 
involving the DYRK1A gene (chapter 3.2). Since then, small deletions and point muta-
tions of the DYRK1A gene have been identified in patients with similar features.76-79 
This reinforces our assumption that DYRK1A haploinsufficiency was the main driver 
of the phenotype of the patients we described. Importantly, DYRK1A has now been 
recognized as one of the major ID genes, being found in 0.1%-0.5% of patients in 
large NGS studies.80,81 Review of (scarce) published imaging data revealed that at least 
an additional three patients have cortical dysplasia, although this is not mentioned 
by the authors.79 DYRK1A is a highly conserved gene located in the so-called Down 
Syndrome critical region (DSCR), a part of chromosome 21 that is responsible for the 
majority of phenotypic features in Down syndrome (OMIM *600855). It encodes a 
member of the dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) 
family and is involved in neuronal proliferation, neuronal differentiation, cell death 
and synaptic plasticity.82 In primary hippocampal rat neurons, Dyrk1a overexpression 
reduced overall axon growth.83 The precise molecular mechanism through which 
DYRK1A regulates neuronal development remains to be elucidated, but interestingly it 
has been found be essential to several pathways related to MCD. For example, Dyrk1a 
is able to alter DCX expression, to down-regulate hedgehog signalling and to affect 
F-actin remodelling.83,84 DYRK1A has also been shown to regulate cell cycle exit and 
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differentiation of neural precursors.85 Taken together, the effect of DYRK1A deficiency 
on brain development is probably multifold, affecting proliferation leading to micro-
cephaly, affecting cytoskeleton dynamics leading to MCD in a subset of patients, and 
affecting axon outgrowth and synaptic plasticity leading to moderate to severe ID in all 
patients.
New developments and challenges in molecular diagnostics
The chapters in this thesis not only present characterisation of MCD-associated 
phenotypes , but also illustrate the rapid evolution in genetic testing over the past 
few years. Starting with a clinical syndrome description (chapter 3.1), to targeted gene 
testing (3.3, 3.4) and submicroscopic aberrations (3.2) to finally mutations detected by 
whole-exome and whole genome sequencing (WES and WGS, 2.1, 3.6, 4.1).
Detection of submicroscopic copy-number variants with SNP-array, targeted next-
generation sequencing and whole-exome sequencing have now become the primary 
diagnostic procedure for this group of patients. In intellectual disability, this has been 
shown to increase the chance of establishing a genetic diagnosis substantially, and is 
expected to increase further with the diagnostic implementation of whole-genome 
sequencing.86,87 However, we are still far away from a 100% mutation discovery rate 
for MCD. An NGS approach using a targeted panel by our center and by others gave a 
detection rate of 6-18%.88,89 No numbers for WES/ WGS have been published, however 
in our center we observe many unsolved cases after WES, especially patients with 
polymicrogyria remain without a molecular diagnosis (G. Mancini, personal observa-
tion). Most of the diagnoses involve genes with an autosomal recessive, autosomal 
dominant de novo, or X-linked inheritance patterns. We might have to expand our 
search to mutations which are more difficult to identify, for example those with an 
autosomal dominant inheritance pattern with reduced penetrance, mutations in 
regulatory non-coding regions of the genome, oligogenic inheritance, or mosaic 
mutations (see next paragraph). Also, non-genetic causes like in utero infections and 
vascular disruptions should be considered.
The discovery of novel variants in known or novel genes in only one or few patients 
complicates the interpretation regarding pathogenicity. To overcome this problem, 
a large effort is needed to develop and implement functional studies of unclassified 
variants in the diagnostic trajectory. Possible assays range from relatively simple (e.g. 
measuring gene expression), to mutant protein expression, localization and interaction 
patterns to more complicated and time-consuming animal studies. In addition, data 
sharing amongst laboratories facilitates the recognition of genotype-phenotype 
correlations regarding rare diseases. However, it does raise other difficulties regard-
ing privacy protection of the patients, data ownership, and authorship of scientific 
publications.
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Mosaicism
An important theme is the relative high prevalence of mosaic mutations which 
complicates molecular testing. Several groups have now published this occurrence 
in a range of MCD including LIS1- and DCX-related subcortical band heterotopia 
90,91, X-linked PNH 92, the PI3K-AKT pathway-related megalencephaly/overgrowth 
syndromes 93, PIK3R2-related bilateral perisylvian polymicrogyria 94, and TUBB2B-related 
pachygyria/polymicrogyria.88
Mosaic mutations have also been detected in apparently unaffected parents of 
children with germline mutations and full-blown phenotypes (chapter 2.2).95-97 These 
findings impose a high recurrence risk on families compared to true de novo germline 
mutations in the offspring. More importantly, sibling recurrences without identification 
of the mutation in either parent have been reported.97,98 For counselling of recurrence 
risks and prenatal diagnostics, careful investigation of parental samples is warranted. 
An accurate estimation of the recurrence risk will remain difficult and the possibility 
of targeted prenatal testing should be considered in the counselling of families with 
apparent de novo inheritance. Even with increased awareness, detection of mosaic 
variants remains extremely difficult with levels as low as a few percent of NGS reads.94 
Analysing whole-exome data with such a low threshold for detection would be an 
immense, if not impossible task for the diagnostic laboratory. Therefore the clinical 
geneticist should make an effort in predicting the possibility of mosaicism during the 
process of clinical phenotyping and to select the genes to be analysed in more detail. 
Detection of somatic mutations present only in affected brain tissue is even more 
difficult and will only be possible in a small group of patients undergoing epilepsy 
surgery.99-101 The potential diagnostic pitfalls and challenges need to be thoroughly 
explained when counselling families of potential mosaic MCD patients.
CONCLUDING REMARKS
Over the past 20 years, with the emergence of high resolution brain imaging and 
next-generation sequencing in clinical diagnostics, our knowledge on MCD has 
expanded exponentially. Nevertheless, this has also taught us that MCD are far more 
heterogeneous on the clinical and genetic level than anyone had ever anticipated. 
Many challenges lay ahead, and research is hampered by lack of recognition, lack of 
funding, and small study cohorts. Rapid and inexpensive functional tests should be 
developed to test the pathogenicity of novel genomic variants. The patient benefits 
from knowledge of the optimal treatment, prognosis, developmental outcome, and 
risks of developing complications. Clinicians should therefore encourage their patients 
to reach out to each other and form international forums, as to efficiently collect and 
exchange this information and prioritize research themes. This approach has already 
General discussion 201
Ch
ap
te
r 5
been applied successfully for other rare disorders.102-104 In addition, scientists and 
molecular geneticists should unite and share their data, feel encouraged to form 
international consortia and publish their findings in open-access journals. Altogether, 
the impact of these measures could become greater than that of the technological 
advances we have witnessed over the past decades.
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SUMMARY
In Chapter 1, the general introduction, our current knowledge on cortical develop-
ment and malformations of cortical development (MCD) is summarized, with a focus 
on heterotopia and microcephaly. Also, an outline of the thesis is provided.
Chapter 2 presents imaging characteristics of subcortical heterotopia (2.1) and a 
cerebellar dysplasia associated with tubulinopathies (2.2).
Searching four MCD databases worldwide, we were able to collect imaging data of 107 
patients with subcortical heterotopia, which is the largest study of this malformation 
to date (2.1). The majority (83%) of patients were scanned during childhood and 79% 
had abnormal cognitive and/or motor development. Seizures were reported in 69% 
with age of onset significantly skewed towards early childhood. We proposed a new 
imaging classification for subcortical heterotopia, with four main groups. We showed 
that several rare bilateral forms can have a genetic etiology but that for the curvilinear 
and deeply infolded subcortical heterotopia a prenatal vascular disruptive etiology 
should be considered. However, de novo germline or mosaic mutations cannot be 
excluded at this point.
In chapter 2.2, we present ten patients with a highly characteristic cerebellar dysplasia. 
Remarkably, in seven of nine patients (78%), targeted sequencing revealed mutations 
in three different tubulin genes (TUBA1A, TUBB2B and TUBB3), occurring de novo or 
inherited from a mosaic parent. In cellular studies, all the studied mutations lead to 
impaired microtubule incorporation. As mutations in tubulin genes are known to cause 
MCD, we carefully re-reviewed the cortex on brain imaging and this revealed only 
an irregular pattern of gyri and sulci, for which we propose the term tubulinopathy-
related dysgyria.
In Chapter 3 the phenotype of several disorders is expanded.
In chapter 3.1 we describe for the first time the presence of periventricular nodular 
heterotopia with KBG syndrome.
In chapter 3.2, two patients are described with an overlapping 21q22 microdeletion. 
We propose that they represent a new syndrome caused by haploinsufficiency of the 
DYRK1A gene. This syndrome is characterized by intellectual disability, absent speech, 
and distinct facial features.
Chapter 3.3 describes the occurrence of periventricular nodular heterotopia and 
polymicrogyria in a patient with an ARX two-residue expansion of the first polyalanine 
tract. The same mutation had been previously reported in a family with non-syndromic 
XLID. Furthermore, the only MCD that had previously been related to ARX was an 
occipital-predominant lissencephaly, being caused by truncating mutations or mis-
sense mutations in the region encoding the homeodomain.
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For the research described in chapter 3.4, we had the unique opportunity to study a 
family of which seven members were shown to harbor a novel no-stop FLNA mutation. 
Five individuals underwent brain imaging and all had periventricular nodular heteroto-
pia. In addition, the three affected males survived into childhood but with multi-organ 
involvement which included severe gastro-intestinal symptoms.
In chapters 3.5 and 3.6 we show that a homozygous frameshift mutation in PNKP 
causes a neurodegenerative disorder starting in early childhood and consisting 
of severe progressive polyneuropathy and cerebellar atrophy, microcephaly, mild 
epilepsy, and intellectual disability. Mutations in PNKP had previously been associated 
with a syndrome of microcephaly, seizures and developmental delay, but without 
neurodegeneration. We showed that patient cells have an increased tendency to 
undergo apoptosis under stress conditions which is in line with the function of PNKP in 
DNA damage repair.
In chapter 4.1 we report that mutations in the Integrator complex subunit 8 gene 
(INTS8) cause a rare neurodevelopmental syndrome. The affected patients, three 
siblings, had profound intellectual disability, seizures and microcephaly. Brain imaging 
showed periventricular nodular heterotopia and cerebellar hypoplasia. Knockdown of 
ints8 in zebrafish embryos led to abnormal brain development. This study therefore 
unveils an essential and evolutionary conserved role of the Integrator complex in brain 
development.
Chapter 5, the general discussion, highlights the main findings of this thesis and 
places these in the context of the current knowledge on cortical development.
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SAMENVATTING
In hoofdstuk 1, de algemene inleiding, is de huidige kennis betreffende de ontwikkel-
ing van de hersenschors en aanlegstoornissen van de hersenschors (MCD) samengevat. 
Er wordt gefocust op twee aandoeningen, heterotopieën en microcefalie. Ook wordt in 
dit hoofdstuk de opbouw van het proefschrift gepresenteerd.
Hoofstuk 2.1 beschrijft een studie van 107 patiënten met subcorticale heterotopieën. 
Dit vormt de tot nu toe grootste studie naar deze hersenafwijking. De meerderheid 
van de patiënten (83%) had op de kinderleeftijd een hersenscan ondergaan. Een 
afwijkende cognitieve en/of motorische ontwikkeling werd gerapporteerd in 79% van 
de patiënten en epilepsie in 69%. De leeftijd van de eerste epileptische aanval vond 
significant vaker plaats op de jonge kinderleeftijd. We stellen een nieuw classificaties-
ysteem voor bestaande uit vier hoofdgroepen. Een aantal zeldzame, bilaterale afwi-
jkingen hebben een genetische oorzaak. De oorzaak van curvilinear en deeply infolded 
subcorticale heterotopieën zou goed een vasculaire disruptie tijdens de zwangerschap 
kunnen zijn. In deze groepen kunnen echter de novo kiembaan en somatische mutaties 
niet worden uitgesloten.
Tien patiënten met een duidelijk herkenbare cerebellaire dysplasie worden beschreven 
in hoofdstuk 2.2. In 7 van de 9 (78%) vonden we mutaties in een tubuline-gen 
(TUBA1A, TUBB2B en TUBB3), nieuw ontstaan of geërfd van een ouder met een 
mutatie in mozaïek vorm. Gebruik makend van een celsysteem laten we zien dat het 
gemuteerde eiwit niet normaal in microtubuli wordt geïncorporeerd. Omdat mutaties 
in deze genen zijn geassocieerd met MCD hebben we de MRI’s van alle patiënten 
opnieuw goed bekeken. We vonden een afwijkend patroon van gyri en sulci, en we 
stellen voor hier de term dysgyrie voor te gebruiken.
Onze observaties beschreven in hoofdstuk 3 verbreden het klinische spectrum van 
verschillende aandoeningen. In hoofdstuk 3.1 beschrijven we voor het eerst een 
patiënt met KBG syndroom en periventriculaire nodulaire heterotopieën.
In hoofdstuk 3.2 beschrijven we twee patiënten met een overlappende 21q22 
microdeletie. Zij hebben een syndroom dat wordt gekenmerkt door een verstandelijke 
beperking, afwezige spraak en bijzondere uiterlijke kenmerken en wat wordt vero-
orzaakt door haplo-insufficiëntie van het DYRK1A gen.
Hoofdstuk 3.3 beschrijft een patiënt met periventriculaire nodulaire heterotopieën 
en polymicrogyrie die een mutatie in het ARX gen bleek te hebben. Dezelfde mutatie 
was eerder beschreven in een familie met niet-syndromale X-gebonden verstandelijke 
beperking. Deze vormen van MCD waren nooit eerder geassocieerd met ARX mutaties.
Voor hoofdstuk 3.4 beschreven wij een unieke familie waarin 7 individuen een nieuwe 
no-stop mutatie in het FLNA gen hadden. Bij alle vijf familieleden die een hersenscan 
ondergingen werden periventriculaire nodulaire heterotopieën aangetoond. Hiernaast 
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hadden drie jongens in deze familie aandoeningen van verschillende organen waar-
onder ernstige gastro-intestinale symptomen.
Hoofdstukken 3.5 en 3.6 laten zien dat een homozygote frameshift mutatie in het 
PNKP gen in twee broers een ernstige neurodegeneratieve aandoening veroorzaakte. 
Deze broers presenteerden zich op de vroege kinderleeftijd met progressieve 
polyneuropathie, cerebellaire atrofie en microcefalie, met daarnaast epilepsie en 
een verstandelijke beperking. Mutaties in het PNKP gen waren eerder beschreven als 
oorzaak van een syndroom met microcefalie, epilepsie en ontwikkelingsachterstand, 
maar zonder neurodegeneratieve afwijkingen. We laten zien dat cellen van patiënten 
onder stressvolle omstandigheden in apoptose gaan, wat past bij de functie van PNKP 
in de reparatie van DNA schade.
Hoofdstuk 4.1 laat zien dat mutaties in Integrator complex subunit 8 (INTS8) een 
zeldzaam syndroom veroorzaken dat wordt gekenmerkt door een ernstige verstan-
delijke beperking, epilepsie en microcefalie. Hersenscans van de patiënten lieten 
periventriculaire nodulaire heterotopieën en onderontwikkeling van het cerebellum 
zien. Uitschakeling van ints8 in zebravis embryo’s leidde tot ernstige afwijkingen in de 
hersenontwikkeling. Nooit eerder werden mutaties in dit complex beschreven en wij 
laten hiermee zien dat het Integrator complex een essentiële rol heeft in de hersenon-
twikkeling en dat deze rol evolutionair geconserveerd is.
In hoofdstuk 5, de algemene beschouwing, worden de belangrijkste bevindingen van 
dit proefschrift uitgelicht en in de context geplaatst van onze huidige kennis betref-
fende de ontwikkeling van de hersenschors.
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LEKENSAMENVATTING
Ik heb onderzoek gedaan naar aangeboren afwijkingen van de hersenen (malforma-
tions of cortical development). Deze afwijkingen kun je zien op een hersenscan (MRI). 
In totaal zijn er nu meer dan 200 verschillende soorten bekend, die allemaal zeldzaam 
zijn. De meest frequente komen voor bij 1 op de 2500 personen. Desondanks vormen 
ze een belangrijke oorzaak van epilepsie, ontwikkelingsachterstand, spasticiteit en 
verstandelijke beperking. De twee aandoeningen waar ik mij in dit promotieonderzoek 
op heb gericht, zijn hersencellen die op de verkeerde plek in de hersenen zitten 
(heterotopieën) en hersenen die te klein zijn (microcefalie). Deze twee aandoeningen 
kunnen samen voorkomen bij een persoon, maar dat hoeft niet.
Veel hersenafwijkingen zijn nog niet of nauwelijks beschreven in de medische 
literatuur. Ik beschrijf in detail de klachten van patiënten en de bij hen geconstateerde 
afwijkingen op de hersenscan. Voor een specifieke afwijking beschrijven we meer dan 
honderd patiënten, de grootste studie tot nu toe. Ook laten we zien dat deze afwijking 
niet per sé een erfelijke (genetische) oorzaak heeft, maar bijvoorbeeld ook het gevolg 
kan zijn van een probleem in de zwangerschap, zoals een verminderde hersendoor-
bloeding.
Bij sommige patiënten vond ik wel een afwijkende samenstelling van de chromosomen 
en het DNA wat daarop ligt (het erfelijk materiaal). We hebben een afwijking op 
chromosoom 21 vastgesteld en veranderingen (mutaties) in verschillende erfelijke 
eigenschappen (genen) die hersenafwijkingen veroorzaken. Een belangrijke ont-
dekking is dat mutaties in het INTS8 gen een hersenaandoening veroorzaken met een 
ernstige verstandelijke beperking, spasticiteit en epilepsie. 
Mijn onderzoek laat zien dat deze aandoeningen een veelheid aan klachten kunnen 
veroorzaken en dat ook de onderliggende oorzaken erg verschillen, meer dan we 
ooit hadden gedacht. Ondanks de ontwikkeling van nieuwe technologieën op het 
gebied van genetisch onderzoek en hersenscans, is bij veel patiënten de oorzaak van 
hun hersenaandoening nog steeds onbekend. Hiervoor zijn verschillende redenen 
te bedenken: (1) de technieken zijn nog niet goed genoeg om elke erfelijke variant 
op te sporen; (2) de afwijkingen van het erfelijk materiaal komen niet voor in elke 
lichaamscel en worden daarom niet gevonden (mozaïek); (3) door de zeldzaamheid 
van de aandoeningen zijn er te weinig patiënten om goed onderzoek te kunnen doen; 
en (4) er zijn gespecialiseerde artsen nodig om de diagnose te stellen.
In de toekomst moeten we daarom nog gerichter op zoek naar erfelijke varianten, en 
moeten internationale netwerken worden ontwikkeld waar zowel patiënten als artsen 
en onderzoekers veilig hun data van zeldzame aandoeningen kunnen delen.
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Mijn dank gaat uit naar de vele patiënten en hun families beschreven in dit proef-
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oorzaken van corticale malformaties. 
Zoveel collega’s hebben bijgedragen aan dit proefschrift, ik zal niet iedereen hier 
kunnen bedanken, maar een aantal van hen wil ik hier zeker noemen.
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me laten zien dat binnen de genetica patiëntenzorg en onderzoek onlosmakelijk met 
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Beste Robert, veel dank dat je mijn promotor wilde zijn. Je gaf mij de kans mijn eigen 
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collaboration did not last very long but has been very productive. Elly, aan jouw hand 
zette ik de eerste stapjes in het lab. Maarten Fornerod, jij hebt de INTS8 paper met jouw 
analyses naar een hoger plan getild.
Heel veel personen op het lab van de 9e, maar ook op de 20e en 24e hebben de 
afgelopen jaren mij met hun tijd, hulp en tips vooruit geholpen. Adriana and Herma, 
without your help with the “visjes“ I would have been completely lost. I realize I have 
asked quite a lot of your time, thank you for that. Simone and Isa, I am grateful to have 
you around in the last phases of my PhD. You were an invaluable source of tips and 
tricks.
Professor Bill Dobyns, I am very grateful for our collaboration, it has been an inspiring 
and stimulating experience which has led to a vital section of this thesis. Thank you for 
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welcoming me to your lab, sharing the data from your huge database and teaching 
me your incredible understanding of MCD. Professor Jim Barkovich and Professor 
Renzo Guerrini thank you for your invaluable input into the heterotopia study, and 
your willingness to share your data and your extensive knowledge. This has taken the 
heterotopia project to a significantly higher level, it has been an honour and a privilege 
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bij het FLNA artikel en voor heel veel meer. Tom de Vries-Lentsch en Ruud Koppenol 
dank voor jullie tomeloze inzet en geduld bij het maken van al die figuren.
Mijn collega arts-assistenten uit Rotterdam, altijd een gezellig clubje waar ik veel 
goede herinneringen aan bewaar. In het bijzonder Marije, vanaf dag 1 in Rotterdam 
was jij mijn neurogenetica buddy, je emigratie is een groot gemis voor mij en voor ge-
netisch Nederland. En Judith, van ANIOS naar AIOS naar promovendus, onze loopbaan 
verliep parallel. Net zoals onze reizen Den Haag – Rotterdam v.v. Je onderzoek gaat als 
een speer, je bent slim en gedreven, jij komt er wel. Ik ben heel blij met jou als para-
nimf. Nog veel succes en plezier met je promotie. Lieve Lieke, jouw optimistische en 
constructieve blik op de wereld heeft je door heel wat moeilijke momenten gesleept. 
Heel jammer dat we geen collega’s meer zijn, ze hebben veel geluk gehad in Grun. Iris, 
Laura, Shimriet, Myrthe, Virginie en Serwet, ik wens jullie heel veel succes en plezier in 
jullie opleiding. Anne en Shimriet, veel succes (en sterkte) bij het afronden van jullie 
promotie. 
René de Coo, onder jouw supervisie op de neurogenetica poli heb ik mijn neurolo-
gische blik verder kunnen ontwikkelen. 
Ik wil mijn nieuwe collega's van de afdeling Genetica in het UMC Utrecht bedanken 
voor het hartelijke welkom op de afdeling. Ik kijk uit naar onze samenwerking, en in 
het bijzonder met mijn neurogenetica collega's Eva, Nienke en Mariëlle. 
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De afgelopen jaren zijn er ook momenten geweest dat ik niet aan het werk was, en 
deze momenten heb ik met heel veel dierbare en gezellige mensen kunnen delen. 
Mijn lieve Amsterdamse vriendinnen, met name Soetinah, Annemarie, Lidewine en 
Annemiek, jullie zijn er altijd voor mij, en ik kijk uit naar vele gezellige etentjes in het 
post-baby, -opleiding en -promotietijdperk. Simone, Jana, Yvonne, Sonja; we kennen 
elkaar al zo lang, het is altijd fijn en vertrouwd om jullie weer te zien. Alle Haagse 
vrienden en de Veldheertjes, wat heerlijk om zulke betrokken mensen vlak om je heen 
te hebben. Juist de vrienden die wat verder weg wonen bedank ik voor hun trouwe 
vriendschap en ik hoop jullie in de nabije toekomst weer wat vaker op te kunnen 
zoeken. 
Wat ben ik blij met zo’n leuke familie. Natuurlijk mijn ouders Bob en Jacobien ben ik 
dankbaar voor hoe jullie ons al die jaren hebben gesteund en gestimuleerd. Ook Els 
en Henk spelen een belangrijke rol in ons leven, net als Kyane, Loran, Dorine, Arjen en 
Bart. Oma Joke en oma Alie, ik ben heel trots af te stammen van deze twee vitale en 
ietwat eigenwijze dames. Gerard en Emmie, Erwin en Saskia, ik bof met zo’n geïnteres-
seerde en hartelijke schoonfamilie, en natuurlijk Jesse en Esra, ik hoop op nog vele 
gezellige logeerpartijtjes.
Tot slot, bedank ik de leukste mannen van de hele wereld. Het is altijd heerlijk 
thuiskomen bij jullie na een drukke werkdag. Lieve Edwin, je kent me niet anders dan 
bezig met werk en promotie. Bedankt voor al je geduld en support. Tijdens moeilijke 
momenten week jij nooit van mijn zijde. Met je brede interesse en enthousiasme voor 
de mooie dingen geef je het leven meer glans. Lieve Casper, je bent lief, vrolijk en 
ondeugend, en ik geniet van je gebrabbel en alle grote kleine avonturen die je beleefd. 
De wereld ligt op je te wachten, en we gaan haar met z'n drieën ontdekken. 
